{"matching_results": 34005, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 1678, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1260}, {"key": "negative", "matching_results": 407}, {"key": "neutral", "matching_results": 11}]}]}, {"key": "icrowdnewswire.com", "matching_results": 1388, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 1245}, {"key": "negative", "matching_results": 138}, {"key": "neutral", "matching_results": 5}]}]}, {"key": "watchlistnews.com", "matching_results": 860, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 622}, {"key": "negative", "matching_results": 238}]}]}, {"key": "tickerreport.com", "matching_results": 851, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 695}, {"key": "negative", "matching_results": 153}, {"key": "neutral", "matching_results": 3}]}]}, {"key": "wkrb13.com", "matching_results": 845, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 647}, {"key": "negative", "matching_results": 197}]}]}, {"key": "dailypolitical.com", "matching_results": 708, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 534}, {"key": "negative", "matching_results": 172}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "theolympiareport.com", "matching_results": 705, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 503}, {"key": "negative", "matching_results": 200}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "zolmax.com", "matching_results": 697, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 502}, {"key": "negative", "matching_results": 191}, {"key": "neutral", "matching_results": 4}]}]}, {"key": "thelincolnianonline.com", "matching_results": 647, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 461}, {"key": "negative", "matching_results": 186}]}]}, {"key": "findmarketresearch.org", "matching_results": 633, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 545}, {"key": "negative", "matching_results": 88}]}]}]}], "results": [{"id": "PAJEJ57S3Jdn_dym4eiFns-sIx1zj_tEt7nMO5QTcba7hktEEJVCe9jBzGksBCyV", "result_metadata": {"score": 36.658882}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.230595, "label": "negative"}, "text": "Norges Bank", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Norges Bank", "relevance": 0.886784, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.881087, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.779571, "label": "/finance/bank"}], "relations": [], "keywords": [{"text": "Bank", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.944017, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.892905, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.858826, "count": 1}]}, "crawl_date": "2018-11-16T13:12:05Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45300777-norges-bank-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T12:37:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norges Bank", "relevance": 0.957808, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.923955, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "YesShire PLC", "relevance": 0.788874, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.7562, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.680231, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.680231, "type": "Quantity"}], "sentiment": {"document": {"score": -0.414576, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2.", "object": {"text": "a cash offer or possible cash offer, state \"N/A\" YesShire PLC 2", "keywords": [{"text": "possible cash offer"}, {"text": "YesShire PLC"}, {"text": "N/A"}], "entities": [{"type": "Company", "text": "YesShire PLC"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945508, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.824762, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Security", "relevance": 0.672196, "dbpedia_resource": "http://dbpedia.org/resource/Security"}], "categories": [{"score": 0.807281, "label": "/real estate/buying and selling homes"}, {"score": 0.764456, "label": "/finance/investing/funds/mutual funds"}, {"score": 0.755369, "label": "/finance/financial news"}], "relations": [], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.848095, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.690763, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.645889, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.637949, "count": 1}, {"text": "Full name of discloser", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.632136, "count": 1}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.630513, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.612733, "count": 1}, {"text": "offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597277, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.740284, "label": "negative"}, "relevance": 0.593487, "count": 2}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.576877, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573881, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.567425, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.567354, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.566652, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.564249, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563963, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561202, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.555905, "count": 1}, {"text": "DISCLOSURE", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.554905, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.5512, "count": 5}, {"text": "PERSON", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.551043, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.548087, "count": 1}, {"text": "offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547646, "count": 2}, {"text": "Interests", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.544582, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54326, "count": 1}, {"text": "disclosure Dealing Disclosure15/11/2018", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540502, "count": 1}, {"text": "Bank", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.538759, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.537861, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536018, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532656, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.528078, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526358, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525723, "count": 1}, {"text": "relevant securities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525613, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523425, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.522381, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517507, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512816, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512633, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.512321, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511421, "count": 1}, {"text": "Code", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.509187, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.499031, "count": 1}, {"text": "controller of interests", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.497197, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.496333, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.492573, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.48565, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.481823, "count": 1}, {"text": "vehicle companies", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.478283, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.470896, "count": 1}]}, "extracted_metadata": {"sha1": "085c6243bcc23de929e845af37d095dc08fd3959", "filename": "1542373925504.zip-fa6fd1eb5cdd61979601d9c4cce99887.xml", "file_type": "json"}, "title": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: Nachrichten zu Unterhaltung"}, {"id": "nomq9oBPB7kGKPB9z9ST6makTnDvfQG_yvQvjhhicDtDG74uqYiBxDQ9HkVUkXlv", "result_metadata": {"score": 36.473125}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.33, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "United States dollar", "relevance": 0.905949, "dbpedia_resource": "http://dbpedia.org/resource/United_States_dollar"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.712, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.854748, "label": "/finance/bank"}, {"score": 0.835532, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.626282, "label": "/finance/investing"}], "relations": [{"type": "employedBy", "sentence": "Takeda Pharmaceutical : Announces Issuance of Unsecured U.S. Dollar Denominated Senior Notes | MarketScreener", "score": 0.670825, "arguments": [{"text": "Dollar Denominated Senior", "location": [61, 86], "entities": [{"type": "Person", "text": "Dollar Denominated Senior"}]}, {"text": "U.S.", "location": [56, 60], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "agentOf", "sentence": "Takeda Pharmaceutical : Announces Issuance of Unsecured U.S. Dollar Denominated Senior Notes | MarketScreener", "score": 0.974926, "arguments": [{"text": "Dollar Denominated Senior", "location": [61, 86], "entities": [{"type": "Person", "text": "Dollar Denominated Senior"}]}, {"text": "Notes", "location": [87, 92], "entities": [{"type": "EventCommunication", "text": "Notes"}]}]}], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.989005, "count": 1}, {"text": "Issuance of Unsecured U.S. Dollar", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.737492, "count": 1}, {"text": "Senior Notes", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.110875, "count": 1}, {"text": "MarketScreener", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.030756, "count": 1}]}, "crawl_date": "2018-11-16T00:30:10Z", "url": "https://www.marketscreener.com/TAKEDA-PHARMACEUTICAL-CO-6491073/news/Takeda-Pharmaceutical-Announces-Issuance-of-Unsecured-U-S-Dollar-Denominated-Senior-Notes-27616815/", "host": "marketscreener.com", "text": "You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure. ### Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co.", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T00:00:00Z", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0.49769, "label": "positive"}, "text": "Takeda", "relevance": 0.774395, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company", "relevance": 0.665174, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 5, "sentiment": {"score": 0.222977, "label": "positive"}, "text": "Takeda", "relevance": 0.66309, "type": "Company"}, {"count": 8, "sentiment": {"score": 0.279812, "label": "positive"}, "text": "U.S.", "relevance": 0.45425, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.443367, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 6, "sentiment": {"score": 0.0777938, "label": "positive"}, "text": "Dealing Disclosures", "relevance": 0.429367, "type": "Company"}, {"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.427841, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.42183, "type": "Company"}, {"count": 2, "sentiment": {"score": 0.33526, "label": "positive"}, "text": "Notes", "relevance": 0.359454, "type": "Person"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "solicitation", "relevance": 0.31953, "type": "Crime"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.297077, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazumi Kobayashi", "relevance": 0.253732, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.639078, "label": "positive"}, "text": "Elissa Johnsen", "relevance": 0.251829, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tsuyoshi Tada", "relevance": 0.251109, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United Kingdom", "relevance": 0.234536, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.234391, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia", "relevance": 0.22515, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.22515, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Kazumi.Kobayashi@takeda.com", "relevance": 0.22515, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Elissa.Johnsen@takeda.com", "relevance": 0.22515, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tsuyoshi.Tada@takeda.com", "relevance": 0.22515, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "364-Day", "relevance": 0.22515, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "#", "relevance": 0.22515, "type": "Hashtag"}], "sentiment": {"document": {"score": 0.496367, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company or ' Takeda ')", "keywords": [{"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"type": "Company", "text": "Takeda"}]}, "sentence": " Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company or ' Takeda ') announces that it has today, November 15, 2018 (London time), launched the offering of its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ').", "object": {"text": "that it has today"}, "action": {"verb": {"text": "announce", "tense": "present"}, "text": "announces", "normalized": "announce"}}, {"subject": {"text": "it"}, "sentence": " Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company or ' Takeda ') announces that it has today, November 15, 2018 (London time), launched the offering of its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ').", "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "it"}, "sentence": " Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company or ' Takeda ') announces that it has today, November 15, 2018 (London time), launched the offering of its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ').", "object": {"text": "the offering of its unsecured U.S. dollar", "keywords": [{"text": "unsecured U.S. dollar"}, {"text": "offering"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "US", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "action": {"verb": {"text": "launch", "tense": "past"}, "text": "launched", "normalized": "launch"}}, {"subject": {"text": "The Notes", "keywords": [{"text": "Notes"}], "entities": [{"type": "Person", "text": "Notes"}]}, "sentence": " The Notes will be issued to investors to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018).", "object": {"text": "to investors", "keywords": [{"text": "investors"}]}, "action": {"verb": {"text": "issue", "tense": "future"}, "text": "will be issued", "normalized": "will be issue"}}, {"subject": {"text": "a portion of the funds necessary", "keywords": [{"text": "portion"}, {"text": "funds"}]}, "sentence": " The Notes will be issued to investors to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018).", "object": {"text": "for the acquisition of Shire plc (the ' Acquisition ')", "keywords": [{"text": "Shire plc"}, {"text": "acquisition"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "action": {"verb": {"text": "finance", "tense": "future"}, "text": "to finance", "normalized": "to finance"}}, {"subject": {"text": "commitments", "keywords": [{"text": "commitments"}]}, "sentence": " The Notes will be issued to investors to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018).", "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "reduce", "normalized": "reduce"}}, {"subject": {"text": "A description of the Notes", "keywords": [{"text": "description"}, {"text": "Notes"}], "entities": [{"type": "Person", "text": "Notes"}]}, "sentence": " A description of the Notes is set out below.", "object": {"text": "set out below"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the Notes", "keywords": [{"text": "Notes"}], "entities": [{"type": "Person", "text": "Notes"}]}, "sentence": " In accordance with Rule 26 of the City Code on Takeovers and Mergers, a copy of the preliminary offering circular in respect of the Notes will be available to view on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the publication thereof.", "object": {"text": "available to view on Takeda's website at www.takeda.com/investors/offer-for-shire", "keywords": [{"text": "Takeda"}, {"text": "website"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "will be", "normalized": "will be"}}, {"subject": {"text": "Senior Notes", "keywords": [{"text": "Senior Notes"}]}, "sentence": " Unsecured US$ Denominated Senior Notes", "object": {"text": "Unsecured US", "entities": [{"type": "Person", "text": "Notes"}]}, "action": {"verb": {"text": "Denominated", "tense": "past"}, "text": "Denominated", "normalized": "Denominated"}}, {"subject": {"text": "the U.S., Europe and Asia with registration rights", "keywords": [{"text": "registration rights"}, {"text": "U.S."}, {"text": "Europe"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "object": {"text": "Private offering in foreign markets", "keywords": [{"text": "Private offering"}, {"text": "foreign markets"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The Notes", "keywords": [{"text": "Notes"}]}, "sentence": " The Notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the U.S. Securities Act of 1933, as amended (the ' Securities Act ').", "action": {"verb": {"text": "sell", "tense": "future"}, "text": "will not be offered or sold", "normalized": "will not be offer or sell"}}, {"subject": {"text": "by Rule 144A", "keywords": [{"text": "Rule 144A"}]}, "sentence": " The Notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the U.S. Securities Act of 1933, as amended (the ' Securities Act ').", "object": {"text": "registration", "keywords": [{"text": "registration"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "provided", "normalized": "provide"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the issuance of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "been prepared to publicly disclose the issuance of the Notes", "keywords": [{"text": "issuance"}, {"text": "Notes"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the issuance of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "prepared to publicly disclose the issuance of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan", "keywords": [{"text": "issuance"}, {"text": "solicitation"}, {"text": "offer"}, {"text": "securities"}], "entities": [{"type": "Crime", "text": "solicitation"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the issuance of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "to publicly disclose the issuance of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan", "keywords": [{"text": "issuance"}, {"text": "solicitation"}, {"text": "offer"}, {"text": "securities"}], "entities": [{"type": "Crime", "text": "solicitation"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "prepare", "tense": "past"}, "text": "prepared", "normalized": "prepare"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the issuance of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "the issuance of the Notes", "keywords": [{"text": "issuance"}, {"text": "Notes"}]}, "action": {"verb": {"text": "disclose", "tense": "present"}, "text": "disclose", "normalized": "disclose"}}, {"subject": {"text": "This document", "keywords": [{"text": "document"}]}, "sentence": " Note: This document has been prepared to publicly disclose the issuance of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "object": {"text": "an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan", "keywords": [{"text": "solicitation"}, {"text": "securities"}, {"text": "offer"}, {"text": "U.S."}], "entities": [{"type": "Crime", "text": "solicitation"}, {"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}]}, "action": {"verb": {"text": "constitute", "tense": "present", "negated": true}, "text": "constitute", "normalized": "constitute"}}, {"subject": {"text": "any securities", "keywords": [{"text": "securities"}]}, "sentence": " Note: This document has been prepared to publicly disclose the issuance of the Notes, and does not constitute an offer to sell or a solicitation of an offer to buy any securities in or outside of the U.S. or Japan.", "action": {"verb": {"text": "buy", "tense": "future"}, "text": "to buy", "normalized": "to buy"}}, {"subject": {"text": "The securities", "keywords": [{"text": "securities"}]}, "sentence": " The securities set forth above have not been and will not be registered under the Securities Act, and may not be offered or sold in the U.S. absent registration or an applicable exemption from the registration requirements of the Securities Act.", "object": {"text": "registered under the Securities Act", "keywords": [{"text": "Securities Act"}]}, "action": {"verb": {"text": "be", "tense": "future", "negated": true}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The securities", "keywords": [{"text": "securities"}]}, "sentence": " The securities set forth above have not been and will not be registered under the Securities Act, and may not be offered or sold in the U.S. absent registration or an applicable exemption from the registration requirements of the Securities Act.", "action": {"verb": {"text": "register", "tense": "future", "negated": true}, "text": "registered", "normalized": "register"}}, {"subject": {"text": "Takeda Pharmaceutical Company Limited ( TSE: 4502 )", "keywords": [{"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Takeda Pharmaceutical Company", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "a global, research and development-driven pharmaceutical company", "keywords": [{"text": "development-driven pharmaceutical company"}, {"text": "research"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "research and development-driven pharmaceutical company", "keywords": [{"text": "development-driven pharmaceutical company"}, {"text": "research"}], "entities": []}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "better health", "keywords": [{"text": "health"}]}, "action": {"verb": {"text": "bring", "tense": "future"}, "text": "bringing", "normalized": "bring"}}, {"subject": {"text": "research and development-driven pharmaceutical company", "keywords": [{"text": "development-driven pharmaceutical company"}, {"text": "research"}], "entities": []}, "sentence": " Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "object": {"text": "science", "keywords": [{"text": "science"}]}, "action": {"verb": {"text": "translate", "tense": "present"}, "text": "translating", "normalized": "translate"}}, {"subject": {"text": "Takeda", "keywords": [{"text": "Takeda"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation.", "object": {"text": "R&D both", "keywords": [{"text": "R&D"}]}, "action": {"verb": {"text": "conduct", "tense": "present"}, "text": "conducts", "normalized": "conduct"}}, {"subject": {"text": "Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets,", "keywords": [{"text": "Innovative products"}, {"text": "Takeda"}, {"text": "gastroenterology"}, {"text": "oncology"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "sentence": " Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets, are currently fueling the growth of Takeda.", "object": {"text": "currently fueling the growth of Takeda", "keywords": [{"text": "Takeda"}, {"text": "growth"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "the growth of Takeda", "keywords": [{"text": "Takeda"}, {"text": "growth"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets, are currently fueling the growth of Takeda.", "object": {"text": "Innovative products, especially in oncology and gastroenterology, as well as Takeda's presence in emerging markets,", "keywords": [{"text": "Innovative products"}, {"text": "Takeda"}, {"text": "gastroenterology"}, {"text": "oncology"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "fuel", "tense": "present"}, "text": "fueling", "normalized": "fuel"}}, {"subject": {"text": "Approximately 30,000 Takeda employees", "keywords": [{"text": "Takeda employees"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "object": {"text": "committed to improving quality of life", "keywords": [{"text": "quality"}, {"text": "life"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Approximately 30,000 Takeda employees", "keywords": [{"text": "Takeda employees"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "object": {"text": "to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries", "keywords": [{"text": "health care"}, {"text": "Takeda"}, {"text": "quality"}, {"text": "life"}], "entities": [{"type": "Person", "text": "Takeda"}]}, "action": {"verb": {"text": "commit", "tense": "past"}, "text": "are committed", "normalized": "be commit"}}, {"subject": {"text": "Approximately 30,000 Takeda employees", "keywords": [{"text": "Takeda employees"}], "entities": [{"type": "Company", "text": "Takeda"}]}, "sentence": " Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "object": {"text": "quality of life", "keywords": [{"text": "quality"}, {"text": "life"}]}, "action": {"verb": {"text": "improve", "tense": "future"}, "text": "improving", "normalized": "improve"}}, {"subject": {"text": "by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions", "keywords": [{"text": "possession"}, {"text": "restrictions"}, {"text": "regulation"}, {"text": "announcement"}]}, "sentence": " The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "object": {"text": "The distribution of this announcement in jurisdictions outside the United Kingdom or Japan", "keywords": [{"text": "jurisdictions"}, {"text": "United Kingdom"}, {"text": "announcement"}, {"text": "distribution"}], "entities": [{"type": "Location", "text": "United Kingdom", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "restrict", "tense": "future"}, "text": "may be restricted", "normalized": "may be restrict"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "object": {"text": "into possession of this announcement", "keywords": [{"text": "possession"}, {"text": "announcement"}]}, "action": {"verb": {"text": "come", "tense": "present"}, "text": "comes", "normalized": "come"}}, {"subject": {"text": "any person who comes into possession of this announcement", "keywords": [{"text": "possession"}, {"text": "announcement"}, {"text": "person"}]}, "sentence": " The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "object": {"text": "themselves"}, "action": {"verb": {"text": "inform", "tense": "future"}, "text": "should inform", "normalized": "should inform"}}, {"subject": {"text": "Any failure to comply with such restrictions", "keywords": [{"text": "restrictions"}, {"text": "failure"}]}, "sentence": " Any failure to comply with such restrictions may constitute a violation of the securities laws or regulations of any such relevant jurisdiction.", "object": {"text": "a violation of the securities laws or regulations of any such relevant jurisdiction", "keywords": [{"text": "relevant jurisdiction"}, {"text": "securities laws"}, {"text": "violation"}, {"text": "regulations"}]}, "action": {"verb": {"text": "constitute", "tense": "future"}, "text": "may constitute", "normalized": "may constitute"}}, {"subject": {"text": "a copy of this announcement", "keywords": [{"text": "announcement"}, {"text": "copy"}]}, "sentence": " In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the date of this announcement.", "object": {"text": "made available (subject to certain restrictions relating to persons resident in restricted jurisdictions", "keywords": [{"text": "certain restrictions"}, {"text": "restricted jurisdictions"}, {"text": "persons resident"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "a copy of this announcement", "keywords": [{"text": "announcement"}, {"text": "copy"}]}, "sentence": " In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the date of this announcement.", "object": {"text": "available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time)", "keywords": [{"text": "(London time)"}, {"text": "restricted jurisdictions"}, {"text": "certain restrictions"}, {"text": "persons resident"}], "entities": [{"type": "Company", "text": "Takeda"}, {"type": "Location", "text": "London", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "OlympicHostCity", "PlaceWithNeighborhoods", "CityTown", "City"], "name": "London", "dbpedia_resource": "http://dbpedia.org/resource/London"}}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "will be made", "normalized": "will be make"}}, {"subject": {"text": "The content of the website", "keywords": [{"text": "content"}, {"text": "website"}]}, "sentence": " The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.", "object": {"text": "to in this announcement", "keywords": [{"text": "announcement"}]}, "action": {"verb": {"text": "refer", "tense": "past"}, "text": "referred", "normalized": "refer"}}, {"subject": {"text": "The content of the website", "keywords": [{"text": "content"}, {"text": "website"}]}, "sentence": " The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.", "object": {"text": "not form part of this announcement", "keywords": [{"text": "announcement"}]}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "does", "normalized": "do"}}, {"subject": {"text": "The content of the website", "keywords": [{"text": "content"}, {"text": "website"}]}, "sentence": " The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.", "object": {"text": "part of this announcement", "keywords": [{"text": "announcement"}]}, "action": {"verb": {"text": "form", "tense": "present", "negated": true}, "text": "form", "normalized": "form"}}, {"subject": {"text": "it"}, "sentence": " Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.", "object": {"text": "announced that its offer", "keywords": [{"text": "offer"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash)", "keywords": [{"text": "securities exchange offeror"}, {"text": "relevant securities"}, {"text": "offeree company"}, {"text": "respect"}], "entities": [{"type": "Quantity", "text": "1"}]}, "sentence": " Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.", "object": {"text": "an Opening Position Disclosure", "keywords": [{"text": "Opening Position Disclosure"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must make", "normalized": "must make"}}, {"subject": {"text": "an Opening Position Disclosure", "keywords": [{"text": "Opening Position Disclosure"}]}, "sentence": " Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any securities exchange offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any securities exchange offeror is first identified.", "object": {"text": "the commencement of the offer period", "keywords": [{"text": "commencement"}, {"text": "offer period"}]}, "action": {"verb": {"text": "follow", "tense": "present"}, "text": "following", "normalized": "follow"}}, {"subject": {"text": "An Opening Position Disclosure", "keywords": [{"text": "Opening Position"}, {"text": "Disclosure"}]}, "sentence": " An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s).", "object": {"text": "details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s)", "keywords": [{"text": "securities exchange offeror"}, {"text": "relevant securities"}, {"text": "short positions"}, {"text": "offeree company"}]}, "action": {"verb": {"text": "contain", "tense": "future"}, "text": "must contain", "normalized": "must contain"}}, {"subject": {"text": "by no later than 3.30 pm (London time)", "keywords": [{"text": "London time"}, {"text": "pm"}], "entities": [{"type": "Location", "text": "London", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified.", "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "any securities exchange offeror", "keywords": [{"text": "securities exchange offeror"}]}, "sentence": " An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified.", "object": {"text": "first identified"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "any securities exchange offeror", "keywords": [{"text": "securities exchange offeror"}]}, "sentence": " An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any securities exchange offeror is first identified.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "Relevant persons", "keywords": [{"text": "Relevant persons"}]}, "sentence": " Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.", "object": {"text": "in the relevant securities of the offeree company or of a securities exchange offeror", "keywords": [{"text": "securities exchange offeror"}, {"text": "relevant securities"}, {"text": "offeree company"}]}, "action": {"verb": {"text": "deal", "tense": "present"}, "text": "deal", "normalized": "deal"}}, {"subject": {"text": "Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure", "keywords": [{"text": "Opening Position Disclosure"}, {"text": "securities exchange offeror"}, {"text": "relevant securities"}, {"text": "offeree company"}]}, "sentence": " Relevant persons who deal in the relevant securities of the offeree company or of a securities exchange offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.", "object": {"text": "a Dealing Disclosure", "keywords": [{"text": "Dealing Disclosure"}], "entities": [{"type": "Company", "text": "Dealing Disclosures"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must instead make", "normalized": "must instead make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror.", "object": {"text": "1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror", "keywords": [{"text": "securities exchange offeror"}, {"text": "relevant securities"}, {"text": "offeree company"}, {"text": "class"}], "entities": [{"type": "Quantity", "text": "1"}]}, "action": {"verb": {"text": "become", "tense": "present"}, "text": "becomes", "normalized": "become"}}, {"subject": {"text": "any securities exchange offeror", "keywords": [{"text": "securities exchange offeror"}]}, "sentence": " Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any securities exchange offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any securities exchange offeror.", "object": {"text": "a Dealing Disclosure", "keywords": [{"text": "Dealing Disclosure"}], "entities": [{"type": "Company", "text": "Dealing Disclosures"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must make", "normalized": "must make"}}, {"subject": {"text": "A Dealing Disclosure", "keywords": [{"text": "Disclosure"}], "entities": [{"type": "Company", "text": "Dealing Disclosures"}]}, "sentence": " A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any securities exchange offeror(s), save to the extent that these details have previously been disclosed under Rule 8.", "object": {"text": "details of the dealing concerned and of the person's interests and short positions in", "keywords": [{"text": "short positions"}, {"text": "person"}, {"text": "details"}, {"text": "interests"}]}, "action": {"verb": {"text": "contain", "tense": "future"}, "text": "must contain", "normalized": "must contain"}}], "concepts": [{"text": "Securities Act of 1933", "relevance": 0.973675, "dbpedia_resource": "http://dbpedia.org/resource/Securities_Act_of_1933"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.84105, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "U.S. Securities and Exchange Commission", "relevance": 0.835678, "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"}, {"text": "Offer and acceptance", "relevance": 0.821178, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}], "categories": [{"score": 0.910969, "label": "/finance/financial news"}, {"score": 0.89823, "label": "/real estate/buying and selling homes"}, {"score": 0.849922, "label": "/law, govt and politics"}], "relations": [{"type": "employedBy", "sentence": "NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Takeda Pharmaceutical Company Limited (TSE: 4502) (the ' Company or ' Takeda ') announces that it has today, November 15, 2018 (London time), launched the offering of its unsecured U.S. dollar (' US$ ') denominated senior notes (the ' Notes ').", "score": 0.523431, "arguments": [{"text": "Takeda", "location": [267, 273], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Company", "location": [254, 261], "entities": [{"type": "Organization", "text": "Securities Act of"}]}]}, {"type": "managerOf", "sentence": "Media and Investor Contacts : Takeda ( Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda ( Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.315032, "arguments": [{"text": "Takeda", "location": [2342, 2348], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Media -", "location": [2351, 2358], "entities": [{"type": "Organization", "text": "Media -"}]}]}, {"type": "locatedAt", "sentence": "Media and Investor Contacts : Takeda ( Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda ( Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.350646, "arguments": [{"text": "Media -", "location": [2351, 2358], "entities": [{"type": "Organization", "text": "Media -"}]}, {"text": "Japan", "location": [2366, 2371], "entities": [{"type": "GeopoliticalEntity", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "employedBy", "sentence": "Media and Investor Contacts : Takeda ( Media - inside Japan) Kazumi Kobayashi Kazumi.Kobayashi@takeda.com +81 3 3278 2095 Takeda ( Media - outside Japan) Tsuyoshi Tada Tsuyoshi.Tada@takeda.com +1 617 551 2933 Elissa Johnsen Elissa.Johnsen@takeda.com +1 312 285 3203 About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited ( TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines.", "score": 0.366621, "arguments": [{"text": "Takeda", "location": [2434, 2440], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "Media", "location": [2443, 2448], "entities": [{"type": "Organization", "text": "Media -"}]}]}, {"type": "colleague", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.265518, "arguments": [{"text": "Takeda", "location": [3246, 3252], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "employees", "location": [3253, 3262], "entities": [{"type": "Person", "text": "employees"}]}]}, {"type": "managerOf", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.547182, "arguments": [{"text": "Takeda", "location": [3333, 3339], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "partners", "location": [3342, 3350], "entities": [{"type": "Organization", "text": "partners"}]}]}, {"type": "locatedAt", "sentence": "Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda's partners in health care in more than 70 countries.", "score": 0.439521, "arguments": [{"text": "partners", "location": [3342, 3350], "entities": [{"type": "Organization", "text": "partners"}]}, {"text": "countries", "location": [3382, 3391], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "score": 0.669947, "arguments": [{"text": "who", "location": [3912, 3915], "entities": [{"type": "Person", "text": "person"}]}, {"text": "announcement", "location": [3946, 3958], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "partOfMany", "sentence": "The distribution of this announcement in jurisdictions outside the United Kingdom or Japan may be restricted by law or regulation and therefore any person who comes into possession of this announcement should inform themselves about, and comply with, such restrictions.", "score": 0.714252, "arguments": [{"text": "who", "location": [3912, 3915], "entities": [{"type": "Person", "text": "person"}]}, {"text": "themselves", "location": [3973, 3983], "entities": [{"type": "Person", "text": "themselves"}]}]}, {"type": "partOf", "sentence": "Publication on Website In accordance with Rule 26.1 of the Code, a copy of this announcement will be made available (subject to certain restrictions relating to persons resident in restricted jurisdictions) on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the date of this announcement.", "score": 0.576713, "arguments": [{"text": "Rule", "location": [4214, 4218], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "Code", "location": [4231, 4235], "entities": [{"type": "Organization", "text": "Code"}]}]}, {"type": "hasAttribute", "sentence": "If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a securities exchange offeror, they will be deemed to be a single person for the purpose of Rule 8.3.", "score": 0.824036, "arguments": [{"text": "Rule", "location": [7148, 7152], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "8.3", "location": [7153, 7156], "entities": [{"type": "Money", "text": "8.3", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "affectedBy", "sentence": "The Notes will be issued to investors to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018).", "score": 0.813219, "arguments": [{"text": "Shire plc", "location": [547, 556], "entities": [{"type": "Organization", "text": "Securities Act of"}]}, {"text": "acquisition", "location": [532, 543], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "participantIn", "sentence": "Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).", "score": 0.508911, "arguments": [{"text": "persons", "location": [7339, 7346], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "concert", "location": [7357, 7364], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified.", "score": 0.457967, "arguments": [{"text": "whose", "location": [7471, 7476], "entities": [{"type": "Person", "text": "whose"}]}, {"text": "companies", "location": [7447, 7456], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "You should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure.", "score": 0.457452, "arguments": [{"text": "Panel", "location": [7818, 7823], "entities": [{"type": "Organization", "text": "Panel"}]}, {"text": "Market Surveillance Unit", "location": [7826, 7850], "entities": [{"type": "Facility", "text": "Market Surveillance Unit"}]}]}, {"type": "agentOf", "sentence": "### Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 16 November 2018 and is solely responsible for the information contained herein.", "score": 0.982494, "arguments": [{"text": "Takeda Pharmaceutical Co. Ltd.", "location": [8048, 8078], "entities": [{"type": "Person", "text": "Takeda Pharmaceutical Co. Ltd."}]}, {"text": "published", "location": [8079, 8088], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "### Attachments Original document Permalink Disclaimer Takeda Pharmaceutical Co. Ltd. published this content on 16 November 2018 and is solely responsible for the information contained herein.", "score": 0.639173, "arguments": [{"text": "November 2018", "location": [8108, 8121], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [8079, 8088], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "agentOf", "sentence": "The Notes will be issued to investors to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018).", "score": 0.539611, "arguments": [{"text": "Acquisition", "location": [680, 691], "entities": [{"type": "Organization", "text": "Acquisition", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisition", "location": [532, 543], "entities": [{"type": "EventBusiness", "text": "acquisition"}]}]}, {"type": "partOf", "sentence": "The Notes will be issued to investors to finance a portion of the funds necessary for the acquisition of Shire plc (the ' Acquisition ') and reduce commitments under the 364-Day Bridge Credit Agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and October 26, 2018).", "score": 0.517602, "arguments": [{"text": "Bridge Credit Agreement", "location": [620, 643], "entities": [{"type": "Organization", "text": "Bridge Credit Agreement"}]}, {"text": "Acquisition", "location": [680, 691], "entities": [{"type": "Organization", "text": "Acquisition", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "In accordance with Rule 26 of the City Code on Takeovers and Mergers, a copy of the preliminary offering circular in respect of the Notes will be available to view on Takeda's website at www.takeda.com/investors/offer-for-shire by no later than 12 noon (London time) on the business day following the publication thereof.", "score": 0.422861, "arguments": [{"text": "Rule", "location": [822, 826], "entities": [{"type": "Organization", "text": "Code\nUnder Rule"}]}, {"text": "City Code", "location": [837, 846], "entities": [{"type": "GeopoliticalEntity", "text": "City Code"}]}]}, {"type": "agentOf", "sentence": "Description of the Notes (a) Types of Notes Unsecured US$ Denominated Senior Notes (b) Maturity Unsecured US$ Denominated Senior Notes due 2020, 2021, 2023 and 2028 (c) Offering Method Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.986445, "arguments": [{"text": "Maturity\nUnsecured US$ Denominated Senior", "location": [1393, 1434], "entities": [{"type": "Person", "text": "Maturity\nUnsecured US$ Denominated Senior"}]}, {"text": "Notes", "location": [1435, 1440], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "Description of the Notes (a) Types of Notes Unsecured US$ Denominated Senior Notes (b) Maturity Unsecured US$ Denominated Senior Notes due 2020, 2021, 2023 and 2028 (c) Offering Method Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.817329, "arguments": [{"text": "2020, 2021", "location": [1445, 1455], "entities": [{"type": "Date", "text": "2020, 2021"}]}, {"text": "Notes", "location": [1435, 1440], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "timeOf", "sentence": "Description of the Notes (a) Types of Notes Unsecured US$ Denominated Senior Notes (b) Maturity Unsecured US$ Denominated Senior Notes due 2020, 2021, 2023 and 2028 (c) Offering Method Private offering in foreign markets including the U.S., Europe and Asia with registration rights.", "score": 0.508481, "arguments": [{"text": "2023", "location": [1457, 1461], "entities": [{"type": "Date", "text": "2023"}]}, {"text": "Notes", "location": [1435, 1440], "entities": [{"type": "EventCommunication", "text": "announcement"}]}]}, {"type": "residesIn", "sentence": "The Notes will not be offered or sold within the U.S. or to U.S. persons, except to 'qualified institutional buyers' in reliance on the exemption from registration provided by Rule 144A under the U.S. Securities Act of 1933, as amended (the ' Securities Act ').", "score": 0.640093, "arguments": [{"text": "persons", "location": [1654, 1661], "entities": [{"type": "Person", "text": "persons"}]}, {"text": "U.S.", "location": [1649, 1653], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "U.S. Securities Act", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.656046, "count": 1}, {"text": "Takeda", "sentiment": {"score": 0.499833, "mixed": "1", "label": "positive"}, "relevance": 0.647344, "count": 5}, {"text": "Takeda's website", "sentiment": {"score": 0.566196, "label": "positive"}, "relevance": 0.632012, "count": 2}, {"text": "Disclosure requirements of the Code", "sentiment": {"score": 0.734496, "label": "positive"}, "relevance": 0.619343, "count": 1}, {"text": "U.S. persons", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.61567, "count": 1}, {"text": "securities exchange offeror", "sentiment": {"score": 0.648153, "label": "positive"}, "relevance": 0.602255, "count": 9}, {"text": "takeda", "sentiment": {"score": 0.566196, "label": "positive"}, "relevance": 0.59987, "count": 2}, {"text": "Opening Position Disclosure", "sentiment": {"score": 0.445066, "mixed": "1", "label": "positive"}, "relevance": 0.597441, "count": 5}, {"text": "senior notes", "sentiment": {"score": -0.903215, "label": "negative"}, "relevance": 0.582957, "count": 1}, {"text": "Company", "sentiment": {"score": -0.903215, "label": "negative"}, "relevance": 0.57936, "count": 1}, {"text": "VIOLATION OF THE RELEVANT LAWS", "sentiment": {"score": -0.903215, "label": "negative"}, "relevance": 0.575004, "count": 1}, {"text": "person", "sentiment": {"score": 0.569774, "label": "positive"}, "relevance": 0.573659, "count": 5}, {"text": "Securities Act", "sentiment": {"score": 0.385966, "label": "positive"}, "relevance": 0.5643, "count": 2}, {"text": "securities", "sentiment": {"score": 0.532591, "label": "positive"}, "relevance": 0.562479, "count": 3}, {"text": "London time", "sentiment": {"score": 0.376588, "mixed": "1", "label": "positive"}, "relevance": 0.561679, "count": 6}, {"text": "offer", "sentiment": {"score": 0.574052, "label": "positive"}, "relevance": 0.558923, "count": 4}, {"text": "pharmaceutical company", "sentiment": {"score": 0.830814, "label": "positive"}, "relevance": 0.557093, "count": 1}, {"text": "Notes", "sentiment": {"score": -0.486306, "mixed": "1", "label": "negative"}, "relevance": 0.556592, "count": 3}, {"text": "unsecured U.S. dollar", "sentiment": {"score": -0.903215, "label": "negative"}, "relevance": 0.551493, "count": 1}, {"text": "Rule", "sentiment": {"score": 0.559597, "label": "positive"}, "relevance": 0.551361, "count": 5}, {"text": "shareholders of both companies", "sentiment": {"score": 0.822383, "label": "positive"}, "relevance": 0.548635, "count": 1}, {"text": "Dealing Disclosure", "sentiment": {"score": 0.391324, "mixed": "1", "label": "positive"}, "relevance": 0.54857, "count": 5}, {"text": "foreign markets", "sentiment": {"score": 0.867016, "label": "positive"}, "relevance": 0.54821, "count": 1}, {"text": "announcement", "sentiment": {"score": 0.527843, "mixed": "1", "label": "positive"}, "relevance": 0.540213, "count": 5}, {"text": "registration rights", "sentiment": {"score": 0.867016, "label": "positive"}, "relevance": 0.538744, "count": 1}, {"text": "acquisition of Shire plc", "sentiment": {"score": 0.532368, "label": "positive"}, "relevance": 0.536226, "count": 1}, {"text": "Website", "sentiment": {"score": 0.356816, "label": "positive"}, "relevance": 0.534491, "count": 1}, {"text": "City Code", "sentiment": {"score": 0.72997, "label": "positive"}, "relevance": 0.534029, "count": 1}, {"text": "364-Day Bridge Credit Agreement", "sentiment": {"score": 0.532368, "label": "positive"}, "relevance": 0.533108, "count": 1}, {"text": "better health", "sentiment": {"score": 0.830814, "label": "positive"}, "relevance": 0.532768, "count": 1}, {"text": "Code", "sentiment": {"score": 0.572035, "label": "positive"}, "relevance": 0.530027, "count": 3}, {"text": "details of the person", "sentiment": {"score": 0.530035, "label": "positive"}, "relevance": 0.529868, "count": 1}, {"text": "offeror", "sentiment": {"score": 0.401749, "mixed": "1", "label": "positive"}, "relevance": 0.526998, "count": 5}, {"text": "investors", "sentiment": {"score": 0.555041, "label": "positive"}, "relevance": 0.526759, "count": 3}, {"text": "Acquisition", "sentiment": {"score": 0.625261, "label": "positive"}, "relevance": 0.526613, "count": 3}, {"text": "www", "sentiment": {"score": 0.709827, "label": "positive"}, "relevance": 0.526416, "count": 3}, {"text": "respect", "sentiment": {"score": 0.734496, "label": "positive"}, "relevance": 0.526047, "count": 1}, {"text": "JURISDICTION", "sentiment": {"score": -0.903215, "label": "negative"}, "relevance": 0.525472, "count": 1}, {"text": "jurisdictions", "sentiment": {"score": 0.356816, "label": "positive"}, "relevance": 0.525472, "count": 2}, {"text": "respect of the Notes", "sentiment": {"score": 0.72997, "label": "positive"}, "relevance": 0.525248, "count": 1}, {"text": "brighter future", "sentiment": {"score": 0.830814, "label": "positive"}, "relevance": 0.523805, "count": 1}, {"text": "accordance", "sentiment": {"score": 0.566196, "label": "positive"}, "relevance": 0.52354, "count": 2}, {"text": "regulations of any such relevant jurisdiction", "sentiment": {"score": -0.37822, "mixed": "1", "label": "negative"}, "relevance": 0.523447, "count": 1}, {"text": "persons resident", "sentiment": {"score": 0.356816, "label": "positive"}, "relevance": 0.52317, "count": 1}, {"text": "markets", "sentiment": {"score": 0.709983, "label": "positive"}, "relevance": 0.522722, "count": 1}, {"text": "copy of the preliminary offering", "sentiment": {"score": 0.72997, "label": "positive"}, "relevance": 0.522387, "count": 1}, {"text": "Rule 144A", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52124, "count": 1}, {"text": "Innovative products", "sentiment": {"score": 0.709983, "label": "positive"}, "relevance": 0.521086, "count": 1}, {"text": "United Kingdom", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520927, "count": 1}, {"text": "offeree company", "sentiment": {"score": 0.440204, "mixed": "1", "label": "positive"}, "relevance": 0.520921, "count": 4}]}, "extracted_metadata": {"sha1": "9315ad4c31e927daea796d1d0be60c230e105f28", "filename": "1542328210859.zip-de6dff4d3a1d2b5de7afb08ecd62688a.xml", "file_type": "json"}, "external_links": ["https://www.takeda.com/newsroom/newsreleases/2018/takeda-announces-issuance-of-unsecured-u.s2.-dollar-denominated-senior-notes/", "https://www.takeda.com/investors/", "http://www.publicnow.com/view/68D8A1D90C2DE67E96C312870374487EC50E8139", "https://www.takeda.com/investors/offer-for-shire/", "https://www.takeda.com/newsroom/"], "title": "Takeda Pharmaceutical : Announces Issuance of Unsecured U.S. Dollar Denominated Senior Notes | MarketScreener", "forum_title": "Stock market news - Company News  - MarketScreener.com"}, {"id": "V-3kytVcz6uGUcCmmKAobBoSYlWXISH_5kNGsyr1Bt2E98aOGQ_qeZMMplhkvitk", "result_metadata": {"score": 35.976513}, "author": "Shashii Pawar", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.684357, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Oral Solid Dosage Pharmaceutical Formulation Market", "keywords": [{"text": "Dosage Pharmaceutical Formulation"}, {"text": "Market"}]}, "sentence": "Oral Solid Dosage Pharmaceutical Formulation Market is Forecasted to Reach a Figure of US$ 926.3 Bn by 2027", "object": {"text": "Forecasted to Reach a Figure of US$ 926.3 Bn", "keywords": [{"text": "Bn"}, {"text": "Figure"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Oral Solid Dosage Pharmaceutical Formulation Market", "keywords": [{"text": "Dosage Pharmaceutical Formulation"}, {"text": "Market"}]}, "sentence": "Oral Solid Dosage Pharmaceutical Formulation Market is Forecasted to Reach a Figure of US$ 926.3 Bn by 2027", "object": {"text": "a Figure of US$ 926.3 Bn", "keywords": [{"text": "Bn"}, {"text": "Figure"}]}, "action": {"verb": {"text": "Reach", "tense": "future"}, "text": "is Forecasted to Reach", "normalized": "be Forecasted to Reach"}}], "concepts": [{"text": "Pharmaceutical formulation", "relevance": 0.895888, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_formulation"}], "categories": [{"score": 0.924423, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.731851, "label": "/health and fitness"}, {"score": 0.704034, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Figure of US", "sentiment": {"score": 0.684357, "label": "positive"}, "relevance": 0.690466, "count": 1}, {"text": "Oral Solid Dosage Pharmaceutical Formulation Market", "sentiment": {"score": 0.684357, "label": "positive"}, "relevance": 0.539257, "count": 1}, {"text": "Bn", "sentiment": {"score": 0.684357, "label": "positive"}, "relevance": 0.276949, "count": 1}]}, "crawl_date": "2018-11-16T12:03:22Z", "url": "https://www.findmarketresearch.org/2018/11/oral-solid-dosage-pharmaceutical-formulation-market-is-forecasted-to-reach-a-figure-of-us-926-3-bn-by-2027/", "host": "findmarketresearch.org", "text": "Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T10:25:00+05:00", "enriched_text": {"entities": [{"count": 14, "sentiment": {"score": -0.254085, "label": "negative"}, "text": "Market", "relevance": 0.890677, "type": "Company"}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mn", "relevance": 0.409573, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 5, "sentiment": {"score": 0.0984138, "label": "positive"}, "text": "North America", "relevance": 0.290873, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 5, "sentiment": {"score": 0.566872, "label": "positive"}, "text": "Latin America", "relevance": 0.28518, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "FMI", "relevance": 0.254282, "type": "Organization", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}, {"count": 3, "sentiment": {"score": -0.625144, "label": "negative"}, "text": "APEJ", "relevance": 0.241942, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": -0.548104, "label": "negative"}, "text": "Japan", "relevance": 0.21719, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Otsuka Pharmaceutical Co.", "relevance": 0.186119, "type": "Company", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"count": 1, "sentiment": {"score": -0.522212, "label": "negative"}, "text": "Hospital pharmacy", "relevance": 0.18216, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.180258, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": -0.530235, "label": "negative"}, "text": "diabetes", "relevance": 0.175494, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Europe", "relevance": 0.170379, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.167862, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.166052, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gilead Sciences", "relevance": 0.161513, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Gilead Sciences", "dbpedia_resource": "http://dbpedia.org/resource/Gilead_Sciences"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.160377, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.156405, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.153568, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.153324, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.1525, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": -0.206781, "label": "negative"}, "text": "Bayer AG", "relevance": 0.152086, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma Inc", "relevance": 0.151295, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biogen Inc.", "relevance": 0.146166, "type": "Company", "disambiguation": {"subtype": [], "name": "Biogen Idec", "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc.", "relevance": 0.144297, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.249578, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.144229, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.143209, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgene Corporation", "relevance": 0.142318, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.141684, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0.571628, "label": "positive"}, "text": "Korea", "relevance": 0.140825, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "Country"], "name": "Korea", "dbpedia_resource": "http://dbpedia.org/resource/Korea"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceticals", "relevance": 0.134928, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.126195, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hoffman-La-Roche Ltd.", "relevance": 0.126052, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc.", "relevance": 0.124704, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.120041, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.571628, "label": "positive"}, "text": "India", "relevance": 0.116975, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.1%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.4%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.5%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "7.4%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.2%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.116975, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.550399, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "oral solid dosage forms", "keywords": [{"text": "oral solid dosage"}]}, "sentence": "Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential.", "object": {"text": "substantial opportunity", "keywords": [{"text": "substantial opportunity"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "hold", "normalized": "hold"}}, {"subject": {"text": "Manufacturers", "keywords": [{"text": "Manufacturers"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations", "keywords": [{"text": "rapid release formulations"}, {"text": "new drug formulations"}, {"text": "various life cycle"}, {"text": "management patent strategies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Manufacturers", "keywords": [{"text": "Manufacturers"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "various life cycle management patent strategies", "keywords": [{"text": "various life cycle"}, {"text": "management patent strategies"}]}, "action": {"verb": {"text": "employ", "tense": "present"}, "text": "are employing", "normalized": "be employ"}}, {"subject": {"text": "obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations", "keywords": [{"text": "rapid release formulations"}, {"text": "new drug formulations"}, {"text": "isomers"}, {"text": "prodrugs"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "cycle management patent strategies", "keywords": [{"text": "cycle management patent"}, {"text": "strategies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "patents", "keywords": [{"text": "patents"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "on isomers", "keywords": [{"text": "isomers"}]}, "action": {"verb": {"text": "obtain", "tense": "present"}, "text": "include obtaining", "normalized": "include obtain"}}, {"subject": {"text": "Future Market Insights (FMI), in its report,", "keywords": [{"text": "Future Market Insights"}, {"text": "FMI"}, {"text": "report"}], "entities": [{"type": "Organization", "text": "FMI", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}]}, "sentence": " Future Market Insights (FMI), in its report, projects the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027.", "object": {"text": "the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "forecast period"}, {"text": "market"}, {"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "6.5"}]}, "action": {"verb": {"text": "project", "tense": "present"}, "text": "projects", "normalized": "project"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Market"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "$ 500,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 500,000"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "will reach", "normalized": "will reach"}}, {"subject": {"text": "2027"}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "further estimated to surpass US$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 900,000"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "to surpass US"}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 900,000"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "US"}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "is further estimated to surpass", "normalized": "be far estimate to surpass"}}, {"subject": {"text": "by Asia Pacific Excluding Japan (APEJ) and Western Europe", "keywords": [{"text": "Asia Pacific Excluding"}, {"text": "Western Europe"}, {"text": "Japan"}, {"text": "APEJ"}], "entities": [{"type": "Organization", "text": "Asia Pacific"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation: North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "object": {"text": "oral solid dosage pharmaceutical formulation,", "keywords": [{"text": "dosage pharmaceutical formulation"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Revenue from the market in North America", "keywords": [{"text": "Revenue"}, {"text": "North America"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Market"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Revenue from the market in North America is expected to surpass US$ 300,000 Mn by 2027-end.", "object": {"text": "$ 300,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 300,000"}]}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "is expected to surpass", "normalized": "be expect to surpass"}}, {"subject": {"text": "APEJ", "keywords": [{"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "APEJ", "keywords": [{"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027.", "object": {"text": "revenue worth US$ 294,750.4 Mn in the market", "keywords": [{"text": "revenue worth"}, {"text": "Mn"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is projected to reach", "normalized": "be project to reach"}}, {"subject": {"text": "Latin America", "keywords": [{"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Latin America is expected to be the fastest growth region in the market, expanding at 9.2% CAGR through 2027.", "object": {"text": "the fastest growth region", "keywords": [{"text": "fastest growth region"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}]}, "sentence": " In contrast, Japan will witness a sluggish growth in the market.", "object": {"text": "a sluggish growth in the market", "keywords": [{"text": "sluggish growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "will witness", "normalized": "will witness"}}, {"subject": {"text": "US"}, "sentence": " By dosage form, tablets will continue to remain preferred in the market, with sales estimated to surpass US$ 500,000 Mn by 2027-end.", "object": {"text": "$ 500,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 500,000"}]}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "estimated to surpass", "normalized": "estimate to surpass"}}, {"subject": {"text": "Sales of tablets", "keywords": [{"text": "tablets"}, {"text": "Sales"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Sales of tablets", "keywords": [{"text": "tablets"}, {"text": "Sales"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "the highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "are anticipated to exhibit", "normalized": "be anticipate to exhibit"}}, {"subject": {"text": "the highest CAGR in the market", "keywords": [{"text": "highest CAGR"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Market"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "by capsules", "keywords": [{"text": "capsules"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Capsules", "keywords": [{"text": "Capsules"}]}, "sentence": " Capsules are expected to be the second most lucrative dosage form in the market, expanding at 6.1% CAGR through 2027.", "object": {"text": "the second most lucrative dosage form in the market", "keywords": [{"text": "lucrative dosage form"}], "entities": [{"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Immediate release", "keywords": [{"text": "Immediate release"}]}, "sentence": " Immediate release is expected to generate revenue over US$ 400,000 Mn by 2027-end.", "object": {"text": "revenue over US$ 400,000 Mn by 2027-end", "keywords": [{"text": "revenue"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "generate", "tense": "future"}, "text": "is expected to generate", "normalized": "be expect to generate"}}, {"subject": {"text": "7.4% CAGR", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "7.4"}]}, "sentence": " Controlled release under extended release segment, is expected to register 7.4% CAGR through 2027.", "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "Retail pharmacy", "keywords": [{"text": "Retail pharmacy"}]}, "sentence": " Retail pharmacy is expected to be the largest end-user of oral solid dosage pharmaceutical formulation market by 2027-end.", "object": {"text": "the largest end-user of oral solid dosage pharmaceutical formulation market by 2027-end", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "largest end-user"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Retail pharmacy", "keywords": [{"text": "Retail pharmacy"}]}, "sentence": " Retail pharmacy is expected to exhibit highest CAGR in the market through 2027.", "object": {"text": "highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "Hospital pharmacy", "keywords": [{"text": "Hospital pharmacy"}], "entities": [{"type": "Facility", "text": "Hospital pharmacy"}]}, "sentence": " In contrast, Hospital pharmacy is expected to exhibit lowest CAGR, even though it stands as second largest end-user in the market during the forecast period.", "object": {"text": "lowest CAGR", "keywords": [{"text": "lowest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "it"}, "sentence": " In contrast, Hospital pharmacy is expected to exhibit lowest CAGR, even though it stands as second largest end-user in the market during the forecast period.", "object": {"text": "as second largest end-user", "keywords": [{"text": "largest end-user"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stands", "normalized": "stand"}}, {"subject": {"text": "Presence of MNCs", "keywords": [{"text": "Presence"}, {"text": "MNCs"}]}, "sentence": " Increasing Presence of MNCs to Drive Market Growth in Latin America: Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "object": {"text": "to Drive Market Growth in Latin America", "keywords": [{"text": "Drive Market Growth"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "Increasing", "tense": "present"}, "text": "Increasing", "normalized": "Increasing"}}, {"subject": {"text": "Latin America", "keywords": [{"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Increasing Presence of MNCs to Drive Market Growth in Latin America: Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "object": {"text": "emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources", "keywords": [{"text": "oral solid dosage"}, {"text": "manufacturing hub"}, {"text": "low-cost resources"}, {"text": "availability"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Multinational companies", "keywords": [{"text": "Multinational companies"}]}, "sentence": " Multinational companies are focusing on expanding their presence in this region.", "object": {"text": "focusing on expanding their presence in this region", "keywords": [{"text": "presence"}, {"text": "region"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Multinational companies", "keywords": [{"text": "Multinational companies"}]}, "sentence": " Multinational companies are focusing on expanding their presence in this region.", "object": {"text": "their presence", "keywords": [{"text": "presence"}]}, "action": {"verb": {"text": "expand", "tense": "future"}, "text": "expanding", "normalized": "expand"}}, {"subject": {"text": "These factors", "keywords": [{"text": "factors"}]}, "sentence": " These factors are expected to propel market growth in Latin America.", "object": {"text": "market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "are expected to propel", "normalized": "be expect to propel"}}, {"subject": {"text": "They"}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region", "keywords": [{"text": "commonly used pharmaceuticals"}, {"text": "various disease conditions"}, {"text": "North America"}, {"text": "turn"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "pharmaceuticals", "keywords": [{"text": "pharmaceuticals"}]}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "for treating various disease conditions in North America, which in turn is driving growth of the market in this region", "keywords": [{"text": "various disease conditions"}, {"text": "North America"}, {"text": "turn"}, {"text": "growth"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "growth of the market in this region", "keywords": [{"text": "growth"}, {"text": "market"}, {"text": "region"}], "entities": [{"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "is driving", "normalized": "be drive"}}, {"subject": {"text": "Growing effluent consumers in APEJ countries such as China, India and Korea", "keywords": [{"text": "effluent consumers"}, {"text": "APEJ countries"}, {"text": "Korea"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Korea", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "Country"], "name": "Korea", "dbpedia_resource": "http://dbpedia.org/resource/Korea"}}]}, "sentence": " Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "object": {"text": "growth of the oral solid dosage pharmaceutical formulation market in this region", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "growth"}, {"text": "market"}, {"text": "region"}]}, "action": {"verb": {"text": "boost", "tense": "present"}, "text": "are boosting", "normalized": "be boost"}}, {"subject": {"text": "Consumers here", "keywords": [{"text": "Consumers"}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity", "keywords": [{"text": "western lifestyle-related diseases"}, {"text": "wealthy-life-fast-paced western lifestyle"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Consumers here", "keywords": [{"text": "Consumers"}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "wealthy-life-fast-paced western lifestyle", "keywords": [{"text": "wealthy-life-fast-paced western lifestyle"}]}, "action": {"verb": {"text": "adopt", "tense": "present"}, "text": "are adopting", "normalized": "be adopt"}}, {"subject": {"text": "diabetes, cancer, and obesity", "keywords": [{"text": "obesity"}, {"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "western lifestyle-related diseases", "keywords": [{"text": "western lifestyle-related diseases"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "This"}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "them"}, "action": {"verb": {"text": "compel", "tense": "present"}, "text": "compels", "normalized": "compel"}}, {"subject": {"text": "them"}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "action": {"verb": {"text": "seek", "tense": "present"}, "text": "seeking", "normalized": "seek"}}, {"subject": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "expected to fuel market growth in APEJ", "keywords": [{"text": "market growth"}, {"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "market growth in APEJ", "keywords": [{"text": "market growth"}, {"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is expected to fuel", "normalized": "be expect to fuel"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "object": {"text": "productivity of Asian manufacturers and containment issues", "keywords": [{"text": "containment issues"}, {"text": "productivity"}, {"text": "Asian manufacturers"}]}, "action": {"verb": {"text": "decrease", "tense": "present"}, "text": "decreasing", "normalized": "decrease"}}, {"subject": {"text": "low R&D expenditure", "keywords": [{"text": "low R&D expenditure"}]}, "sentence": " However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "object": {"text": "with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ", "keywords": [{"text": "USFDA compliance"}, {"text": "challenges"}, {"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Market"}, {"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "couple", "tense": "past"}, "text": "coupled", "normalized": "couple"}}, {"subject": {"text": "Key players", "keywords": [{"text": "Key players"}]}, "sentence": " Key players identified in FMI\u2019s report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc", "keywords": [{"text": "Boehringer Ingelheim GmbH"}, {"text": "Bristol-Myers Squibb Company"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "AstraZeneca Plc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Gilead Sciences", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Gilead Sciences", "dbpedia_resource": "http://dbpedia.org/resource/Gilead_Sciences"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Hoffman-La-Roche Ltd."}, {"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "Biogen Inc.", "disambiguation": {"subtype": ["Company"], "name": "Biogen Idec", "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Teva Pharmaceticals"}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Company", "text": "Otsuka Pharmaceutical Co.", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"type": "Company", "text": "Ltd."}, {"type": "Company", "text": "Shire Plc."}, {"type": "Company", "text": "Celgene Corporation", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"type": "Company", "text": "Astellas Pharma Inc"}]}, "sentence": " Key players identified in FMI\u2019s report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "object": {"text": "Key players identified in FMI\u2019s report", "keywords": [{"text": "FMI\u2019s report"}, {"text": "Key players"}], "entities": [{"type": "Organization", "text": "FMI", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "A Sample of this Report", "keywords": [{"text": "Sample"}, {"text": "Report"}]}, "sentence": " A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "object": {"text": "Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "keywords": [{"text": "Request  https://www.futuremarketinsights.com/reports/sample/rep-gb-2782"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.982685, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "North America", "relevance": 0.898337, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacy", "relevance": 0.897225, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmaceutical formulation", "relevance": 0.804676, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_formulation"}, {"text": "Bristol-Myers Squibb", "relevance": 0.758359, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Multinational companies", "relevance": 0.602286, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "United States", "relevance": 0.599382, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Pharmaceutical companies of Japan", "relevance": 0.572255, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_Japan"}, {"text": "Boehringer Ingelheim", "relevance": 0.570354, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Biotechnology companies", "relevance": 0.560896, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Americas", "relevance": 0.542542, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Americas", "relevance": 0.514023, "dbpedia_resource": "http://dbpedia.org/resource/Americas_(terminology)"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.506005, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmaceutical industry", "relevance": 0.483771, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pfizer", "relevance": 0.47511, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Novartis", "relevance": 0.473654, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Ingelheim am Rhein", "relevance": 0.464848, "dbpedia_resource": "http://dbpedia.org/resource/Ingelheim_am_Rhein"}, {"text": "Latin America", "relevance": 0.463666, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "AstraZeneca", "relevance": 0.46108, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.450094, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Clopidogrel", "relevance": 0.434296, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Dosage forms", "relevance": 0.420102, "dbpedia_resource": "http://dbpedia.org/resource/Dosage_forms"}, {"text": "Pharmaceutical drug", "relevance": 0.410939, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Indigenous peoples of the Americas", "relevance": 0.403027, "dbpedia_resource": "http://dbpedia.org/resource/Indigenous_peoples_of_the_Americas"}], "categories": [{"score": 0.945123, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.859266, "label": "/business and industrial/manufacturing"}, {"score": 0.781923, "label": "/health and fitness/drugs"}], "relations": [{"type": "hasAttribute", "sentence": "North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation: North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "score": 0.96908, "arguments": [{"text": "Asia Pacific Excluding Japan", "location": [940, 968], "entities": [{"type": "Organization", "text": "Asia Pacific Excluding Japan", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "APEJ", "location": [970, 974], "entities": [{"type": "Ticker", "text": "APEJ"}]}]}, {"type": "locatedAt", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.459042, "arguments": [{"text": "players", "location": [3738, 3745], "entities": [{"type": "Person", "text": "players"}]}, {"text": "FMI", "location": [3760, 3763], "entities": [{"type": "GeopoliticalEntity", "text": "FMI"}]}]}, {"type": "agentOf", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.774054, "arguments": [{"text": "FMI", "location": [3760, 3763], "entities": [{"type": "GeopoliticalEntity", "text": "FMI"}]}, {"text": "report", "location": [3766, 3772], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "residesIn", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.474656, "arguments": [{"text": "Hoffman", "location": [3953, 3960], "entities": [{"type": "Person", "text": "Hoffman"}]}, {"text": "La", "location": [3961, 3963], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "employedBy", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.498404, "arguments": [{"text": "Hoffman", "location": [3953, 3960], "entities": [{"type": "Person", "text": "Hoffman"}]}, {"text": "Roche Ltd.", "location": [3964, 3974], "entities": [{"type": "Organization", "text": "Roche Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.71673, "arguments": [{"text": "Astellas Pharma Inc.", "location": [4153, 4173], "entities": [{"type": "Organization", "text": "Astellas Pharma Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "@", "location": [4224, 4225], "entities": [{"type": "Money", "text": "@", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "locatedAt", "sentence": "North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation: North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "score": 0.891566, "arguments": [{"text": "Western", "location": [980, 987], "entities": [{"type": "Location", "text": "Western"}]}, {"text": "Europe", "location": [988, 994], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Increasing Presence of MNCs to Drive Market Growth in Latin America: Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "score": 0.586785, "arguments": [{"text": "Market Growth", "location": [2474, 2487], "entities": [{"type": "Organization", "text": "Market for Oral Solid Dosage Pharmaceutical Formulation"}]}, {"text": "Latin America", "location": [2491, 2504], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.620649, "arguments": [{"text": "consumers", "location": [3071, 3080], "entities": [{"type": "Person", "text": "Consumers"}]}, {"text": "countries", "location": [3089, 3098], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.915942, "arguments": [{"text": "countries", "location": [3089, 3098], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "APEJ", "location": [3084, 3088], "entities": [{"type": "GeopoliticalEntity", "text": "APEJ"}]}]}, {"type": "partOfMany", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.233982, "arguments": [{"text": "China", "location": [3107, 3112], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3089, 3098], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.353547, "arguments": [{"text": "India", "location": [3114, 3119], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3089, 3098], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "score": 0.669607, "arguments": [{"text": "them", "location": [3304, 3308], "entities": [{"type": "Person", "text": "their"}]}, {"text": "diseases", "location": [3345, 3353], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "basedIn", "sentence": "However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "score": 0.771607, "arguments": [{"text": "manufacturers", "location": [3566, 3579], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Asian", "location": [3560, 3565], "entities": [{"type": "GeopoliticalEntity", "text": "Asian", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "oral solid dosage forms", "sentiment": {"score": 0.914972, "label": "positive"}, "relevance": 0.677174, "count": 2}, {"text": "Future Market Insights", "sentiment": {"score": 0.86537, "label": "positive"}, "relevance": 0.637345, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.616324, "count": 1}, {"text": "Multinational companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601332, "count": 1}, {"text": "North America", "sentiment": {"score": 0.73753, "mixed": "1", "label": "positive"}, "relevance": 0.600193, "count": 4}, {"text": "Oral Solid Dosage Pharmaceutical Formulation", "sentiment": {"score": 0.965383, "label": "positive"}, "relevance": 0.580266, "count": 1}, {"text": "Immediate Release", "sentiment": {"score": -0.545022, "label": "negative"}, "relevance": 0.570973, "count": 1}, {"text": "effluent consumers", "sentiment": {"score": 0.889941, "label": "positive"}, "relevance": 0.565814, "count": 1}, {"text": "rapid release formulations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.565705, "count": 1}, {"text": "Largest Market", "sentiment": {"score": 0.965383, "label": "positive"}, "relevance": 0.563968, "count": 1}, {"text": "pharmaceutical formulation market", "sentiment": {"score": 0.679277, "mixed": "1", "label": "positive"}, "relevance": 0.559206, "count": 3}, {"text": "Latin America", "sentiment": {"score": 0.882643, "label": "positive"}, "relevance": 0.55887, "count": 4}, {"text": "growth potential", "sentiment": {"score": 0.979025, "label": "positive"}, "relevance": 0.558341, "count": 1}, {"text": "market", "sentiment": {"score": 0.284889, "mixed": "1", "label": "positive"}, "relevance": 0.558182, "count": 11}, {"text": "new drug formulations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551392, "count": 1}, {"text": "solid dosage", "sentiment": {"score": 0.878234, "label": "positive"}, "relevance": 0.548927, "count": 2}, {"text": "pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548593, "count": 1}, {"text": "Western Europe", "sentiment": {"score": 0.566327, "mixed": "1", "label": "positive"}, "relevance": 0.545547, "count": 1}, {"text": "patent cliff challenges", "sentiment": {"score": 0.979025, "label": "positive"}, "relevance": 0.544182, "count": 1}, {"text": "Consumers", "sentiment": {"score": -0.569076, "label": "negative"}, "relevance": 0.542609, "count": 1}, {"text": "largest market", "sentiment": {"score": 0.965383, "label": "positive"}, "relevance": 0.542134, "count": 1}, {"text": "Pfizer Inc.", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.54143, "count": 1}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0.547526, "label": "positive"}, "relevance": 0.541284, "count": 1}, {"text": "Manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541001, "count": 1}, {"text": "Key players", "sentiment": {"score": 0.547526, "label": "positive"}, "relevance": 0.539356, "count": 1}, {"text": "factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536763, "count": 1}, {"text": "immediate release", "sentiment": {"score": -0.545022, "label": "negative"}, "relevance": 0.535667, "count": 1}, {"text": "pipeline productivity", "sentiment": {"score": 0.979025, "label": "positive"}, "relevance": 0.535469, "count": 1}, {"text": "Company", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.533194, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.530732, "count": 2}, {"text": "report", "sentiment": {"score": 0.86537, "label": "positive"}, "relevance": 0.529862, "count": 1}, {"text": "Novartis AG", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.529467, "count": 1}, {"text": "contrast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529079, "count": 2}, {"text": "Ltd", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.526257, "count": 1}, {"text": "Immediate release", "sentiment": {"score": -0.756403, "label": "negative"}, "relevance": 0.526163, "count": 1}, {"text": "productivity of Asian manufacturers", "sentiment": {"score": -0.878136, "label": "negative"}, "relevance": 0.526126, "count": 1}, {"text": "Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.525508, "count": 1}, {"text": "AstraZeneca Plc", "sentiment": {"score": 0.547526, "label": "positive"}, "relevance": 0.525235, "count": 1}, {"text": "patents", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524288, "count": 1}, {"text": "Boehringer Ingelheim GmbH", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.523633, "count": 1}, {"text": "AbbVie Inc.", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.521355, "count": 1}, {"text": "Revenue", "sentiment": {"score": -0.459459, "label": "negative"}, "relevance": 0.519653, "count": 1}, {"text": "tablets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518814, "count": 1}, {"text": "challenges", "sentiment": {"score": -0.878136, "label": "negative"}, "relevance": 0.51852, "count": 1}, {"text": "sales", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517407, "count": 1}, {"text": "global oral", "sentiment": {"score": 0.86537, "label": "positive"}, "relevance": 0.51728, "count": 1}, {"text": "Merck", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.516537, "count": 1}, {"text": "release", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516401, "count": 1}, {"text": "isomers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516246, "count": 1}, {"text": "metabolites", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514338, "count": 1}]}, "extracted_metadata": {"sha1": "157064cb70fbc641941bdedc7fc2cf4b3e879fb6", "filename": "1542369802993.zip-a1445037c41781a71828c46fb4d12dc0.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market", "https://www.futuremarketinsights.com/reports/sample/rep-gb-2782"], "title": "Oral Solid Dosage Pharmaceutical Formulation Market is Forecasted to Reach a Figure of US$ 926.3 Bn by 2027", "forum_title": "Research Insights | Find Market Research - Part 17"}, {"id": "FVKWVM5hC1oVtgnccQukt9KKLSEZLltPThs2MVWysvwLT14dDbrI90nYn_ZjWtdq", "result_metadata": {"score": 35.724}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Paradigm Biopharmaceuticals Ltd", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0.791228, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Pfizer", "relevance": 0.938227, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Growth hormone", "relevance": 0.73932, "dbpedia_resource": "http://dbpedia.org/resource/Growth_hormone"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.644805, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.855313, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.696563, "label": "/real estate/buying and selling homes"}, {"score": 0.674901, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "partOf", "sentence": "Collagenase 3 Market Explore Growth Analysis 2018-2025 by Global Key Players: Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd: Market Expertz", "score": 0.435238, "arguments": [{"text": "Global Key Players", "location": [58, 76], "entities": [{"type": "Organization", "text": "Paradigm Biopharmaceuticals Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Collagenase 3 Market Explore Growth Analysis", "location": [0, 44], "entities": [{"type": "Organization", "text": "Collagenase 3 Market Explore Growth Analysis"}]}]}], "keywords": [{"text": "Market", "sentiment": {"score": 0.791228, "label": "positive"}, "relevance": 0.79428, "count": 1}, {"text": "Paradigm Biopharmaceuticals Ltd", "sentiment": {"score": 0.791228, "label": "positive"}, "relevance": 0.7355, "count": 1}, {"text": "Global Key Players", "sentiment": {"score": 0.791228, "label": "positive"}, "relevance": 0.683651, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0.791228, "label": "positive"}, "relevance": 0.617795, "count": 1}, {"text": "Growth Analysis", "sentiment": {"score": 0.791228, "label": "positive"}, "relevance": 0.601791, "count": 1}, {"text": "Pfizer Inc", "sentiment": {"score": 0.791228, "label": "positive"}, "relevance": 0.498577, "count": 1}, {"text": "Market Expertz", "sentiment": {"score": 0.791228, "label": "positive"}, "relevance": 0.298899, "count": 1}, {"text": "Collagenase", "sentiment": {"score": 0.791228, "label": "positive"}, "relevance": 0.285374, "count": 1}]}, "crawl_date": "2018-11-15T22:21:07Z", "url": "http://www.sbwire.com/press-releases/collagenase-3-market-explore-growth-analysis-2018-2025-by-global-key-players-paradigm-biopharmaceuticals-ltd-pfizer-inc-takeda-pharmaceutical-co-ltd-market-expertz-1085903.htm", "host": "sbwire.com", "text": "RSS Collagenase 3 Market Explore Growth Analysis 2018-2025 by Global Key Players: Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd: Market Expertz A closer look at the aspects including but not limited to Collagenase 3 market segmentation by the end-user, end-use, geography, type, and application forms an integral part", "main_image_url": "http://media.releasewire.com/photos/show/?id=138454", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-15T22:18:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0.319933, "label": "positive"}, "text": "Paradigm Biopharmaceuticals Ltd", "relevance": 0.807706, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc", "relevance": 0.580944, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.508594, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.393106, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.392783, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New York", "relevance": 0.392329, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "FilmScreeningVenue", "City"], "name": "New York City", "dbpedia_resource": "http://dbpedia.org/resource/New_York_City"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NY", "relevance": 0.383093, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "PlaceWithNeighborhoods", "WineRegion", "CityTown", "FilmScreeningVenue", "StateOrCounty"], "name": "New York", "dbpedia_resource": "http://dbpedia.org/resource/New_York"}}, {"count": 2, "sentiment": {"score": 0.4781, "label": "positive"}, "text": "South America", "relevance": 0.377187, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "South America", "dbpedia_resource": "http://dbpedia.org/resource/South_America"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.35971, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.346271, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Manufacturing Base", "relevance": 0.331627, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.323807, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.301489, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "CompanyShareholder", "Country"], "name": "Brazil", "dbpedia_resource": "http://dbpedia.org/resource/Brazil"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.298858, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "Germany", "dbpedia_resource": "http://dbpedia.org/resource/Germany"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "United States", "relevance": 0.298053, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Argentina", "relevance": 0.289168, "type": "Location", "disambiguation": {"subtype": ["Region", "GovernmentalJurisdiction", "Country"], "name": "Argentina", "dbpedia_resource": "http://dbpedia.org/resource/Argentina"}}, {"count": 1, "sentiment": {"score": 0.201106, "label": "positive"}, "text": "Saudi Arabia", "relevance": 0.287573, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "MilitaryPost", "CityTown", "Country"], "name": "Saudi Arabia", "dbpedia_resource": "http://dbpedia.org/resource/Saudi_Arabia"}}, {"count": 1, "sentiment": {"score": -0.201753, "label": "negative"}, "text": "Turkey", "relevance": 0.286813, "type": "Location", "disambiguation": {"subtype": ["Brand", "GovernmentalJurisdiction", "ProjectParticipant", "Country"], "name": "Turkey", "dbpedia_resource": "http://dbpedia.org/resource/Turkey"}}, {"count": 1, "sentiment": {"score": 0.281376, "label": "positive"}, "text": "South Korea", "relevance": 0.286261, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "South Korea", "dbpedia_resource": "http://dbpedia.org/resource/South_Korea"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.27887, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Indonesia", "relevance": 0.277284, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Country"], "name": "Indonesia", "dbpedia_resource": "http://dbpedia.org/resource/Indonesia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Singapore", "relevance": 0.275983, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Singapore", "dbpedia_resource": "http://dbpedia.org/resource/Singapore"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.275108, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mexico", "relevance": 0.274825, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spain", "relevance": 0.274654, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.274004, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0.353103, "label": "positive"}, "text": "China", "relevance": 0.27393, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Australia", "relevance": 0.272289, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "Country"], "name": "Australia", "dbpedia_resource": "http://dbpedia.org/resource/Australia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.272238, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK", "relevance": 0.270838, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Russia", "relevance": 0.262848, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.248165, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.1.2.1", "relevance": 0.248165, "type": "IPAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.2.2.1", "relevance": 0.248165, "type": "IPAddress"}], "sentiment": {"document": {"score": 0.61992, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "but not limited to Collagenase 3 market segmentation by the end-user, end-use, geography, type, and application forms an integral part of the research report", "keywords": [{"text": "market segmentation"}, {"text": "research report"}, {"text": "end-use"}, {"text": "end-user"}]}, "sentence": "RSS Collagenase 3 Market Explore Growth Analysis 2018-2025 by Global Key Players: Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd: Market Expertz A closer look at the aspects including but not limited to Collagenase 3 market segmentation by the end-user, end-use, geography, type, and application forms an integral part of the research report.", "object": {"text": "the aspects", "keywords": [{"text": "aspects"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "2018 \u2013 2025"}, "sentence": " New York, NY -- ( SBWIRE ) -- 11/15/2018 -- The latest research report on the Collagenase 3 market for the forecast period, 2018 \u2013 2025 is involved in screening the business environment and the companies operating in the Collagenase 3industry.", "object": {"text": "involved in screening the business environment and the companies operating in the Collagenase 3industry", "keywords": [{"text": "business environment"}, {"text": "Collagenase 3industry"}, {"text": "companies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "2018 \u2013 2025"}, "sentence": " New York, NY -- ( SBWIRE ) -- 11/15/2018 -- The latest research report on the Collagenase 3 market for the forecast period, 2018 \u2013 2025 is involved in screening the business environment and the companies operating in the Collagenase 3industry.", "object": {"text": "in screening the business environment and the companies operating in the Collagenase 3industry", "keywords": [{"text": "business environment"}, {"text": "Collagenase 3industry"}, {"text": "companies"}]}, "action": {"verb": {"text": "involve", "tense": "past"}, "text": "is involved", "normalized": "be involve"}}, {"subject": {"text": "the business environment", "keywords": [{"text": "business environment"}]}, "sentence": " New York, NY -- ( SBWIRE ) -- 11/15/2018 -- The latest research report on the Collagenase 3 market for the forecast period, 2018 \u2013 2025 is involved in screening the business environment and the companies operating in the Collagenase 3industry.", "object": {"text": "operating in the Collagenase 3industry", "keywords": [{"text": "Collagenase 3industry"}, {"text": "operating"}]}, "action": {"verb": {"text": "screen", "tense": "present"}, "text": "screening", "normalized": "screen"}}, {"subject": {"text": "the companies", "keywords": [{"text": "companies"}]}, "sentence": " New York, NY -- ( SBWIRE ) -- 11/15/2018 -- The latest research report on the Collagenase 3 market for the forecast period, 2018 \u2013 2025 is involved in screening the business environment and the companies operating in the Collagenase 3industry.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "the research", "keywords": [{"text": "research"}]}, "sentence": " Importantly, the research sheds a lot of light on their winning strategies to help stakeholders, business owners, and field marketing executives stay ahead in the competition.", "object": {"text": "a lot of light"}, "action": {"verb": {"text": "shed", "tense": "present"}, "text": "sheds", "normalized": "shed"}}, {"subject": {"text": "their winning strategies", "keywords": [{"text": "strategies"}]}, "sentence": " Importantly, the research sheds a lot of light on their winning strategies to help stakeholders, business owners, and field marketing executives stay ahead in the competition.", "object": {"text": "stakeholders", "keywords": [{"text": "stakeholders"}]}, "action": {"verb": {"text": "help", "tense": "future"}, "text": "to help", "normalized": "to help"}}, {"subject": {"text": "field marketing executives", "keywords": [{"text": "field marketing executives"}]}, "sentence": " Importantly, the research sheds a lot of light on their winning strategies to help stakeholders, business owners, and field marketing executives stay ahead in the competition.", "action": {"verb": {"text": "stay", "tense": "present"}, "text": "stay", "normalized": "stay"}}, {"subject": {"text": "the industry", "keywords": [{"text": "industry"}]}, "sentence": " Besides, the industry is thoroughly weighed upon on the basis of the total revenue generated as well as the output/volume produced year after year.", "action": {"verb": {"text": "weigh", "tense": "past"}, "text": "weighed", "normalized": "weigh"}}, {"subject": {"text": "the total revenue", "keywords": [{"text": "total revenue"}]}, "sentence": " Besides, the industry is thoroughly weighed upon on the basis of the total revenue generated as well as the output/volume produced year after year.", "action": {"verb": {"text": "generate", "tense": "past"}, "text": "generated", "normalized": "generate"}}, {"subject": {"text": "the output/volume", "keywords": [{"text": "output/volume"}]}, "sentence": " Besides, the industry is thoroughly weighed upon on the basis of the total revenue generated as well as the output/volume produced year after year.", "object": {"text": "year"}, "action": {"verb": {"text": "produce", "tense": "past"}, "text": "produced", "normalized": "produce"}}, {"subject": {"text": "but not limited to the market drivers, key opportunities and probable restraints", "keywords": [{"text": "probable restraints"}, {"text": "market drivers"}, {"text": "key opportunities"}]}, "sentence": " Other aspects including but not limited to the market drivers, key opportunities and probable restraints are thoroughly assessed during the study.", "object": {"text": "Other aspects", "keywords": [{"text": "aspects"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "key opportunities and probable restraints", "keywords": [{"text": "probable restraints"}, {"text": "key opportunities"}]}, "sentence": " Other aspects including but not limited to the market drivers, key opportunities and probable restraints are thoroughly assessed during the study.", "object": {"text": "thoroughly assessed during the study", "keywords": [{"text": "study"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Other aspects including but not limited to the market drivers, key opportunities and probable restraints", "keywords": [{"text": "probable restraints"}, {"text": "market drivers"}, {"text": "key opportunities"}, {"text": "aspects"}]}, "sentence": " Other aspects including but not limited to the market drivers, key opportunities and probable restraints are thoroughly assessed during the study.", "action": {"verb": {"text": "assess", "tense": "past"}, "text": "assessed", "normalized": "assess"}}, {"subject": {"text": "the report", "keywords": [{"text": "report"}]}, "sentence": " Request for free sample copy@ https://www.marketexpertz.com/sample-enquiry-form/23039 In market segmentation by manufacturers, the report covers the following companies- Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd In market segmentation by types of the Collagenase 3systems, the report covers- - PF-152 In market segmentation by applications of the Collagenase 3, the report covers the following uses- - Hospital - ASCs Scope: The Collagenase 3market is further segmented in terms of applications, end-user, end-use, geographic presence, by-products as well as services.", "object": {"text": "the following companies- Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd In market segmentation by types of the Collagenase 3systems, the report covers- - PF-152 In market segmentation by applications of the Collagenase 3, the report covers the following uses- - Hospital - ASCs Scope: The Collagenase 3market is further segmented in terms of applications, end-user, end-use, geographic presence, by-products as well as services", "keywords": [{"text": "market segmentation"}, {"text": "Paradigm Biopharmaceuticals"}, {"text": "ASCs Scope"}, {"text": "Takeda Pharmaceutical"}], "entities": [{"type": "Company", "text": "Paradigm Biopharmaceuticals Ltd"}, {"type": "Company", "text": "Pfizer Inc", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co Ltd"}]}, "action": {"verb": {"text": "cover", "tense": "present"}, "text": "covers", "normalized": "cover"}}, {"subject": {"text": "the subject matter experts", "keywords": [{"text": "subject matter"}, {"text": "experts"}]}, "sentence": " In addition, the subject matter experts evaluating the industry provide an all-inclusive category-specific industry outlook.", "object": {"text": "the industry provide an all-inclusive category-specific industry outlook", "keywords": [{"text": "all-inclusive category-specific industry"}, {"text": "outlook"}]}, "action": {"verb": {"text": "evaluate", "tense": "present"}, "text": "evaluating", "normalized": "evaluate"}}, {"subject": {"text": "the subject matter experts evaluating the industry", "keywords": [{"text": "subject matter experts"}, {"text": "industry"}]}, "sentence": " In addition, the subject matter experts evaluating the industry provide an all-inclusive category-specific industry outlook.", "object": {"text": "an all-inclusive category-specific industry outlook", "keywords": [{"text": "all-inclusive category-specific industry"}, {"text": "outlook"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provide", "normalized": "provide"}}, {"subject": {"text": "data on major companies", "keywords": [{"text": "major companies"}, {"text": "data"}]}, "sentence": " A comprehensive collection of data on major companies occupying a strong foothold in the industry adds immense value to the overall research.", "object": {"text": "a strong foothold", "keywords": [{"text": "strong foothold"}]}, "action": {"verb": {"text": "occupy", "tense": "present"}, "text": "occupying", "normalized": "occupy"}}, {"subject": {"text": "A comprehensive collection of data on major companies occupying a strong foothold in the industry", "keywords": [{"text": "strong foothold"}, {"text": "comprehensive collection"}, {"text": "major companies"}, {"text": "data"}]}, "sentence": " A comprehensive collection of data on major companies occupying a strong foothold in the industry adds immense value to the overall research.", "object": {"text": "immense value", "keywords": [{"text": "immense value"}]}, "action": {"verb": {"text": "add", "tense": "present"}, "text": "adds", "normalized": "add"}}, {"subject": {"text": "by these companies", "keywords": [{"text": "companies"}]}, "sentence": " The assessment of the wining strategies followed by these companies can help business owners not only strategize but also execute business operations by referring the statistics about competitor analysis.", "object": {"text": "The assessment of the wining strategies", "keywords": [{"text": "wining strategies"}, {"text": "assessment"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "The assessment of the wining strategies followed by these companies", "keywords": [{"text": "wining strategies"}, {"text": "assessment"}, {"text": "companies"}]}, "sentence": " The assessment of the wining strategies followed by these companies can help business owners not only strategize but also execute business operations by referring the statistics about competitor analysis.", "object": {"text": "business owners", "keywords": [{"text": "business owners"}]}, "action": {"verb": {"text": "help", "tense": "future"}, "text": "can help", "normalized": "can help"}}, {"subject": {"text": "The assessment of the wining strategies", "keywords": [{"text": "wining strategies"}, {"text": "assessment"}]}, "sentence": " The assessment of the wining strategies followed by these companies can help business owners not only strategize but also execute business operations by referring the statistics about competitor analysis.", "object": {"text": "business operations", "keywords": [{"text": "business operations"}]}, "action": {"verb": {"text": "execute", "tense": "present"}, "text": "also execute", "normalized": "also execute"}}, {"subject": {"text": "The assessment of the wining strategies followed by these companies", "keywords": [{"text": "wining strategies"}, {"text": "assessment"}, {"text": "companies"}]}, "sentence": " The assessment of the wining strategies followed by these companies can help business owners not only strategize but also execute business operations by referring the statistics about competitor analysis.", "object": {"text": "the statistics about competitor analysis", "keywords": [{"text": "competitor analysis"}, {"text": "statistics"}]}, "action": {"verb": {"text": "refer", "tense": "present"}, "text": "referring", "normalized": "refer"}}, {"subject": {"text": "share and growth rate", "keywords": [{"text": "growth rate"}, {"text": "share"}]}, "sentence": " Careful assessment of the industry analysis across different regions along with vital information on the market size, share and growth rate makes this report a wonderful resource for business evangelists.", "object": {"text": "this report", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "makes", "normalized": "make"}}, {"subject": {"text": "information", "keywords": [{"text": "information"}]}, "sentence": " Thus, a conscious effort to dive deep and unearth hard to find information pertaining to the growing market landscape and growth prospects over the next few years is clearly visible in the study.", "object": {"text": "to the growing market landscape and growth prospects over the next few years", "keywords": [{"text": "growth prospects"}, {"text": "market landscape"}]}, "action": {"verb": {"text": "pertain", "tense": "present"}, "text": "pertaining", "normalized": "pertain"}}, {"subject": {"text": "a conscious effort to dive deep and unearth hard to find information pertaining to the growing market landscape and growth prospects over the next few years", "keywords": [{"text": "conscious effort"}, {"text": "growth prospects"}, {"text": "market landscape"}, {"text": "information"}]}, "sentence": " Thus, a conscious effort to dive deep and unearth hard to find information pertaining to the growing market landscape and growth prospects over the next few years is clearly visible in the study.", "object": {"text": "clearly visible in the study", "keywords": [{"text": "study"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the major vendors", "keywords": [{"text": "major vendors"}]}, "sentence": " The market intelligence report further comprises of discussions about the major vendors operating in the Collagenase 3space.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "the trends", "keywords": [{"text": "trends"}]}, "sentence": " Knowing the trends influencing the industry performance Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels.", "object": {"text": "the industry performance Stakeholders", "keywords": [{"text": "industry performance Stakeholders"}]}, "action": {"verb": {"text": "influence", "tense": "present"}, "text": "influencing", "normalized": "influence"}}, {"subject": {"text": "marketing executives and business owners", "keywords": [{"text": "executives"}, {"text": "business owners"}]}, "sentence": " Knowing the trends influencing the industry performance Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels.", "object": {"text": "to refer a market research report", "keywords": [{"text": "market research report"}]}, "action": {"verb": {"text": "plan", "tense": "present"}, "text": "planning", "normalized": "plan"}}, {"subject": {"text": "Stakeholders, marketing executives and business owners", "keywords": [{"text": "marketing executives"}, {"text": "Stakeholders"}, {"text": "business owners"}]}, "sentence": " Knowing the trends influencing the industry performance Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels.", "object": {"text": "a market research report", "keywords": [{"text": "market research report"}]}, "action": {"verb": {"text": "refer", "tense": "future"}, "text": "planning to refer", "normalized": "plan to refer"}}, {"subject": {"text": "a market research report", "keywords": [{"text": "market research report"}]}, "sentence": " Knowing the trends influencing the industry performance Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels.", "object": {"text": "this study", "keywords": [{"text": "study"}]}, "action": {"verb": {"text": "use", "tense": "future"}, "text": "can use", "normalized": "can use"}}, {"subject": {"text": "competitors", "keywords": [{"text": "competitors"}]}, "sentence": " Knowing the trends influencing the industry performance Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels.", "object": {"text": "their potential customers", "keywords": [{"text": "potential customers"}]}, "action": {"verb": {"text": "attract", "tense": "present"}, "text": "attract", "normalized": "attract"}}, {"subject": {"text": "competitors", "keywords": [{"text": "competitors"}]}, "sentence": " Knowing the trends influencing the industry performance Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels.", "object": {"text": "their supply and distribution channels", "keywords": [{"text": "distribution channels"}, {"text": "supply"}]}, "action": {"verb": {"text": "manage", "tense": "present"}, "text": "manage", "normalized": "manage"}}, {"subject": {"text": "researchers", "keywords": [{"text": "researchers"}]}, "sentence": " When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour.", "object": {"text": "the trends", "keywords": [{"text": "trends"}]}, "action": {"verb": {"text": "track", "tense": "present"}, "text": "tracking", "normalized": "track"}}, {"subject": {"text": "researchers", "keywords": [{"text": "researchers"}]}, "sentence": " When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour.", "object": {"text": "made a conscious effort", "keywords": [{"text": "conscious effort"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "tracking the trends researchers", "keywords": [{"text": "trends"}, {"text": "researchers"}]}, "sentence": " When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour.", "object": {"text": "a conscious effort", "keywords": [{"text": "conscious effort"}]}, "action": {"verb": {"text": "make", "tense": "past"}, "text": "have made", "normalized": "have make"}}, {"subject": {"text": "researchers", "keywords": [{"text": "researchers"}]}, "sentence": " When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour.", "object": {"text": "the consumer behaviour", "keywords": [{"text": "consumer behaviour"}]}, "action": {"verb": {"text": "analyze", "tense": "future"}, "text": "to analyze and interpret", "normalized": "to analyze and interpret"}}, {"subject": {"text": "researchers", "keywords": [{"text": "researchers"}]}, "sentence": " When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour.", "object": {"text": "the consumer behaviour", "keywords": [{"text": "consumer behaviour"}]}, "action": {"verb": {"text": "interpret", "tense": "present"}, "text": "to analyze and interpret", "normalized": "to analyze and interpret"}}, {"subject": {"text": "the research", "keywords": [{"text": "research"}]}, "sentence": " Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.", "object": {"text": "product owners", "keywords": [{"text": "product owners"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "helps", "normalized": "help"}}, {"subject": {"text": "the research helps product owners", "keywords": [{"text": "product owners"}, {"text": "research"}]}, "sentence": " Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.", "object": {"text": "the changes in culture", "keywords": [{"text": "changes"}, {"text": "culture"}]}, "action": {"verb": {"text": "understand", "tense": "future"}, "text": "to understand", "normalized": "to understand"}}, {"subject": {"text": "they"}, "sentence": " Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.", "object": {"text": "the attention of the potential customers more", "keywords": [{"text": "attention"}, {"text": "potential customers"}]}, "action": {"verb": {"text": "draw", "tense": "future"}, "text": "can draw", "normalized": "can draw"}}, {"subject": {"text": "The research", "keywords": [{"text": "research"}]}, "sentence": " Buy full report@ https://www.marketexpertz.com/checkout-form/23039 The research provides answers to the following key questions: - What will be the size of the Collagenase 3market and growth rate for the forecast period 2018 \u2013 2025? - Who are prominent players dominating the Collagenase 3market?", "object": {"text": "answers to the following key questions", "keywords": [{"text": "following key questions"}, {"text": "answers"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "prominent players", "keywords": [{"text": "prominent players"}]}, "sentence": " Buy full report@ https://www.marketexpertz.com/checkout-form/23039 The research provides answers to the following key questions: - What will be the size of the Collagenase 3market and growth rate for the forecast period 2018 \u2013 2025? - Who are prominent players dominating the Collagenase 3market?", "object": {"text": "the Collagenase 3market", "keywords": [{"text": "Collagenase 3market"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominating", "normalized": "dominate"}}, {"subject": {"text": "been their winning strategies", "keywords": [{"text": "winning strategies"}]}, "sentence": " What have been their winning strategies so far?", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "What"}, "sentence": " - What are the key trends anticipated to influence the development of the industry worldwide?", "object": {"text": "the key trends anticipated to influence the development of the industry worldwide", "keywords": [{"text": "key trends"}, {"text": "industry worldwide"}, {"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "What"}, "sentence": " - What are major threats and challenges hindering the growth of the market across different regions?", "object": {"text": "major threats", "keywords": [{"text": "major threats"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "challenges", "keywords": [{"text": "challenges"}]}, "sentence": " - What are major threats and challenges hindering the growth of the market across different regions?", "object": {"text": "the growth of the market across different regions", "keywords": [{"text": "different regions"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hinder", "tense": "present"}, "text": "hindering", "normalized": "hinder"}}, {"subject": {"text": "the opportunities prominent vendors", "keywords": [{"text": "opportunities prominent vendors"}]}, "sentence": " - What are the opportunities prominent vendors are eyeing to stay competitive in the global market?", "object": {"text": "eyeing to stay competitive in the global market", "keywords": [{"text": "global market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "marketexpertz", "keywords": [{"text": "marketexpertz"}]}, "sentence": " Then marketexpertz has just the thing for you - reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate.", "object": {"text": "just the thing for you - reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography", "keywords": [{"text": "vital insights"}, {"text": "prominent publishers"}, {"text": "different geography"}, {"text": "individuals catch-up"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "There"}, "sentence": " There's more to what we offer to our customers.", "object": {"text": "more to what we offer to our customers", "keywords": [{"text": "customers"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}], "concepts": [{"text": "Marketing", "relevance": 0.956075, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Competitor analysis", "relevance": 0.633708, "dbpedia_resource": "http://dbpedia.org/resource/Competitor_analysis"}, {"text": "Pfizer", "relevance": 0.457107, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "South America", "relevance": 0.448702, "dbpedia_resource": "http://dbpedia.org/resource/South_America"}, {"text": "Manufacturing", "relevance": 0.416612, "dbpedia_resource": "http://dbpedia.org/resource/Manufacturing"}, {"text": "Market research", "relevance": 0.40936, "dbpedia_resource": "http://dbpedia.org/resource/Market_research"}, {"text": "Abbas Kiarostami", "relevance": 0.385238, "dbpedia_resource": "http://dbpedia.org/resource/Abbas_Kiarostami"}, {"text": "Competition", "relevance": 0.376115, "dbpedia_resource": "http://dbpedia.org/resource/Competition"}, {"text": "Following", "relevance": 0.37161, "dbpedia_resource": "http://dbpedia.org/resource/Following"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.37138, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "The Key", "relevance": 0.371203, "dbpedia_resource": "http://dbpedia.org/resource/The_Key_(novel)"}, {"text": "Region", "relevance": 0.361813, "dbpedia_resource": "http://dbpedia.org/resource/Region"}, {"text": "Market Intelligence", "relevance": 0.35364, "dbpedia_resource": "http://dbpedia.org/resource/Market_Intelligence"}, {"text": "Revenue", "relevance": 0.35286, "dbpedia_resource": "http://dbpedia.org/resource/Revenue"}, {"text": "Industry or market research", "relevance": 0.344779, "dbpedia_resource": "http://dbpedia.org/resource/Industry_or_market_research"}, {"text": "Christopher Nolan", "relevance": 0.33801, "dbpedia_resource": "http://dbpedia.org/resource/Christopher_Nolan"}], "categories": [{"score": 0.978536, "label": "/business and industrial/advertising and marketing/marketing"}, {"score": 0.862926, "label": "/business and industrial/business operations/management/business process"}, {"score": 0.75067, "label": "/finance/financial news"}], "relations": [{"type": "partOf", "sentence": "RSS Collagenase 3 Market Explore Growth Analysis 2018-2025 by Global Key Players: Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd: Market Expertz A closer look at the aspects including but not limited to Collagenase 3 market segmentation by the end-user, end-use, geography, type, and application forms an integral part of the research report.", "score": 0.457293, "arguments": [{"text": "Global Key Players", "location": [62, 80], "entities": [{"type": "Organization", "text": "Paradigm Biopharmaceuticals Ltd Collagenase 3 Sales", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "RSS Collagenase 3 Market Explore Growth Analysis", "location": [0, 48], "entities": [{"type": "Organization", "text": "RSS Collagenase 3 Market Explore Growth Analysis"}]}]}, {"type": "partOf", "sentence": "Key points for table of content: 9 Global Collagenase 3 Players/Suppliers Profiles and Sales Data 9.1 Paradigm Biopharmaceuticals Ltd 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Collagenase 3 Product Category, Application and Specification 9.1.2.1 Product A 9.1.3 Paradigm Biopharmaceuticals Ltd Collagenase 3 Sales, Revenue, Price and Gross Margin (2018-2025) 9.1.4 Main Business/Business Overview 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Collagenase 3 Product Category, Application and Specification 9.2.2.1 Product A 9.2.3 Pfizer Inc Collagenase 3 Sales, Revenue, Price and Gross Margin (2018-2025) Browse complete report description@ https://www.marketexpertz.com/industry-overview/collagenase-3-market About MarketExpertz Planning to invest in market intelligence products or offerings on the web?", "score": 0.651436, "arguments": [{"text": "Company", "location": [4770, 4777], "entities": [{"type": "Organization", "text": "Basic Information"}]}, {"text": "Paradigm Biopharmaceuticals Ltd", "location": [4732, 4763], "entities": [{"type": "Organization", "text": "Paradigm Biopharmaceuticals Ltd Collagenase 3 Sales", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Key points for table of content: 9 Global Collagenase 3 Players/Suppliers Profiles and Sales Data 9.1 Paradigm Biopharmaceuticals Ltd 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Collagenase 3 Product Category, Application and Specification 9.1.2.1 Product A 9.1.3 Paradigm Biopharmaceuticals Ltd Collagenase 3 Sales, Revenue, Price and Gross Margin (2018-2025) 9.1.4 Main Business/Business Overview 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Collagenase 3 Product Category, Application and Specification 9.2.2.1 Product A 9.2.3 Pfizer Inc Collagenase 3 Sales, Revenue, Price and Gross Margin (2018-2025) Browse complete report description@ https://www.marketexpertz.com/industry-overview/collagenase-3-market About MarketExpertz Planning to invest in market intelligence products or offerings on the web?", "score": 0.352926, "arguments": [{"text": "Business Overview", "location": [5041, 5058], "entities": [{"type": "Organization", "text": "Business Overview", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Main Business", "location": [5027, 5040], "entities": [{"type": "Organization", "text": "Main Business", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "New York, NY -- ( SBWIRE ) -- 11/15/2018 -- The latest research report on the Collagenase 3 market for the forecast period, 2018 - 2025 is involved in screening the business environment and the companies operating in the Collagenase 3industry.", "score": 0.981427, "arguments": [{"text": "New York", "location": [370, 378], "entities": [{"type": "GeopoliticalEntity", "text": "New York"}]}, {"text": "NY", "location": [380, 382], "entities": [{"type": "GeopoliticalEntity", "text": "NY"}]}]}, {"type": "partOf", "sentence": "Request for free sample copy@ https://www.marketexpertz.com/sample-enquiry-form/23039 In market segmentation by manufacturers, the report covers the following companies- Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd In market segmentation by types of the Collagenase 3systems, the report covers- - PF-152 In market segmentation by applications of the Collagenase 3, the report covers the following uses- - Hospital - ASCs Scope: The Collagenase 3market is further segmented in terms of applications, end-user, end-use, geographic presence, by-products as well as services.", "score": 0.292373, "arguments": [{"text": "Paradigm Biopharmaceuticals Ltd", "location": [1255, 1286], "entities": [{"type": "Organization", "text": "Paradigm Biopharmaceuticals Ltd Collagenase 3 Sales", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Pfizer Inc", "location": [1288, 1298], "entities": [{"type": "Organization", "text": "Pfizer Inc Collagenase 3 Sales", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Request for free sample copy@ https://www.marketexpertz.com/sample-enquiry-form/23039 In market segmentation by manufacturers, the report covers the following companies- Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd In market segmentation by types of the Collagenase 3systems, the report covers- - PF-152 In market segmentation by applications of the Collagenase 3, the report covers the following uses- - Hospital - ASCs Scope: The Collagenase 3market is further segmented in terms of applications, end-user, end-use, geographic presence, by-products as well as services.", "score": 0.828409, "arguments": [{"text": "Scope", "location": [1535, 1540], "entities": [{"type": "Person", "text": "Scope"}]}, {"text": "Hospital - ASCs", "location": [1519, 1534], "entities": [{"type": "Organization", "text": "Hospital - ASCs", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Ask for discount@ https://www.marketexpertz.com/discount-enquiry-form/23039 In market segmentation by geographical regions, the report has analysed the following regions- - North America - India We also provide customized report for following regions: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa The study has been conducted on the basis of inputs from the industry leaders.", "score": 0.628764, "arguments": [{"text": "regions", "location": [2525, 2532], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "North America", "location": [2536, 2549], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Ask for discount@ https://www.marketexpertz.com/discount-enquiry-form/23039 In market segmentation by geographical regions, the report has analysed the following regions- - North America - India We also provide customized report for following regions: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa The study has been conducted on the basis of inputs from the industry leaders.", "score": 0.601237, "arguments": [{"text": "Brazil", "location": [2856, 2862], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil"}]}, {"text": "Argentina", "location": [2864, 2873], "entities": [{"type": "GeopoliticalEntity", "text": "Argentina"}]}]}, {"type": "locatedAt", "sentence": "Ask for discount@ https://www.marketexpertz.com/discount-enquiry-form/23039 In market segmentation by geographical regions, the report has analysed the following regions- - North America - India We also provide customized report for following regions: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa The study has been conducted on the basis of inputs from the industry leaders.", "score": 0.503031, "arguments": [{"text": "Rest of South America", "location": [2875, 2896], "entities": [{"type": "GeopoliticalEntity", "text": "Rest of South America"}]}, {"text": "Middle East", "location": [2898, 2909], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East"}]}]}, {"type": "residesIn", "sentence": "Ask for discount@ https://www.marketexpertz.com/discount-enquiry-form/23039 In market segmentation by geographical regions, the report has analysed the following regions- - North America - India We also provide customized report for following regions: North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central & South America, Brazil, Argentina, Rest of South America, Middle East & Africa, Saudi Arabia, Turkey, Rest of Middle East & Africa The study has been conducted on the basis of inputs from the industry leaders.", "score": 0.710239, "arguments": [{"text": "Rest", "location": [2942, 2946], "entities": [{"type": "Cardinal", "text": "Rest"}]}, {"text": "Middle East", "location": [2950, 2961], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East"}]}]}, {"type": "productOf", "sentence": "Key points for table of content: 9 Global Collagenase 3 Players/Suppliers Profiles and Sales Data 9.1 Paradigm Biopharmaceuticals Ltd 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Collagenase 3 Product Category, Application and Specification 9.1.2.1 Product A 9.1.3 Paradigm Biopharmaceuticals Ltd Collagenase 3 Sales, Revenue, Price and Gross Margin (2018-2025) 9.1.4 Main Business/Business Overview 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Collagenase 3 Product Category, Application and Specification 9.2.2.1 Product A 9.2.3 Pfizer Inc Collagenase 3 Sales, Revenue, Price and Gross Margin (2018-2025) Browse complete report description@ https://www.marketexpertz.com/industry-overview/collagenase-3-market About MarketExpertz Planning to invest in market intelligence products or offerings on the web?", "score": 0.574009, "arguments": [{"text": "Data 9.1", "location": [4723, 4731], "entities": [{"type": "Product", "text": "Data 9.1"}]}, {"text": "Suppliers Profiles", "location": [4694, 4712], "entities": [{"type": "Organization", "text": "Suppliers Profiles", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "integral part of the research report", "sentiment": {"score": -0.39809, "label": "negative"}, "relevance": 0.669671, "count": 1}, {"text": "RSS Collagenase", "sentiment": {"score": 0.79364, "label": "positive"}, "relevance": 0.623767, "count": 1}, {"text": "Market", "sentiment": {"score": 0.79364, "label": "positive"}, "relevance": 0.607276, "count": 1}, {"text": "Paradigm Biopharmaceuticals Ltd", "sentiment": {"score": 0.688261, "label": "positive"}, "relevance": 0.581231, "count": 3}, {"text": "Market Expertz", "sentiment": {"score": 0.79364, "label": "positive"}, "relevance": 0.581053, "count": 1}, {"text": "business environment", "sentiment": {"score": -0.39809, "label": "negative"}, "relevance": 0.579007, "count": 1}, {"text": "Global Key Players", "sentiment": {"score": 0.79364, "label": "positive"}, "relevance": 0.577842, "count": 1}, {"text": "North America", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.576566, "count": 2}, {"text": "latest research report", "sentiment": {"score": -0.39809, "label": "negative"}, "relevance": 0.573671, "count": 1}, {"text": "Collagenase 3industry", "sentiment": {"score": 0.561836, "mixed": "1", "label": "positive"}, "relevance": 0.565725, "count": 1}, {"text": "different regions", "sentiment": {"score": 0.995663, "label": "positive"}, "relevance": 0.565518, "count": 2}, {"text": "market segmentation", "sentiment": {"score": 0.669264, "label": "positive"}, "relevance": 0.564696, "count": 5}, {"text": "major companies", "sentiment": {"score": 0.775354, "label": "positive"}, "relevance": 0.561793, "count": 1}, {"text": "business owners", "sentiment": {"score": 0.820973, "label": "positive"}, "relevance": 0.561329, "count": 3}, {"text": "report", "sentiment": {"score": 0.751611, "label": "positive"}, "relevance": 0.560776, "count": 5}, {"text": "Sales Data", "sentiment": {"score": 0.593849, "label": "positive"}, "relevance": 0.55585, "count": 1}, {"text": "South Korea", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.555832, "count": 1}, {"text": "market", "sentiment": {"score": -0.39809, "label": "negative"}, "relevance": 0.55427, "count": 1}, {"text": "end-user", "sentiment": {"score": 0.677303, "label": "positive"}, "relevance": 0.552163, "count": 2}, {"text": "prominent players", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.551858, "count": 1}, {"text": "conscious effort", "sentiment": {"score": 0.519026, "mixed": "1", "label": "positive"}, "relevance": 0.550768, "count": 2}, {"text": "vital information", "sentiment": {"score": 0.995663, "label": "positive"}, "relevance": 0.550686, "count": 1}, {"text": "Collagenase", "sentiment": {"score": 0.476831, "mixed": "1", "label": "positive"}, "relevance": 0.547514, "count": 4}, {"text": "industry", "sentiment": {"score": 0.653674, "label": "positive"}, "relevance": 0.543913, "count": 3}, {"text": "Middle East", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.542155, "count": 1}, {"text": "companies", "sentiment": {"score": 0.701389, "mixed": "1", "label": "positive"}, "relevance": 0.540303, "count": 4}, {"text": "Rest of Asia-Pacific", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.539106, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0.736052, "label": "positive"}, "relevance": 0.537236, "count": 2}, {"text": "application forms", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536655, "count": 1}, {"text": "growth rate", "sentiment": {"score": 0.641051, "label": "positive"}, "relevance": 0.534465, "count": 3}, {"text": "Manufacturing Base", "sentiment": {"score": 0.593849, "label": "positive"}, "relevance": 0.534409, "count": 2}, {"text": "products", "sentiment": {"score": 0.677303, "label": "positive"}, "relevance": 0.534268, "count": 1}, {"text": "South America", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.53411, "count": 1}, {"text": "market size", "sentiment": {"score": 0.995663, "label": "positive"}, "relevance": 0.534015, "count": 1}, {"text": "subject matter experts", "sentiment": {"score": 0.390653, "label": "positive"}, "relevance": 0.533379, "count": 1}, {"text": "United States", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.533369, "count": 1}, {"text": "closer look", "sentiment": {"score": 0.79364, "label": "positive"}, "relevance": 0.532997, "count": 1}, {"text": "Pfizer Inc", "sentiment": {"score": 0.736052, "label": "positive"}, "relevance": 0.532412, "count": 2}, {"text": "trends", "sentiment": {"score": 0.696527, "label": "positive"}, "relevance": 0.531939, "count": 2}, {"text": "Growth Analysis", "sentiment": {"score": 0.79364, "label": "positive"}, "relevance": 0.53187, "count": 1}, {"text": "research", "sentiment": {"score": 0.734803, "label": "positive"}, "relevance": 0.531283, "count": 3}, {"text": "geographical regions", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.530491, "count": 1}, {"text": "report covers", "sentiment": {"score": 0.677303, "label": "positive"}, "relevance": 0.530403, "count": 1}, {"text": "Gross Margin", "sentiment": {"score": 0.593849, "label": "positive"}, "relevance": 0.529413, "count": 2}, {"text": "Asia-Pacific", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.527696, "count": 1}, {"text": "complete report description", "sentiment": {"score": 0.593849, "label": "positive"}, "relevance": 0.527424, "count": 1}, {"text": "major threats", "sentiment": {"score": -0.877023, "label": "negative"}, "relevance": 0.527265, "count": 1}, {"text": "Sales", "sentiment": {"score": 0.593849, "label": "positive"}, "relevance": 0.52672, "count": 2}, {"text": "Saudi Arabia", "sentiment": {"score": 0.644113, "label": "positive"}, "relevance": 0.526642, "count": 1}, {"text": "basis of the total revenue", "sentiment": {"score": 0.736734, "label": "positive"}, "relevance": 0.525867, "count": 1}]}, "extracted_metadata": {"sha1": "ea8aae5a73245b80227ecec16437893cb677747f", "filename": "1542320467907.zip-8e9f1adc1398d15c3b189a25a76a0b79.xml", "file_type": "json"}, "external_links": ["https://www.marketexpertz.com/checkout-form/23039", "https://www.marketexpertz.com/industry-overview/collagenase-3-market", "http://www.releasewire.com/rss/", "https://www.marketexpertz.com/sample-enquiry-form/23039", "https://www.marketexpertz.com/discount-enquiry-form/23039"], "title": "Collagenase 3 Market Explore Growth Analysis 2018-2025 by Global Key Players: Paradigm Biopharmaceuticals Ltd, Pfizer Inc, Takeda Pharmaceutical Co Ltd: Market Expertz", "forum_title": "ReleaseWire - Latest Press Releases"}, {"id": "QNlS1y8WaDBOjE-08PImYN2KClj7mxEHRaDDgII34iadYW8Vabjks3_Me3D4s3xG", "result_metadata": {"score": 35.63435}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Management", "relevance": 0.909559, "dbpedia_resource": "http://dbpedia.org/resource/Management"}, {"text": "Board of directors", "relevance": 0.7832, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}, {"text": "Corporate governance", "relevance": 0.7128, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}], "categories": [{"score": 0.520277, "label": "/business and industrial/company"}, {"score": 0.517884, "label": "/business and industrial/construction"}, {"score": 0.461894, "label": "/technology and computing/operating systems"}], "relations": [{"type": "partOf", "sentence": "20182019 ISPE Board of Directors Installed at Annual Meeting & Expo", "score": 0.779752, "arguments": [{"text": "Board of Directors Installed", "location": [14, 42], "entities": [{"type": "Organization", "text": "Board of Directors Installed"}]}, {"text": "Annual Meeting & Expo", "location": [46, 67], "entities": [{"type": "Organization", "text": "Annual Meeting & Expo", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "ISPE Board", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.954451}, {"text": "Annual Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.720056}, {"text": "Expo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57331}, {"text": "Directors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.360849}]}, "crawl_date": "2018-11-15T16:39:23Z", "url": "https://www.bioportfolio.com/news/article/3818048/2018-2019-ISPE-Board-of-Directors-Installed-at-Annual-Meeting-Expo.html", "host": "bioportfolio.com", "text": "Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd.", "country": "GB", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-15T16:00:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President", "relevance": 0.848696, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2018\u20132019 ISPE International Board of Directors", "relevance": 0.634198, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ISPE", "relevance": 0.580456, "type": "Company", "disambiguation": {"subtype": [], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}, {"count": 1, "sentiment": {"score": 0.565671, "label": "positive"}, "text": "ISPE\u2019s International Board", "relevance": 0.522595, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "International Society for Pharmaceutical Engineering", "relevance": 0.520088, "type": "Organization", "disambiguation": {"subtype": [], "name": "International Society for Pharmaceutical Engineering", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmaceutical_Engineering"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President of GMP Operations", "relevance": 0.515114, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President of Strategy and Development", "relevance": 0.484534, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President", "relevance": 0.466787, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President Project Management", "relevance": 0.457773, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and CEO", "relevance": 0.448603, "type": "JobTitle"}, {"count": 4, "sentiment": {"score": 0.565671, "label": "positive"}, "text": "Director", "relevance": 0.424137, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.417164, "label": "negative"}, "text": "Vice Chair", "relevance": 0.385973, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "International Board of Directors", "relevance": 0.373507, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Engineering", "relevance": 0.311697, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Head and Executive Director", "relevance": 0.296167, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.417164, "label": "negative"}, "text": "Janssen Pharmaceuticals", "relevance": 0.273235, "type": "Company", "disambiguation": {"subtype": [], "name": "Janssen Pharmaceutica", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Pharmaceutica"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals International", "relevance": 0.25146, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biopharm CMC", "relevance": 0.24843, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Society", "relevance": 0.243587, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glenmark Pharmaceuticals Flemming Dahl", "relevance": 0.24133, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vivianne J. Arencibia", "relevance": 0.240456, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.238912, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Company Past Chair", "relevance": 0.237345, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Project Lead Biologics Expansion", "relevance": 0.236243, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk", "relevance": 0.23598, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Executive Director", "relevance": 0.233845, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.416015, "label": "positive"}, "text": "Arencibia Quality Compliance Associates", "relevance": 0.230236, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer", "relevance": 0.230039, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Timothy P. Howard", "relevance": 0.229523, "type": "Person", "disambiguation": {"subtype": [], "name": "Jen\u0151 Rejt\u0151", "dbpedia_resource": "http://dbpedia.org/resource/Jen\u0151_Rejt\u0151"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "WuXi Biologics", "relevance": 0.227706, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.411794, "label": "positive"}, "text": "Michael Rutherford", "relevance": 0.227409, "type": "Person", "disambiguation": {"subtype": ["MusicalArtist", "Guitarist", "MusicalGroupMember", "FilmActor"], "name": "Mike Rutherford", "dbpedia_resource": "http://dbpedia.org/resource/Mike_Rutherford"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Manager QA Validation", "relevance": 0.227188, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frances M. Zipp", "relevance": 0.227003, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.259805, "label": "positive"}, "text": "Joanne R. Barrick", "relevance": 0.22655, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "James Breen Jr.", "relevance": 0.226535, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lachman Consultant Services", "relevance": 0.224221, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.234787, "label": "negative"}, "text": "Merck", "relevance": 0.222668, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gunter Baumgartner", "relevance": 0.222381, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Treasurer", "relevance": 0.220791, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Process Engineer", "relevance": 0.219393, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.313197, "label": "positive"}, "text": "LeAnna Pearson", "relevance": 0.21776, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Thomas Hartman", "relevance": 0.213513, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tampa", "relevance": 0.213341, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Tampa, Florida", "dbpedia_resource": "http://dbpedia.org/resource/Tampa,_Florida"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christine M.V. Moore", "relevance": 0.211693, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Operations", "relevance": 0.211051, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Computer Systems Quality and Data Integrity", "relevance": 0.21101, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Caroline Rocks", "relevance": 0.209778, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Florida", "relevance": 0.208169, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Florida", "dbpedia_resource": "http://dbpedia.org/resource/Florida"}}], "sentiment": {"document": {"score": 0.896684, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "ISPE Releases", "keywords": [{"text": "ISPE Releases"}]}, "sentence": "ISPE Releases ISPE GAMP\u00ae RDI Good Practice Guide: Data Integrity \u2013 Key Concepts", "object": {"text": "GAMP\u00ae RDI Good Practice Guide", "keywords": [{"text": "RDI Good Practice"}, {"text": "GAMP\u00ae"}]}, "action": {"verb": {"text": "ISPE", "tense": "present"}, "text": "ISPE", "normalized": "ISPE"}}, {"subject": {"text": "The International Society for Pharmaceutical Engineering (ISPE)", "keywords": [{"text": "Engineering (ISPE)"}, {"text": "International Society"}], "entities": [{"type": "Organization", "text": "International Society for Pharmaceutical Engineering", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmaceutical Engineering", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmaceutical_Engineering"}}]}, "sentence": " The International Society for Pharmaceutical Engineering (ISPE) installed its 2018\u20132019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "object": {"text": "its 2018\u20132019 International Board of Directors", "keywords": [{"text": "International Board"}, {"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "International Board of Directors"}]}, "action": {"verb": {"text": "instal install", "tense": "past"}, "text": "installed", "normalized": "instal install"}}, {"subject": {"text": "The Board", "keywords": [{"text": "Board"}]}, "sentence": " The Board is responsible for the governance and strategic direction of the Society.", "object": {"text": "responsible for the governance", "keywords": [{"text": "governance"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The following pharmaceutical industry leaders", "keywords": [{"text": "following pharmaceutical industry"}, {"text": "leaders"}], "entities": []}, "sentence": " The following pharmaceutical industry leaders have been elected to the 2018\u20132019 ISPE International Board of Directors:", "object": {"text": "elected to the 2018\u20132019 ISPE International Board of Directors", "keywords": [{"text": "ISPE International Board"}, {"text": "Directors"}], "entities": [{"type": "Organization", "text": "2018\u20132019 ISPE International Board of Directors"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The following pharmaceutical industry leaders", "keywords": [{"text": "following pharmaceutical industry"}, {"text": "leaders"}], "entities": []}, "sentence": " The following pharmaceutical industry leaders have been elected to the 2018\u20132019 ISPE International Board of Directors:", "object": {"text": "to the 2018\u20132019 ISPE International Board of Directors", "keywords": [{"text": "ISPE International Board"}, {"text": "Directors"}], "entities": [{"type": "Organization", "text": "2018\u20132019 ISPE International Board of Directors"}]}, "action": {"verb": {"text": "elect", "tense": "past"}, "text": "have been elected", "normalized": "have be elect"}}, {"subject": {"text": "James Breen Jr., PE, Vice President, Project", "keywords": [{"text": "James Breen Jr."}, {"text": "Vice President"}, {"text": "PE"}], "entities": [{"type": "Person", "text": "James Breen Jr."}, {"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Project Lead Biologics Expansion"}]}, "sentence": " Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc.", "object": {"text": "Biologics Expansion, Janssen Pharmaceuticals Vice Chair", "keywords": [{"text": "Janssen Pharmaceuticals Vice"}, {"text": "Biologics Expansion"}, {"text": "Chair"}], "entities": [{"type": "Company", "text": "Janssen Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Janssen Pharmaceutica", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Pharmaceutica"}}, {"type": "JobTitle", "text": "Vice Chair"}]}, "action": {"verb": {"text": "Lead", "tense": "present"}, "text": "Lead", "normalized": "Lead"}}, {"subject": {"text": "Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development,", "keywords": [{"text": "Timothy P. Howard"}, {"text": "Vice President"}, {"text": "PE"}, {"text": "Strategy"}], "entities": [{"type": "Person", "text": "Timothy P. Howard", "disambiguation": {"subtype": [], "name": "Jen\u0151 Rejt\u0151", "dbpedia_resource": "http://dbpedia.org/resource/Jen\u0151_Rejt\u0151"}}, {"type": "JobTitle", "text": "Vice President of Strategy and Development"}]}, "sentence": " Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc.", "object": {"text": "Agents", "keywords": [{"text": "Agents"}]}, "action": {"verb": {"text": "Commissioning", "tense": "present"}, "text": "Commissioning", "normalized": "Commissioning"}}, {"subject": {"text": "Vivianne J. Arencibia, President,", "keywords": [{"text": "Vivianne J. Arencibia"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Vivianne J. Arencibia"}, {"type": "JobTitle", "text": "President and CEO"}]}, "sentence": " New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President, Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc.", "object": {"text": "Quality Compliance Associates, LLC Gunter Baumgartner, Vice President, Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks", "keywords": [{"text": "LLC Gunter Baumgartner"}, {"text": "AG Caroline Rocks"}, {"text": "Quality Compliance Associates"}, {"text": "Vice President"}], "entities": [{"type": "Person", "text": "Gunter Baumgartner"}, {"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Global Engineering"}, {"type": "Company", "text": "Takeda Pharmaceuticals International"}, {"type": "Person", "text": "Caroline Rocks"}]}, "action": {"verb": {"text": "Arencibia", "tense": "present"}, "text": "Arencibia", "normalized": "Arencibia"}}, {"subject": {"text": "CEng", "keywords": [{"text": "CEng"}]}, "sentence": " New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President, Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc.", "object": {"text": "MEngSc, Senior Process Engineer, AbbVie, Inc", "keywords": [{"text": "Senior Process Engineer"}, {"text": "AbbVie"}], "entities": [{"type": "JobTitle", "text": "Senior Process Engineer"}]}, "action": {"verb": {"text": "BE", "tense": "present"}, "text": "BE", "normalized": "BE"}}, {"subject": {"text": "Director", "keywords": [{"text": "Director"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "sentence": " Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd.", "object": {"text": "Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Chris Chen"}, {"text": "Biologics"}, {"text": "Co."}], "entities": [{"type": "Person", "text": "Chris Chen"}, {"type": "JobTitle", "text": "Chief Executive Officer"}, {"type": "Company", "text": "WuXi Biologics"}, {"type": "Company", "text": "Shanghai) Co."}]}, "action": {"verb": {"text": "Appointed", "tense": "past"}, "text": "Appointed", "normalized": "Appointed"}}, {"subject": {"text": "those"}, "sentence": " Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc.", "object": {"text": "above"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the following Directors", "keywords": [{"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "sentence": " Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc.", "object": {"text": "elected in 2017"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "the following Directors", "keywords": [{"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "sentence": " Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc.", "object": {"text": "to serve a two-year term", "keywords": [{"text": "two-year term"}], "entities": [{"type": "Quantity", "text": "two-year"}]}, "action": {"verb": {"text": "elect", "tense": "past"}, "text": "were elected", "normalized": "be elect"}}, {"subject": {"text": "the following Directors", "keywords": [{"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "sentence": " Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc.", "object": {"text": "their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc", "keywords": [{"text": "Vice President"}, {"text": "Senior Vice President"}, {"text": "Vice President Project"}, {"text": "Novo Nordisk A/S"}], "entities": [{"type": "Person", "text": "Tony"}, {"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Global Engineering"}, {"type": "Company", "text": "Glenmark Pharmaceuticals Flemming Dahl"}, {"type": "JobTitle", "text": "Senior Vice President"}, {"type": "Company", "text": "Novo Nordisk", "disambiguation": {"subtype": ["Company"], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"type": "Person", "text": "Kelly Keen"}, {"type": "JobTitle", "text": "Vice President Project Management"}, {"type": "Person", "text": "Alice Redmond"}, {"type": "JobTitle", "text": "Vice President"}, {"type": "Organization", "text": "European Operations"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "will continue", "normalized": "will continue"}}, {"subject": {"text": "Complete biographical information on all of ISPE\u2019s International Board", "keywords": [{"text": "ISPE\u2019s International"}, {"text": "Complete biographical information"}, {"text": "Board"}], "entities": [{"type": "Organization", "text": "ISPE\u2019s International Board"}]}, "sentence": " Complete biographical information on all of ISPE\u2019s International Board can be found at the ISPE Board of Directors webpage.", "action": {"verb": {"text": "find", "tense": "future"}, "text": "can be found", "normalized": "can be find"}}, {"subject": {"text": "largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle", "keywords": [{"text": "entire pharmaceutical lifecycle"}, {"text": "largest not-for-profit association"}, {"text": "regulatory advancement"}, {"text": "members"}]}, "sentence": " About ISPE The International Society for Pharmaceutical Engineering (ISPE) is the world\u2019s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle.", "object": {"text": "the world", "keywords": [{"text": "world"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The 18,500 members of ISPE", "keywords": [{"text": "ISPE"}, {"text": "members"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.", "object": {"text": "building solutions", "keywords": [{"text": "building solutions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The 18,500 members of ISPE", "keywords": [{"text": "ISPE"}, {"text": "members"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.", "object": {"text": "solutions", "keywords": [{"text": "solutions"}]}, "action": {"verb": {"text": "build", "tense": "present"}, "text": "are building", "normalized": "be build"}}, {"subject": {"text": "ISPE", "keywords": [{"text": "ISPE"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit http://www.ISPE.org for more information.", "action": {"verb": {"text": "Founded", "tense": "past"}, "text": "Founded", "normalized": "Founded"}}, {"subject": {"text": "ISPE", "keywords": [{"text": "ISPE"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit http://www.ISPE.org for more information.", "object": {"text": "its worldwide headquarters and training center", "keywords": [{"text": "worldwide headquarters"}, {"text": "center"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "ISPE", "keywords": [{"text": "ISPE"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit http://www.ISPE.org for more information.", "object": {"text": "center", "keywords": [{"text": "center"}]}, "action": {"verb": {"text": "train", "tense": "present"}, "text": "training", "normalized": "train"}}], "concepts": [{"text": "Corporate governance", "relevance": 0.989982, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Board of directors", "relevance": 0.943464, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}, {"text": "Management occupations", "relevance": 0.937704, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Chairman", "relevance": 0.829274, "dbpedia_resource": "http://dbpedia.org/resource/Chairman"}, {"text": "Executive director", "relevance": 0.821013, "dbpedia_resource": "http://dbpedia.org/resource/Executive_director"}, {"text": "Management", "relevance": 0.80285, "dbpedia_resource": "http://dbpedia.org/resource/Management"}, {"text": "Corporate title", "relevance": 0.777063, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_title"}, {"text": "Chief executives", "relevance": 0.774017, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Chief executive officer", "relevance": 0.749105, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Non-executive director", "relevance": 0.711587, "dbpedia_resource": "http://dbpedia.org/resource/Non-executive_director"}, {"text": "Executive officer", "relevance": 0.670985, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Managing director", "relevance": 0.657495, "dbpedia_resource": "http://dbpedia.org/resource/Managing_director"}, {"text": "Pharmacy", "relevance": 0.628889, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmacology", "relevance": 0.562247, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Conflict of interest", "relevance": 0.559881, "dbpedia_resource": "http://dbpedia.org/resource/Conflict_of_interest"}], "categories": [{"score": 0.847607, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "participantIn", "sentence": "ISPE Releases ISPE GAMP\u00ae RDI Good Practice Guide: Data Integrity - Key Concepts The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.956041, "arguments": [{"text": "their", "location": [204, 209], "entities": [{"type": "Person", "text": "leaders"}]}, {"text": "Meeting", "location": [222, 229], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.859905, "arguments": [{"text": "Directors", "location": [1146, 1155], "entities": [{"type": "Person", "text": "Directors"}]}, {"text": "Merck\nNew", "location": [1136, 1145], "entities": [{"type": "Organization", "text": "Merck\nNew", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.876099, "arguments": [{"text": "Vivianne J. Arencibia", "location": [1157, 1178], "entities": [{"type": "Person", "text": "Vivianne J. Arencibia"}]}, {"text": "Directors", "location": [1146, 1155], "entities": [{"type": "Person", "text": "Directors"}]}]}, {"type": "partOfMany", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.820266, "arguments": [{"text": "Gunter Baumgartner", "location": [1236, 1254], "entities": [{"type": "Person", "text": "Gunter Baumgartner"}]}, {"text": "Directors", "location": [1146, 1155], "entities": [{"type": "Person", "text": "Directors"}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.734559, "arguments": [{"text": "Gunter Baumgartner", "location": [1236, 1254], "entities": [{"type": "Person", "text": "Gunter Baumgartner"}]}, {"text": "LLC", "location": [1232, 1235], "entities": [{"type": "Organization", "text": "LLC"}]}]}, {"type": "agentOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.605926, "arguments": [{"text": "Global Engineering", "location": [1272, 1290], "entities": [{"type": "Organization", "text": "Global Engineering", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Appointed", "location": [1402, 1411], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.633244, "arguments": [{"text": "Caroline Rocks", "location": [1332, 1346], "entities": [{"type": "Person", "text": "Caroline Rocks"}]}, {"text": "Takeda Pharmaceuticals International AG", "location": [1292, 1331], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals International AG", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.58079, "arguments": [{"text": "Caroline Rocks", "location": [1332, 1346], "entities": [{"type": "Person", "text": "Caroline Rocks"}]}, {"text": "Appointed", "location": [1402, 1411], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "agentOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.747738, "arguments": [{"text": "AbbVie, Inc.", "location": [1389, 1401], "entities": [{"type": "Organization", "text": "AbbVie, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Appointed", "location": [1402, 1411], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "affectedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.825382, "arguments": [{"text": "Director", "location": [1412, 1420], "entities": [{"type": "Person", "text": "Director"}]}, {"text": "Appointed", "location": [1402, 1411], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "agentOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.518901, "arguments": [{"text": "Directors", "location": [1569, 1578], "entities": [{"type": "Person", "text": "Directors"}]}, {"text": "elected", "location": [1584, 1591], "entities": [{"type": "EventElection", "text": "elected"}]}]}, {"type": "agentOf", "sentence": "ISPE Releases ISPE GAMP\u00ae RDI Good Practice Guide: Data Integrity - Key Concepts The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.628689, "arguments": [{"text": "their", "location": [204, 209], "entities": [{"type": "Person", "text": "leaders"}]}, {"text": "revealing", "location": [239, 248], "entities": [{"type": "EventCommunication", "text": "revealing"}]}]}, {"type": "timeOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.97167, "arguments": [{"text": "2017", "location": [1595, 1599], "entities": [{"type": "Date", "text": "2017"}]}, {"text": "elected", "location": [1584, 1591], "entities": [{"type": "EventElection", "text": "elected"}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.605097, "arguments": [{"text": "Flemming Dahl", "location": [1761, 1774], "entities": [{"type": "Person", "text": "Flemming Dahl"}]}, {"text": "Glenmark Pharmaceuticals", "location": [1736, 1760], "entities": [{"type": "Organization", "text": "Glenmark Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.669721, "arguments": [{"text": "Kelly Keen", "location": [1816, 1826], "entities": [{"type": "Person", "text": "Kelly Keen"}]}, {"text": "Novo Nordisk A/S", "location": [1799, 1815], "entities": [{"type": "Organization", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.911623, "arguments": [{"text": "Redmond", "location": [1885, 1892], "entities": [{"type": "GeopoliticalEntity", "text": "Redmond"}]}, {"text": "PhD", "location": [1894, 1897], "entities": [{"type": "GeopoliticalEntity", "text": "PhD"}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.613265, "arguments": [{"text": "Michael Rutherford", "location": [1963, 1981], "entities": [{"type": "Person", "text": "Michael Rutherford"}]}, {"text": "Commissioning Agents, Inc.", "location": [1936, 1962], "entities": [{"type": "Organization", "text": "Commissioning Agents, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.483481, "arguments": [{"text": "Representative", "location": [2082, 2096], "entities": [{"type": "Person", "text": "Officio"}]}, {"text": "Syneos Health\nYoung Professionals", "location": [2048, 2081], "entities": [{"type": "Organization", "text": "Syneos Health\nYoung Professionals"}]}]}, {"type": "partOf", "sentence": "Manager QA Validation, bluebird bio Complete biographical information on all of ISPE's International Board can be found at the ISPE Board of Directors webpage.", "score": 0.898381, "arguments": [{"text": "International Board", "location": [2214, 2233], "entities": [{"type": "Organization", "text": "International Board of Directors"}]}, {"text": "ISPE", "location": [2207, 2211], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}]}, {"type": "locatedAt", "sentence": "About ISPE The International Society for Pharmaceutical Engineering (ISPE) is the world's largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle.", "score": 0.36725, "arguments": [{"text": "association", "location": [2400, 2411], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}, {"text": "world", "location": [2369, 2374], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "memberOf", "sentence": "About ISPE The International Society for Pharmaceutical Engineering (ISPE) is the world's largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle.", "score": 0.51025, "arguments": [{"text": "members", "location": [2424, 2431], "entities": [{"type": "Person", "text": "members"}]}, {"text": "its", "location": [2420, 2423], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}]}, {"type": "employedBy", "sentence": "The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.", "score": 0.47713, "arguments": [{"text": "members", "location": [2553, 2560], "entities": [{"type": "Person", "text": "members"}]}, {"text": "ISPE", "location": [2564, 2568], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}]}, {"type": "timeOf", "sentence": "ISPE Releases ISPE GAMP\u00ae RDI Good Practice Guide: Data Integrity - Key Concepts The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.870034, "arguments": [{"text": "2018 Annual", "location": [210, 221], "entities": [{"type": "Date", "text": "2018 Annual"}]}, {"text": "Meeting", "location": [222, 229], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "locatedAt", "sentence": "The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.", "score": 0.891991, "arguments": [{"text": "countries", "location": [2730, 2739], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "world", "location": [2751, 2756], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "foundedOn", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.645247, "arguments": [{"text": "ISPE", "location": [2775, 2779], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}, {"text": "1980", "location": [2769, 2773], "entities": [{"type": "Date", "text": "1980", "disambiguation": {"subtype": ["Starting"]}}]}]}, {"type": "ownerOf", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.437513, "arguments": [{"text": "its", "location": [2784, 2787], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}, {"text": "headquarters", "location": [2798, 2810], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.896329, "arguments": [{"text": "training center", "location": [2815, 2830], "entities": [{"type": "Facility", "text": "training center"}]}, {"text": "North Bethesda", "location": [2834, 2848], "entities": [{"type": "GeopoliticalEntity", "text": "North Bethesda"}]}]}, {"type": "locatedAt", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.997647, "arguments": [{"text": "North Bethesda", "location": [2834, 2848], "entities": [{"type": "GeopoliticalEntity", "text": "North Bethesda"}]}, {"text": "Maryland USA", "location": [2850, 2862], "entities": [{"type": "GeopoliticalEntity", "text": "Maryland USA"}]}]}, {"type": "basedIn", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.515868, "arguments": [{"text": "its", "location": [2868, 2871], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}, {"text": "Tampa", "location": [2893, 2898], "entities": [{"type": "GeopoliticalEntity", "text": "Tampa"}]}]}, {"type": "locatedAt", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.995242, "arguments": [{"text": "Tampa", "location": [2893, 2898], "entities": [{"type": "GeopoliticalEntity", "text": "Tampa"}]}, {"text": "Florida USA", "location": [2900, 2911], "entities": [{"type": "GeopoliticalEntity", "text": "Florida USA"}]}]}, {"type": "timeOf", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.78154, "arguments": [{"text": "2018\u20132019", "location": [493, 502], "entities": [{"type": "Date", "text": "2018\u20132019"}]}, {"text": "elected", "location": [478, 485], "entities": [{"type": "EventElection", "text": "elected"}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.621162, "arguments": [{"text": "Treasurer", "location": [736, 745], "entities": [{"type": "Person", "text": "Thomas Hartman"}]}, {"text": "Lachman Consultant Services, Inc.", "location": [702, 735], "entities": [{"type": "Organization", "text": "Lachman Consultant Services, Inc."}]}]}, {"type": "managerOf", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.636559, "arguments": [{"text": "Vice President of", "location": [763, 780], "entities": [{"type": "Person", "text": "Thomas Hartman"}]}, {"text": "GMP Operations", "location": [781, 795], "entities": [{"type": "Organization", "text": "GMP Operations", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.703911, "arguments": [{"text": "Secretary", "location": [827, 836], "entities": [{"type": "Person", "text": "Secretary"}]}, {"text": "GlaxoSmithKline", "location": [811, 826], "entities": [{"type": "Organization", "text": "GlaxoSmithKline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.494979, "arguments": [{"text": "Timothy P. Howard", "location": [932, 949], "entities": [{"type": "Person", "text": "Timothy P. Howard"}]}, {"text": "CPIP", "location": [951, 955], "entities": [{"type": "Organization", "text": "CPIP"}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.516869, "arguments": [{"text": "Director", "location": [1043, 1051], "entities": [{"type": "Person", "text": "Director"}]}, {"text": "Inc.\nRe-Elected", "location": [1027, 1042], "entities": [{"type": "Organization", "text": "Inc.\nRe-Elected", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.941788}, {"text": "ISPE International Board", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.649944}, {"text": "ISPE Releases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54008}, {"text": "Senior Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.521362}, {"text": "Vice President Project", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520275}, {"text": "ISPE Board", "sentiment": {"score": 0.565671, "label": "positive"}, "relevance": 0.479986}, {"text": "Pharmaceuticals Vice Chair", "sentiment": {"score": -0.417164, "label": "negative"}, "relevance": 0.477302}, {"text": "ISPE\u2019s International", "sentiment": {"score": 0.565671, "label": "positive"}, "relevance": 0.475999}, {"text": "ISPE The International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.472049}, {"text": "pharmaceutical industry sectors", "sentiment": {"score": 0.627106, "label": "positive"}, "relevance": 0.332918}, {"text": "pharmaceutical industry leaders", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.327634}, {"text": "Pharmaceuticals International AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.326536}, {"text": "RDI Good Practice", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.322158}, {"text": "International Society", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.309616}, {"text": "Global Validation Support", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306528}, {"text": "Company Past Chair", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.306346}, {"text": "Pharmaceuticals Flemming Dahl", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.305636}, {"text": "Data Integrity", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.302144}, {"text": "Lachman Consultant Services", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.301506}, {"text": "Vivianne J. Arencibia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.300198}, {"text": "Joanne R. Barrick", "sentiment": {"score": 0.259805, "label": "positive"}, "relevance": 0.29865}, {"text": "Global Engineering", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.295115}, {"text": "LLC Gunter Baumgartner", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.294313}, {"text": "Executive Director", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.292476}, {"text": "Quality Compliance Associates", "sentiment": {"score": 0.416015, "label": "positive"}, "relevance": 0.286568}, {"text": "Novo Nordisk A/S", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.285424}, {"text": "entire pharmaceutical lifecycle", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.282441}, {"text": "Senior Process Engineer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.280617}, {"text": "Complete biographical information", "sentiment": {"score": 0.565671, "label": "positive"}, "relevance": 0.277881}, {"text": "Timothy P. Howard", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.276581}, {"text": "Chief Executive Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.27604}, {"text": "Manager QA Validation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.275404}, {"text": "Christine M.V. Moore", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.275357}, {"text": "Celonic AG Alice", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.270468}, {"text": "medical delivery devices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264435}, {"text": "Florida USA. Visit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.264245}, {"text": "largest not-for-profit association", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.261233}, {"text": "Board Members", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.234516}, {"text": "Biopharm CMC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.232174}, {"text": "Biologics Expansion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.220888}, {"text": "strategic leaders", "sentiment": {"score": 0.627106, "label": "positive"}, "relevance": 0.220505}, {"text": "New Directors", "sentiment": {"score": 0.596324, "label": "positive"}, "relevance": 0.219242}, {"text": "GRACS CMC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.216018}, {"text": "Global Head", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.214725}, {"text": "Key Concepts", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.214617}, {"text": "Annual Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.21337}, {"text": "GMP Operations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.212942}, {"text": "Directors webpage", "sentiment": {"score": 0.565671, "label": "positive"}, "relevance": 0.205105}]}, "extracted_metadata": {"sha1": "c46ef05e32f6c130742af9a9b78f4ac1db04204f", "filename": "1542299963401.zip-4838bc2f6424753cb5c6964d969ccff2.xml", "file_type": "json"}, "external_links": ["https://ispe.org/about/international-board-directors#2018-2019-board", "https://ispe.org/conferences/2018-annual-meeting-expo"], "title": "20182019 ISPE Board of Directors Installed at Annual Meeting & Expo", "forum_title": "BioPortfolio Kinex Pharmaceuticals Announces First Patient Dosed with Phase News"}, {"id": "LF--IlPZt0UJzABhuAlq5WmIjLd8ChmF9YFo5AVNx9Fb-dDAoZMK8nhFIqk-rIBn", "result_metadata": {"score": 35.267536}, "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Management", "relevance": 0.909559, "dbpedia_resource": "http://dbpedia.org/resource/Management"}, {"text": "Board of directors", "relevance": 0.7832, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}, {"text": "Corporate governance", "relevance": 0.7128, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}], "categories": [{"score": 0.584375, "label": "/business and industrial/business operations/business plans"}, {"score": 0.575841, "label": "/business and industrial/construction"}, {"score": 0.559784, "label": "/business and industrial/company"}], "relations": [{"type": "partOf", "sentence": "2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo", "score": 0.779752, "arguments": [{"text": "Board of Directors Installed", "location": [15, 43], "entities": [{"type": "Organization", "text": "Board of Directors Installed"}]}, {"text": "Annual Meeting & Expo", "location": [47, 68], "entities": [{"type": "Organization", "text": "Annual Meeting & Expo", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "ISPE Board of Directors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.974642, "count": 1}, {"text": "Annual Meeting", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.949084, "count": 1}, {"text": "Expo", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.682989, "count": 1}]}, "crawl_date": "2018-11-15T22:23:32Z", "url": "https://www.prweb.com/releases/2018_2019_ispe_board_of_directors_installed_at_annual_meeting_expo/prweb15921614.htm", "host": "prweb.com", "text": "Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-15T16:00:00Z", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President", "relevance": 0.889889, "type": "JobTitle"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "International Society for Pharmaceutical Engineering", "relevance": 0.793607, "type": "Organization", "disambiguation": {"subtype": [], "name": "International Society for Pharmaceutical Engineering", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmaceutical_Engineering"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "2018\u20132019 ISPE International Board of Directors", "relevance": 0.725725, "type": "Organization"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "ISPE", "relevance": 0.629465, "type": "Company", "disambiguation": {"subtype": [], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "International Board of Directors", "relevance": 0.611522, "type": "JobTitle"}, {"count": 5, "sentiment": {"score": 0.510769, "label": "positive"}, "text": "Director", "relevance": 0.60142, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President of GMP Operations", "relevance": 0.558537, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.510769, "label": "positive"}, "text": "ISPE\u2019s International Board", "relevance": 0.55435, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President of Strategy and Development", "relevance": 0.526484, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Vice President", "relevance": 0.507433, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vice President Project Management", "relevance": 0.497736, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and CEO", "relevance": 0.489542, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.417149, "label": "negative"}, "text": "Vice Chair", "relevance": 0.425083, "type": "JobTitle"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "BETHESDA", "relevance": 0.358616, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Bethesda, Gwynedd", "dbpedia_resource": "http://dbpedia.org/resource/Bethesda,_Gwynedd"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Engineering", "relevance": 0.356031, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Global Head and Executive Director", "relevance": 0.325712, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": -0.417149, "label": "negative"}, "text": "Janssen Pharmaceuticals", "relevance": 0.309717, "type": "Company", "disambiguation": {"subtype": [], "name": "Janssen Pharmaceutica", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Pharmaceutica"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceuticals International", "relevance": 0.294368, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Society", "relevance": 0.288103, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biopharm CMC", "relevance": 0.280462, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.273025, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glenmark Pharmaceuticals Flemming Dahl", "relevance": 0.269409, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk", "relevance": 0.269195, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Company Past Chair", "relevance": 0.268346, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Project Lead Biologics Expansion", "relevance": 0.265204, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Timothy P. Howard", "relevance": 0.263059, "type": "Person", "disambiguation": {"subtype": [], "name": "Jen\u0151 Rejt\u0151", "dbpedia_resource": "http://dbpedia.org/resource/Jen\u0151_Rejt\u0151"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Vivianne J. Arencibia", "relevance": 0.262688, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.407361, "label": "positive"}, "text": "Arencibia Quality Compliance Associates", "relevance": 0.262048, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Chief Executive Officer", "relevance": 0.260602, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Executive Director", "relevance": 0.25924, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.409909, "label": "positive"}, "text": "Michael Rutherford", "relevance": 0.258705, "type": "Person", "disambiguation": {"subtype": ["MusicalArtist", "Guitarist", "MusicalGroupMember", "FilmActor"], "name": "Mike Rutherford", "dbpedia_resource": "http://dbpedia.org/resource/Mike_Rutherford"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frances M. Zipp", "relevance": 0.258657, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.259805, "label": "positive"}, "text": "Joanne R. Barrick", "relevance": 0.257519, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "WuXi Biologics", "relevance": 0.257257, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Lachman Consultant Services", "relevance": 0.255897, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gunter Baumgartner", "relevance": 0.253706, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Treasurer", "relevance": 0.252854, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Md.", "relevance": 0.252366, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Manager QA Validation", "relevance": 0.251208, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Process Engineer", "relevance": 0.250146, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "James Breen Jr.", "relevance": 0.248388, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tampa", "relevance": 0.247504, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "PlaceWithNeighborhoods", "City"], "name": "Tampa, Florida", "dbpedia_resource": "http://dbpedia.org/resource/Tampa,_Florida"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Thomas Hartman", "relevance": 0.243751, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Florida", "relevance": 0.241974, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Florida", "dbpedia_resource": "http://dbpedia.org/resource/Florida"}}, {"count": 1, "sentiment": {"score": 0.316871, "label": "positive"}, "text": "LeAnna Pearson", "relevance": 0.241827, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Caroline Rocks", "relevance": 0.240318, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European Operations", "relevance": 0.239977, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Christine M.V. Moore", "relevance": 0.239227, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Secretary", "relevance": 0.234952, "type": "JobTitle"}], "sentiment": {"document": {"score": 0.874552, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo Share Article The International Society for Pharmaceutical Engineering (ISPE)", "keywords": [{"text": "Engineering (ISPE)"}, {"text": "ISPE Board"}, {"text": "Expo Share Article"}, {"text": "Annual Meeting"}], "entities": [{"type": "JobTitle", "text": "Director"}, {"type": "Organization", "text": "International Society for Pharmaceutical Engineering", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmaceutical Engineering", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmaceutical_Engineering"}}]}, "sentence": "2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo Share Article The International Society for Pharmaceutical Engineering (ISPE) installed its 2018\u20132019 International Board of Directors at their 2018 Annual Meeting & Expo, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "object": {"text": "its 2018\u20132019 International Board of Directors", "keywords": [{"text": "International Board"}, {"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "International Board of Directors"}]}, "action": {"verb": {"text": "instal install", "tense": "past"}, "text": "installed", "normalized": "instal install"}}, {"subject": {"text": "NORTH BETHESDA, Md. (PRWEB) November 15, 2018 The International Society for Pharmaceutical Engineering (ISPE)", "keywords": [{"text": "Engineering (ISPE)"}, {"text": "NOH BETHESDA"}, {"text": "International Society"}, {"text": "Md."}], "entities": [{"type": "Location", "text": "BETHESDA", "disambiguation": {"subtype": ["CityTown", "City"], "name": "Bethesda, Gwynedd", "dbpedia_resource": "http://dbpedia.org/resource/Bethesda,_Gwynedd"}}, {"type": "Location", "text": "Md.", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Organization", "text": "International Society for Pharmaceutical Engineering", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmaceutical Engineering", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmaceutical_Engineering"}}]}, "sentence": " NORTH BETHESDA, Md. (PRWEB) November 15, 2018 The International Society for Pharmaceutical Engineering (ISPE) installed its 2018\u20132019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "object": {"text": "its 2018\u20132019 International Board of Directors", "keywords": [{"text": "International Board"}, {"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "International Board of Directors"}]}, "action": {"verb": {"text": "instal install", "tense": "past"}, "text": "installed", "normalized": "instal install"}}, {"subject": {"text": "a slate of strategic leaders", "keywords": [{"text": "slate"}, {"text": "strategic leaders"}]}, "sentence": " NORTH BETHESDA, Md. (PRWEB) November 15, 2018 The International Society for Pharmaceutical Engineering (ISPE) installed its 2018\u20132019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "object": {"text": "a variety of pharmaceutical industry sectors", "keywords": [{"text": "pharmaceutical industry sectors"}, {"text": "variety"}], "entities": []}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represent", "normalized": "represent"}}, {"subject": {"text": "The Board", "keywords": [{"text": "Board"}]}, "sentence": " The Board is responsible for the governance and strategic direction of the Society.", "object": {"text": "responsible for the governance", "keywords": [{"text": "governance"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The following pharmaceutical industry leaders", "keywords": [{"text": "following pharmaceutical industry"}, {"text": "leaders"}], "entities": []}, "sentence": " The following pharmaceutical industry leaders have been elected to the 2018\u20132019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc.", "object": {"text": "elected to the 2018\u20132019 ISPE International Board of Directors", "keywords": [{"text": "ISPE International Board"}, {"text": "Directors"}], "entities": [{"type": "Organization", "text": "2018\u20132019 ISPE International Board of Directors"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The following pharmaceutical industry leaders", "keywords": [{"text": "following pharmaceutical industry"}, {"text": "leaders"}], "entities": []}, "sentence": " The following pharmaceutical industry leaders have been elected to the 2018\u20132019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc.", "object": {"text": "to the 2018\u20132019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc", "keywords": [{"text": "Pharmaceuticals Vice Chair"}, {"text": "Frances M. Zipp"}, {"text": "ISPE International Board"}, {"text": "Lead Biologics Expansion"}], "entities": [{"type": "Organization", "text": "2018\u20132019 ISPE International Board of Directors"}, {"type": "Person", "text": "James Breen Jr."}, {"type": "JobTitle", "text": "Vice President"}, {"type": "JobTitle", "text": "Project Lead Biologics Expansion"}, {"type": "Company", "text": "Janssen Pharmaceuticals", "disambiguation": {"subtype": ["Company"], "name": "Janssen Pharmaceutica", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Pharmaceutica"}}, {"type": "JobTitle", "text": "Vice Chair"}, {"type": "Person", "text": "Frances M. Zipp"}, {"type": "JobTitle", "text": "President and CEO"}, {"type": "Company", "text": "Lachman Consultant Services"}]}, "action": {"verb": {"text": "elect", "tense": "past"}, "text": "have been elected", "normalized": "have be elect"}}, {"subject": {"text": "Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development,", "keywords": [{"text": "Timothy P. Howard"}, {"text": "Vice President"}, {"text": "PE"}, {"text": "Strategy"}], "entities": [{"type": "Person", "text": "Timothy P. Howard", "disambiguation": {"subtype": [], "name": "Jen\u0151 Rejt\u0151", "dbpedia_resource": "http://dbpedia.org/resource/Jen\u0151_Rejt\u0151"}}, {"type": "JobTitle", "text": "Vice President of Strategy and Development"}]}, "sentence": " Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc.", "object": {"text": "Agents", "keywords": [{"text": "Agents"}]}, "action": {"verb": {"text": "Commissioning", "tense": "present"}, "text": "Commissioning", "normalized": "Commissioning"}}, {"subject": {"text": "Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC \u2013 Policy, Merck New Directors", "keywords": [{"text": "Christine M.V. Moore"}, {"text": "Merck New Directors"}, {"text": "GRACS CMC"}, {"text": "Global Head"}], "entities": [{"type": "Person", "text": "Christine M.V. Moore"}, {"type": "JobTitle", "text": "Global Head and Executive Director"}]}, "sentence": " Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC \u2013 Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President, Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc.", "object": {"text": "Director", "keywords": [{"text": "Director"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "action": {"verb": {"text": "Re-Elected", "tense": "past"}, "text": "Re-Elected", "normalized": "Re-Elected"}}, {"subject": {"text": "Vivianne J. Arencibia, President,", "keywords": [{"text": "Vivianne J. Arencibia"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Vivianne J. Arencibia"}, {"type": "JobTitle", "text": "President and CEO"}]}, "sentence": " Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC \u2013 Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President, Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc.", "object": {"text": "Quality Compliance Associates, LLC Gunter Baumgartner, Vice President, Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks", "keywords": [{"text": "LLC Gunter Baumgartner"}, {"text": "AG Caroline Rocks"}, {"text": "Quality Compliance Associates"}, {"text": "Vice President"}], "entities": [{"type": "Person", "text": "Gunter Baumgartner"}, {"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Global Engineering"}, {"type": "Company", "text": "Takeda Pharmaceuticals International"}, {"type": "Person", "text": "Caroline Rocks"}]}, "action": {"verb": {"text": "Arencibia", "tense": "present"}, "text": "Arencibia", "normalized": "Arencibia"}}, {"subject": {"text": "CEng", "keywords": [{"text": "CEng"}]}, "sentence": " Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC \u2013 Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President, Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc.", "object": {"text": "MEngSc, Senior Process Engineer, AbbVie, Inc", "keywords": [{"text": "Senior Process Engineer"}, {"text": "AbbVie"}], "entities": [{"type": "JobTitle", "text": "Senior Process Engineer"}]}, "action": {"verb": {"text": "BE", "tense": "present"}, "text": "BE", "normalized": "BE"}}, {"subject": {"text": "Director", "keywords": [{"text": "Director"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "sentence": " Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd.", "object": {"text": "Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Chris Chen"}, {"text": "Biologics"}, {"text": "Co."}], "entities": [{"type": "Person", "text": "Chris Chen"}, {"type": "JobTitle", "text": "Chief Executive Officer"}, {"type": "Company", "text": "WuXi Biologics"}, {"type": "Company", "text": "Shanghai) Co."}]}, "action": {"verb": {"text": "Appointed", "tense": "past"}, "text": "Appointed", "normalized": "Appointed"}}, {"subject": {"text": "those"}, "sentence": " Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc.", "object": {"text": "above"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the following Directors", "keywords": [{"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "sentence": " Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc.", "object": {"text": "elected in 2017"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "the following Directors", "keywords": [{"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "sentence": " Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc.", "object": {"text": "to serve a two-year term", "keywords": [{"text": "two-year term"}], "entities": [{"type": "Quantity", "text": "two-year"}]}, "action": {"verb": {"text": "elect", "tense": "past"}, "text": "were elected", "normalized": "be elect"}}, {"subject": {"text": "the following Directors", "keywords": [{"text": "Directors"}], "entities": [{"type": "JobTitle", "text": "Director"}]}, "sentence": " Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc.", "object": {"text": "their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc", "keywords": [{"text": "Vice President"}, {"text": "Senior Vice President"}, {"text": "Vice President Project"}, {"text": "Novo Nordisk A/S"}], "entities": [{"type": "Person", "text": "Tony"}, {"type": "JobTitle", "text": "Vice President"}, {"type": "Company", "text": "Global Engineering"}, {"type": "Company", "text": "Glenmark Pharmaceuticals Flemming Dahl"}, {"type": "JobTitle", "text": "Senior Vice President"}, {"type": "Company", "text": "Novo Nordisk", "disambiguation": {"subtype": ["Company"], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"type": "Person", "text": "Kelly Keen"}, {"type": "JobTitle", "text": "Vice President Project Management"}, {"type": "Person", "text": "Alice Redmond"}, {"type": "JobTitle", "text": "Vice President"}, {"type": "Organization", "text": "European Operations"}]}, "action": {"verb": {"text": "continue", "tense": "future"}, "text": "will continue", "normalized": "will continue"}}, {"subject": {"text": "all of ISPE\u2019s International Board", "keywords": [{"text": "ISPE\u2019s International"}, {"text": "Board"}], "entities": [{"type": "Organization", "text": "ISPE\u2019s International Board"}]}, "sentence": " Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson, Manager QA Validation, bluebird bio Complete biographical information on all of ISPE\u2019s International Board can be found at the ISPE Board of Directors webpage.", "action": {"verb": {"text": "find", "tense": "future"}, "text": "can be found", "normalized": "can be find"}}, {"subject": {"text": "largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle", "keywords": [{"text": "entire pharmaceutical lifecycle"}, {"text": "largest not-for-profit association"}, {"text": "regulatory advancement"}, {"text": "members"}]}, "sentence": " About ISPE The International Society for Pharmaceutical Engineering (ISPE) is the world\u2019s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle.", "object": {"text": "the world", "keywords": [{"text": "world"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The 18,500 members of ISPE", "keywords": [{"text": "ISPE"}, {"text": "members"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.", "object": {"text": "building solutions", "keywords": [{"text": "building solutions"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The 18,500 members of ISPE", "keywords": [{"text": "ISPE"}, {"text": "members"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.", "object": {"text": "solutions", "keywords": [{"text": "solutions"}]}, "action": {"verb": {"text": "build", "tense": "present"}, "text": "are building", "normalized": "be build"}}, {"subject": {"text": "ISPE", "keywords": [{"text": "ISPE"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit http://www.ISPE.org for more information.", "action": {"verb": {"text": "Founded", "tense": "past"}, "text": "Founded", "normalized": "Founded"}}, {"subject": {"text": "ISPE", "keywords": [{"text": "ISPE"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit http://www.ISPE.org for more information.", "object": {"text": "its worldwide headquarters and training center", "keywords": [{"text": "worldwide headquarters"}, {"text": "center"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "ISPE", "keywords": [{"text": "ISPE"}], "entities": [{"type": "Company", "text": "ISPE", "disambiguation": {"subtype": ["Organization"], "name": "International Society for Pharmacoepidemiology", "dbpedia_resource": "http://dbpedia.org/resource/International_Society_for_Pharmacoepidemiology"}}]}, "sentence": " Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA. Visit http://www.ISPE.org for more information.", "object": {"text": "center", "keywords": [{"text": "center"}]}, "action": {"verb": {"text": "train", "tense": "present"}, "text": "training", "normalized": "train"}}], "concepts": [{"text": "Corporate governance", "relevance": 0.973406, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Board of directors", "relevance": 0.927151, "dbpedia_resource": "http://dbpedia.org/resource/Board_of_directors"}, {"text": "Management occupations", "relevance": 0.901461, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Management", "relevance": 0.884015, "dbpedia_resource": "http://dbpedia.org/resource/Management"}, {"text": "Executive director", "relevance": 0.845889, "dbpedia_resource": "http://dbpedia.org/resource/Executive_director"}, {"text": "Chairman", "relevance": 0.843575, "dbpedia_resource": "http://dbpedia.org/resource/Chairman"}, {"text": "Corporate title", "relevance": 0.795327, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_title"}, {"text": "Chief executives", "relevance": 0.744509, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Non-executive director", "relevance": 0.736007, "dbpedia_resource": "http://dbpedia.org/resource/Non-executive_director"}, {"text": "Chief executive officer", "relevance": 0.732216, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Managing director", "relevance": 0.677705, "dbpedia_resource": "http://dbpedia.org/resource/Managing_director"}, {"text": "Executive officer", "relevance": 0.659765, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Pharmacy", "relevance": 0.606083, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Conflict of interest", "relevance": 0.584949, "dbpedia_resource": "http://dbpedia.org/resource/Conflict_of_interest"}, {"text": "Pharmacology", "relevance": 0.551935, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}], "categories": [{"score": 0.975815, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "partOf", "sentence": "2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo Share Article The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.544004, "arguments": [{"text": "Board of Directors Installed", "location": [15, 43], "entities": [{"type": "Organization", "text": "Board of Directors Installed"}]}, {"text": "Annual Meeting & Expo", "location": [47, 68], "entities": [{"type": "Organization", "text": "Annual Meeting & Expo", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.636559, "arguments": [{"text": "Vice President of", "location": [1069, 1086], "entities": [{"type": "Person", "text": "Thomas Hartman"}]}, {"text": "GMP Operations", "location": [1087, 1101], "entities": [{"type": "Organization", "text": "GMP Operations", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "managerOf", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.703911, "arguments": [{"text": "Secretary", "location": [1133, 1142], "entities": [{"type": "Person", "text": "Secretary"}]}, {"text": "GlaxoSmithKline", "location": [1117, 1132], "entities": [{"type": "Organization", "text": "GlaxoSmithKline", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.494979, "arguments": [{"text": "Timothy P. Howard", "location": [1238, 1255], "entities": [{"type": "Person", "text": "Timothy P. Howard"}]}, {"text": "CPIP", "location": [1257, 1261], "entities": [{"type": "Organization", "text": "CPIP"}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.516869, "arguments": [{"text": "Director", "location": [1349, 1357], "entities": [{"type": "Person", "text": "Director"}]}, {"text": "Inc. Re-Elected", "location": [1333, 1348], "entities": [{"type": "Organization", "text": "Inc. Re-Elected", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.859905, "arguments": [{"text": "Directors", "location": [1452, 1461], "entities": [{"type": "Person", "text": "Directors"}]}, {"text": "Merck New", "location": [1442, 1451], "entities": [{"type": "Organization", "text": "Merck New", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.876099, "arguments": [{"text": "Vivianne J. Arencibia", "location": [1463, 1484], "entities": [{"type": "Person", "text": "Vivianne J. Arencibia"}]}, {"text": "Directors", "location": [1452, 1461], "entities": [{"type": "Person", "text": "Directors"}]}]}, {"type": "partOfMany", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.820266, "arguments": [{"text": "Gunter Baumgartner", "location": [1542, 1560], "entities": [{"type": "Person", "text": "Gunter Baumgartner"}]}, {"text": "Directors", "location": [1452, 1461], "entities": [{"type": "Person", "text": "Directors"}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.734559, "arguments": [{"text": "Gunter Baumgartner", "location": [1542, 1560], "entities": [{"type": "Person", "text": "Gunter Baumgartner"}]}, {"text": "LLC", "location": [1538, 1541], "entities": [{"type": "Organization", "text": "LLC"}]}]}, {"type": "agentOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.605926, "arguments": [{"text": "Global Engineering", "location": [1578, 1596], "entities": [{"type": "Organization", "text": "Global Engineering", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Appointed", "location": [1708, 1717], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.633244, "arguments": [{"text": "Caroline Rocks", "location": [1638, 1652], "entities": [{"type": "Person", "text": "Caroline Rocks"}]}, {"text": "Takeda Pharmaceuticals International AG", "location": [1598, 1637], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals International AG", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo Share Article The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.532475, "arguments": [{"text": "its", "location": [157, 160], "entities": [{"type": "Organization", "text": "Annual Meeting & Expo", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "revealing", "location": [241, 250], "entities": [{"type": "EventCommunication", "text": "revealing"}]}]}, {"type": "agentOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.58079, "arguments": [{"text": "Caroline Rocks", "location": [1638, 1652], "entities": [{"type": "Person", "text": "Caroline Rocks"}]}, {"text": "Appointed", "location": [1708, 1717], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "agentOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.747738, "arguments": [{"text": "AbbVie, Inc.", "location": [1695, 1707], "entities": [{"type": "Organization", "text": "AbbVie, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Appointed", "location": [1708, 1717], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "affectedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.825382, "arguments": [{"text": "Director", "location": [1718, 1726], "entities": [{"type": "Person", "text": "Director"}]}, {"text": "Appointed", "location": [1708, 1717], "entities": [{"type": "EventPersonnel", "text": "Appointed"}]}]}, {"type": "agentOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.518901, "arguments": [{"text": "Directors", "location": [1875, 1884], "entities": [{"type": "Person", "text": "Directors"}]}, {"text": "elected", "location": [1890, 1897], "entities": [{"type": "EventElection", "text": "elected"}]}]}, {"type": "timeOf", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.97167, "arguments": [{"text": "2017", "location": [1901, 1905], "entities": [{"type": "Date", "text": "2017"}]}, {"text": "elected", "location": [1890, 1897], "entities": [{"type": "EventElection", "text": "elected"}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.605097, "arguments": [{"text": "Flemming Dahl", "location": [2067, 2080], "entities": [{"type": "Person", "text": "Flemming Dahl"}]}, {"text": "Glenmark Pharmaceuticals", "location": [2042, 2066], "entities": [{"type": "Organization", "text": "Glenmark Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.669721, "arguments": [{"text": "Kelly Keen", "location": [2122, 2132], "entities": [{"type": "Person", "text": "Kelly Keen"}]}, {"text": "Novo Nordisk A/S", "location": [2105, 2121], "entities": [{"type": "Organization", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.911623, "arguments": [{"text": "Redmond", "location": [2191, 2198], "entities": [{"type": "GeopoliticalEntity", "text": "Redmond"}]}, {"text": "PhD", "location": [2200, 2203], "entities": [{"type": "GeopoliticalEntity", "text": "PhD"}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.613265, "arguments": [{"text": "Michael Rutherford", "location": [2269, 2287], "entities": [{"type": "Person", "text": "Michael Rutherford"}]}, {"text": "Commissioning Agents, Inc.", "location": [2242, 2268], "entities": [{"type": "Organization", "text": "Commissioning Agents, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Global Engineering, Takeda Pharmaceuticals International AG Caroline Rocks, CEng BE MEngSc, Senior Process Engineer, AbbVie, Inc. Appointed Director: Chris Chen, Chief Executive Officer, WuXi Biologics (Shanghai) Co., Ltd. Continuing Board Members: In addition to those named above, the following Directors were elected in 2017 to serve a two-year term and will continue their service on the Board: Tony (Antonio) Crincoli, PE, Vice President, Global Engineering, Glenmark Pharmaceuticals Flemming Dahl, Senior Vice President, Novo Nordisk A/S Kelly Keen, Vice President Project Management, PMO, Celonic AG Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc. Michael Rutherford, Executive Director, Computer Systems Quality and Data Integrity, Syneos Health Young Professionals Representative (Ex Officio): LeAnna Pearson,", "score": 0.483481, "arguments": [{"text": "Representative", "location": [2388, 2402], "entities": [{"type": "Person", "text": "Officio"}]}, {"text": "Syneos Health Young Professionals", "location": [2354, 2387], "entities": [{"type": "Organization", "text": "Syneos Health Young Professionals"}]}]}, {"type": "participantIn", "sentence": "2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo Share Article The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.955916, "arguments": [{"text": "their", "location": [207, 212], "entities": [{"type": "Person", "text": "leaders"}]}, {"text": "Meeting", "location": [225, 232], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "participantIn", "sentence": "NORTH BETHESDA, Md. (PRWEB) November 15, 2018 The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.867839, "arguments": [{"text": "their", "location": [510, 515], "entities": [{"type": "Person", "text": "leaders"}]}, {"text": "Meeting", "location": [528, 535], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "partOf", "sentence": "Manager QA Validation, bluebird bio Complete biographical information on all of ISPE's International Board can be found at the ISPE Board of Directors webpage.", "score": 0.898381, "arguments": [{"text": "International Board", "location": [2520, 2539], "entities": [{"type": "Organization", "text": "International Board of Directors"}]}, {"text": "ISPE", "location": [2513, 2517], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}]}, {"type": "locatedAt", "sentence": "About ISPE The International Society for Pharmaceutical Engineering (ISPE) is the world's largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle.", "score": 0.36725, "arguments": [{"text": "association", "location": [2706, 2717], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}, {"text": "world", "location": [2675, 2680], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "memberOf", "sentence": "About ISPE The International Society for Pharmaceutical Engineering (ISPE) is the world's largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle.", "score": 0.51025, "arguments": [{"text": "members", "location": [2730, 2737], "entities": [{"type": "Person", "text": "members"}]}, {"text": "its", "location": [2726, 2729], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}]}, {"type": "employedBy", "sentence": "The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.", "score": 0.47713, "arguments": [{"text": "members", "location": [2859, 2866], "entities": [{"type": "Person", "text": "members"}]}, {"text": "ISPE", "location": [2870, 2874], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}]}, {"type": "locatedAt", "sentence": "The 18,500 members of ISPE are building solutions in the development and manufacture of safe, effective pharmaceutical and biologic medicines, and medical delivery devices in more than 90 countries around the world.", "score": 0.891991, "arguments": [{"text": "countries", "location": [3036, 3045], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "world", "location": [3057, 3062], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "foundedOn", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.645247, "arguments": [{"text": "ISPE", "location": [3081, 3085], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}, {"text": "1980", "location": [3075, 3079], "entities": [{"type": "Date", "text": "1980", "disambiguation": {"subtype": ["Starting"]}}]}]}, {"type": "ownerOf", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.437513, "arguments": [{"text": "its", "location": [3090, 3093], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}, {"text": "headquarters", "location": [3104, 3116], "entities": [{"type": "Facility", "text": "headquarters"}]}]}, {"type": "locatedAt", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.896329, "arguments": [{"text": "training center", "location": [3121, 3136], "entities": [{"type": "Facility", "text": "training center"}]}, {"text": "North Bethesda", "location": [3140, 3154], "entities": [{"type": "GeopoliticalEntity", "text": "NORTH BETHESDA"}]}]}, {"type": "locatedAt", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.997647, "arguments": [{"text": "North Bethesda", "location": [3140, 3154], "entities": [{"type": "GeopoliticalEntity", "text": "NORTH BETHESDA"}]}, {"text": "Maryland USA", "location": [3156, 3168], "entities": [{"type": "GeopoliticalEntity", "text": "Maryland USA"}]}]}, {"type": "basedIn", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.515868, "arguments": [{"text": "its", "location": [3174, 3177], "entities": [{"type": "Organization", "text": "ISPE The International Society for Pharmaceutical Engineering"}]}, {"text": "Tampa", "location": [3199, 3204], "entities": [{"type": "GeopoliticalEntity", "text": "Tampa"}]}]}, {"type": "timeOf", "sentence": "2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo Share Article The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.833405, "arguments": [{"text": "2018 Annual", "location": [213, 224], "entities": [{"type": "Date", "text": "2018 Annual"}]}, {"text": "Meeting", "location": [225, 232], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "locatedAt", "sentence": "Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland USA, and its operations center in Tampa, Florida USA.", "score": 0.995242, "arguments": [{"text": "Tampa", "location": [3199, 3204], "entities": [{"type": "GeopoliticalEntity", "text": "Tampa"}]}, {"text": "Florida USA", "location": [3206, 3217], "entities": [{"type": "GeopoliticalEntity", "text": "Florida USA"}]}]}, {"type": "locatedAt", "sentence": "NORTH BETHESDA, Md. (PRWEB) November 15, 2018 The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.939501, "arguments": [{"text": "NORTH BETHESDA", "location": [340, 354], "entities": [{"type": "GeopoliticalEntity", "text": "NORTH BETHESDA"}]}, {"text": "Md.", "location": [356, 359], "entities": [{"type": "GeopoliticalEntity", "text": "Md."}]}]}, {"type": "participantIn", "sentence": "NORTH BETHESDA, Md. (PRWEB) November 15, 2018 The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.5632, "arguments": [{"text": "International Board of Directors", "location": [474, 506], "entities": [{"type": "Organization", "text": "International Board of Directors"}]}, {"text": "Meeting", "location": [528, 535], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "NORTH BETHESDA, Md. (PRWEB) November 15, 2018 The International Society for Pharmaceutical Engineering (ISPE) installed its 2018-2019 International Board of Directors at their 2018 Annual Meeting & Expo , revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors.", "score": 0.820832, "arguments": [{"text": "2018 Annual", "location": [516, 527], "entities": [{"type": "Date", "text": "2018 Annual"}]}, {"text": "Meeting", "location": [528, 535], "entities": [{"type": "EventMeeting", "text": "Meeting"}]}]}, {"type": "timeOf", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.78154, "arguments": [{"text": "2018\u20132019", "location": [799, 808], "entities": [{"type": "Date", "text": "2018\u20132019"}]}, {"text": "elected", "location": [784, 791], "entities": [{"type": "EventElection", "text": "elected"}]}]}, {"type": "employedBy", "sentence": "The following pharmaceutical industry leaders have been elected to the 2018-2019 ISPE International Board of Directors: Officers: Chair: James Breen Jr., PE, Vice President, Project Lead Biologics Expansion, Janssen Pharmaceuticals Vice Chair: Frances M. Zipp, President and CEO, Lachman Consultant Services, Inc. Treasurer: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline Secretary: Joanne R. Barrick, RPh, Advisor, Global Validation Support, Eli Lilly and Company Past Chair: Timothy P. Howard, CPIP, PE, Vice President of Strategy and Development, Commissioning Agents, Inc. Re-Elected Director: Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC - Policy, Merck New Directors: Vivianne J. Arencibia, President, Arencibia Quality Compliance Associates, LLC Gunter Baumgartner, Vice President,", "score": 0.621162, "arguments": [{"text": "Treasurer", "location": [1042, 1051], "entities": [{"type": "Person", "text": "Thomas Hartman"}]}, {"text": "Lachman Consultant Services, Inc.", "location": [1008, 1041], "entities": [{"type": "Organization", "text": "Lachman Consultant Services, Inc."}]}]}], "keywords": [{"text": "ISPE Board of Directors", "sentiment": {"score": 0.90467, "label": "positive"}, "relevance": 0.774367, "count": 1}, {"text": "Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.762695, "count": 4}, {"text": "International Society", "sentiment": {"score": 0.846856, "label": "positive"}, "relevance": 0.672091, "count": 3}, {"text": "Pharmaceutical Engineering", "sentiment": {"score": 0.846856, "label": "positive"}, "relevance": 0.615148, "count": 3}, {"text": "President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.613434, "count": 2}, {"text": "International Board of Directors", "sentiment": {"score": 0.890356, "label": "positive"}, "relevance": 0.611393, "count": 2}, {"text": "Board Members", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589377, "count": 1}, {"text": "Vice President of GMP Operations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586876, "count": 1}, {"text": "Annual Meeting", "sentiment": {"score": 0.895169, "label": "positive"}, "relevance": 0.572186, "count": 3}, {"text": "Global Validation Support", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566022, "count": 1}, {"text": "Executive Director", "sentiment": {"score": 0.90395, "label": "positive"}, "relevance": 0.563357, "count": 2}, {"text": "ISPE", "sentiment": {"score": 0.82396, "label": "positive"}, "relevance": 0.562512, "count": 5}, {"text": "Global Head", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555629, "count": 1}, {"text": "Data Integrity", "sentiment": {"score": 0.90395, "label": "positive"}, "relevance": 0.55092, "count": 1}, {"text": "profit association", "sentiment": {"score": 0.750699, "label": "positive"}, "relevance": 0.550016, "count": 1}, {"text": "Board", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547669, "count": 2}, {"text": "Senior Vice President", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547035, "count": 1}, {"text": "2018\u20132019 ISPE International Board of Directors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.544415, "count": 1}, {"text": "members", "sentiment": {"score": 0.750699, "label": "positive"}, "relevance": 0.542169, "count": 1}, {"text": "Director", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540421, "count": 2}, {"text": "European Operations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540099, "count": 1}, {"text": "Vice President of Strategy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53766, "count": 1}, {"text": "Past Chair", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53759, "count": 1}, {"text": "Chair", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536779, "count": 2}, {"text": "training center", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535229, "count": 1}, {"text": "Inc. Treasurer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535078, "count": 1}, {"text": "Project Lead Biologics Expansion", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530443, "count": 1}, {"text": "Syneos Health Young Professionals Representative", "sentiment": {"score": 0.90395, "label": "positive"}, "relevance": 0.52862, "count": 1}, {"text": "Janssen Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528269, "count": 1}, {"text": "Arencibia Quality Compliance Associates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528105, "count": 1}, {"text": "Expo", "sentiment": {"score": 0.890356, "label": "positive"}, "relevance": 0.526181, "count": 2}, {"text": "service", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525285, "count": 1}, {"text": "operations center", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524834, "count": 1}, {"text": "Agents", "sentiment": {"score": 0.90395, "label": "positive"}, "relevance": 0.524785, "count": 2}, {"text": "PhD", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523252, "count": 2}, {"text": "Development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522759, "count": 1}, {"text": "development", "sentiment": {"score": 0.91695, "label": "positive"}, "relevance": 0.522759, "count": 1}, {"text": "Directors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.52249, "count": 1}, {"text": "slate of strategic leaders", "sentiment": {"score": 0.890356, "label": "positive"}, "relevance": 0.519884, "count": 2}, {"text": "variety of pharmaceutical industry sectors", "sentiment": {"score": 0.890356, "label": "positive"}, "relevance": 0.518816, "count": 2}, {"text": "world", "sentiment": {"score": 0.750699, "label": "positive"}, "relevance": 0.518409, "count": 2}, {"text": "Vivianne J. Arencibia", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518279, "count": 1}, {"text": "2018\u20132019", "sentiment": {"score": 0.890356, "label": "positive"}, "relevance": 0.517305, "count": 2}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516871, "count": 1}, {"text": "information", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516208, "count": 2}, {"text": "Biopharm CMC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515311, "count": 1}, {"text": "Advisor", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515111, "count": 1}, {"text": "Lachman Consultant Services", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514835, "count": 1}, {"text": "Company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514532, "count": 1}, {"text": "Policy", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514169, "count": 1}]}, "extracted_metadata": {"sha1": "af280f7ba2958a7852c8449f7bdbbcea1067999b", "filename": "1542320612831.zip-99964134a987d45a81e7ee6c6f514aed.xml", "file_type": "json"}, "external_links": ["https://ispe.org/about/international-board-directors#2018-2019-board", "https://ispe.org/conferences/2018-annual-meeting-expo"], "title": "2018-2019 ISPE Board of Directors Installed at Annual Meeting & Expo", "forum_title": "PRWeb - Daily News Feed"}, {"id": "PenGMNNI7-Ec1cZylAX148zzT_RpGGkw6JyKRswaOgnbTUPmXJkzWyaSNfnFd6Y_", "result_metadata": {"score": 34.530834}, "author": "Ankush Nikam", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Penicillin", "relevance": 0.33, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Streptomycin Global Industry", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Years in the future", "relevance": 0.862267, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Capitalism", "relevance": 0.772153, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}], "categories": [{"score": 0.868124, "label": "/business and industrial/paper industry"}, {"score": 0.848609, "label": "/business and industrial/war industry"}, {"score": 0.685155, "label": "/health and fitness/disease"}], "relations": [], "keywords": [{"text": "Penicillin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.993224, "count": 1}, {"text": "Streptomycin Global Industry Analysis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.988309, "count": 1}, {"text": "Forecast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.754742, "count": 1}, {"text": "\u2013", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.052241, "count": 1}]}, "crawl_date": "2018-11-16T11:48:31Z", "url": "https://www.findmarketresearch.org/2018/11/penicillin-and-streptomycin-market-global-industry-analysis-and-forecast-2017-2025/", "host": "findmarketresearch.org", "text": "Request For Report Sample: https://www.persistencemarketresearch.com/samples/13582 The major players operating in this market include Astellas Pharma Inc., GlaxoSmithKline Plc, MiddleBrook Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Gilead Sciences Inc., Toyama Chemical Co., Ltd, Eli Lilly and Company, Astra Zeneca, Takeda Pharmaceutical Company Ltd., among other significant players", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T11:50:00+05:00", "enriched_text": {"entities": [{"count": 11, "sentiment": {"score": -0.499254, "label": "negative"}, "text": "Streptomycin", "relevance": 0.917453, "type": "Drug"}, {"count": 10, "sentiment": {"score": -0.51844, "label": "negative"}, "text": "Penicillin", "relevance": 0.789016, "type": "Drug"}, {"count": 5, "sentiment": {"score": -0.473192, "label": "negative"}, "text": "penicillin", "relevance": 0.526209, "type": "Drug"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.150762, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "CDC", "relevance": 0.132748, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "Centers for Disease Control and Prevention", "dbpedia_resource": "http://dbpedia.org/resource/Centers_for_Disease_Control_and_Prevention"}}, {"count": 1, "sentiment": {"score": -0.721183, "label": "negative"}, "text": "meningitis", "relevance": 0.128791, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "RiskFactor", "Symptom"], "name": "Meningitis", "dbpedia_resource": "http://dbpedia.org/resource/Meningitis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.12828, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": -0.368546, "label": "negative"}, "text": "Tuberculosis", "relevance": 0.12775, "type": "HealthCondition", "disambiguation": {"subtype": ["Location", "DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Tuberculosis", "dbpedia_resource": "http://dbpedia.org/resource/Tuberculosis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astra Zeneca", "relevance": 0.121452, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma Inc.", "relevance": 0.117491, "type": "Company", "disambiguation": {"subtype": [], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"count": 1, "sentiment": {"score": -0.656977, "label": "negative"}, "text": "Mn", "relevance": 0.116026, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.113477, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mexico", "relevance": 0.110382, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.109935, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.107303, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": -0.598278, "label": "negative"}, "text": "Asia Pacific", "relevance": 0.107097, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.106898, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.598278, "label": "negative"}, "text": "MRSA", "relevance": 0.106263, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline Plc", "relevance": 0.105846, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.10528, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Toyama Chemical Co.", "relevance": 0.101002, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.244428, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.100566, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.0995497, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gilead Sciences Inc.", "relevance": 0.0962408, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.405612, "label": "negative"}, "text": "MiddleBrook Pharmaceuticals", "relevance": 0.0962088, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Brazil", "relevance": 0.0961303, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.0941434, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": -0.514352, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "An antibiotic"}, "sentence": "An antibiotic is a substance or compound is an antimicrobial agent that kills bacterial infections or inhibits bacterial growth.", "object": {"text": "a substance or compound", "keywords": [{"text": "compound"}, {"text": "substance"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "An antibiotic is a substance or compound", "keywords": [{"text": "compound"}, {"text": "substance"}]}, "sentence": "An antibiotic is a substance or compound is an antimicrobial agent that kills bacterial infections or inhibits bacterial growth.", "object": {"text": "an antimicrobial agent that kills bacterial infections or inhibits bacterial growth", "keywords": [{"text": "bacterial infections"}, {"text": "bacterial growth"}, {"text": "antimicrobial agent"}, {"text": "inhibits"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an antimicrobial agent", "keywords": [{"text": "antimicrobial agent"}]}, "sentence": "An antibiotic is a substance or compound is an antimicrobial agent that kills bacterial infections or inhibits bacterial growth.", "object": {"text": "bacterial infections", "keywords": [{"text": "bacterial infections"}]}, "action": {"verb": {"text": "kill", "tense": "present"}, "text": "kills", "normalized": "kill"}}, {"subject": {"text": "Penicillin and Streptomycin", "keywords": [{"text": "Streptomycin"}, {"text": "Penicillin"}], "entities": [{"type": "Drug", "text": "Penicillin"}, {"type": "Drug", "text": "Streptomycin"}]}, "sentence": " Penicillin and Streptomycin are two types of antibiotics used in several bacterial infection treatment.", "object": {"text": "two types of antibiotics", "keywords": [{"text": "antibiotics"}, {"text": "types"}], "entities": [{"type": "Drug", "text": "Penicillin"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "antibiotics", "keywords": [{"text": "antibiotics"}]}, "sentence": " Penicillin and Streptomycin are two types of antibiotics used in several bacterial infection treatment.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "no treatment", "keywords": [{"text": "treatment"}]}, "sentence": " In the last century, when no treatment was available, a minor infection could cost lives.", "object": {"text": "available, a minor infection", "keywords": [{"text": "minor infection"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "a minor infection", "keywords": [{"text": "minor infection"}]}, "sentence": " In the last century, when no treatment was available, a minor infection could cost lives.", "object": {"text": "lives", "keywords": [{"text": "lives"}]}, "action": {"verb": {"text": "cost", "tense": "future"}, "text": "could cost", "normalized": "could cost"}}, {"subject": {"text": "Bacterial infections", "keywords": [{"text": "Bacterial infections"}]}, "sentence": " Bacterial infections were the major cause of mortality at that time.", "object": {"text": "the major cause of mortality at that time", "keywords": [{"text": "major cause"}, {"text": "mortality"}, {"text": "time"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "The discovery of Penicillin", "keywords": [{"text": "Penicillin"}, {"text": "discovery"}], "entities": [{"type": "Drug", "text": "Penicillin"}]}, "sentence": " The discovery of Penicillin revolutionized pharmaceutical and medical sciences.", "object": {"text": "pharmaceutical and medical sciences", "keywords": [{"text": "medical sciences"}]}, "action": {"verb": {"text": "revolutionize", "tense": "past"}, "text": "revolutionized", "normalized": "revolutionize"}}, {"subject": {"text": "Penicillin drugs", "keywords": [{"text": "Penicillin drugs"}], "entities": [{"type": "Drug", "text": "penicillin"}]}, "sentence": " Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis and so on.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "are used", "normalized": "be use"}}, {"subject": {"text": "Streptomycin", "keywords": [{"text": "Streptomycin"}], "entities": [{"type": "Drug", "text": "Streptomycin"}]}, "sentence": " Streptomycin is used in Tuberculosis treatment.", "action": {"verb": {"text": "use", "tense": "past"}, "text": "is used", "normalized": "be use"}}, {"subject": {"text": "Penicillin and streptomycin market", "keywords": [{"text": "streptomycin market"}, {"text": "Penicillin"}], "entities": [{"type": "Drug", "text": "Penicillin"}, {"type": "Drug", "text": "Streptomycin"}]}, "sentence": " Penicillin and streptomycin market is witnessing high growth due to increased investment in research & development activity with new product innovations.", "object": {"text": "witnessing high growth due to increased investment in research & development activity with new product innovations", "keywords": [{"text": "new product innovations"}, {"text": "high growth"}, {"text": "development activity"}, {"text": "investment"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Penicillin and streptomycin market", "keywords": [{"text": "streptomycin market"}, {"text": "Penicillin"}], "entities": [{"type": "Drug", "text": "Penicillin"}, {"type": "Drug", "text": "Streptomycin"}]}, "sentence": " Penicillin and streptomycin market is witnessing high growth due to increased investment in research & development activity with new product innovations.", "object": {"text": "high growth due to increased investment in research & development activity with new product innovations", "keywords": [{"text": "new product innovations"}, {"text": "high growth"}, {"text": "development activity"}, {"text": "investment"}]}, "action": {"verb": {"text": "witness", "tense": "present"}, "text": "is witnessing", "normalized": "be witness"}}, {"subject": {"text": "various government and non-government organizations", "keywords": [{"text": "non-government organizations"}, {"text": "various government"}]}, "sentence": " Moreover, the other regulatory initiatives and creating awareness by various government and non-government organizations to control the bacterial infectious disease among people are also expected to drive the growth of the global penicillin and streptomycin market.", "object": {"text": "the bacterial infectious disease", "keywords": [{"text": "bacterial infectious disease"}]}, "action": {"verb": {"text": "control", "tense": "future"}, "text": "to control", "normalized": "to control"}}, {"subject": {"text": "the other regulatory initiatives and creating awareness by various government and non-government organizations to control the bacterial infectious disease among people", "keywords": [{"text": "bacterial infectious disease"}, {"text": "non-government organizations"}, {"text": "regulatory initiatives"}, {"text": "various government"}]}, "sentence": " Moreover, the other regulatory initiatives and creating awareness by various government and non-government organizations to control the bacterial infectious disease among people are also expected to drive the growth of the global penicillin and streptomycin market.", "object": {"text": "the growth of the global penicillin and streptomycin market", "keywords": [{"text": "streptomycin market"}, {"text": "global penicillin"}, {"text": "growth"}], "entities": []}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "are also expected to drive", "normalized": "be also expect to drive"}}, {"subject": {"text": "by the penicillin and streptomycin market", "keywords": [{"text": "streptomycin market"}, {"text": "penicillin"}], "entities": [{"type": "Drug", "text": "Penicillin"}, {"type": "Drug", "text": "Streptomycin"}]}, "sentence": " However, the biggest challenge faced by the penicillin and streptomycin market is the development of antibiotic resistance in many bacteria.", "object": {"text": "the biggest challenge", "keywords": [{"text": "biggest challenge"}]}, "action": {"verb": {"text": "face", "tense": "past"}, "text": "faced", "normalized": "face"}}, {"subject": {"text": "Mutation in bacteria", "keywords": [{"text": "Mutation"}, {"text": "bacteria"}]}, "sentence": " Mutation in bacteria provides immune resistance to antibiotics such as penicillin and streptomycin.", "object": {"text": "immune resistance", "keywords": [{"text": "immune resistance"}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Bacteria such as Enterobacteriacea, Gram-negative bacteria, and various Staphylococcus strains", "keywords": [{"text": "Gram-negative bacteria"}, {"text": "various Staphylococcus strains"}]}, "sentence": " Bacteria such as Enterobacteriacea, Gram-negative bacteria, and various Staphylococcus strains are resistant to penicillin.", "object": {"text": "resistant to penicillin", "keywords": [{"text": "resistant"}], "entities": [{"type": "Drug", "text": "penicillin"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Increasing resistance to antibiotics", "keywords": [{"text": "antibiotics"}, {"text": "resistance"}]}, "sentence": " Increasing resistance to antibiotics is the major public health problem worldwide which is the major restraining factor for the growth of the global penicillin and streptomycin market.", "object": {"text": "the major public health problem worldwide which is the major restraining factor for the growth of the global penicillin and streptomycin market", "keywords": [{"text": "major restraining factor"}, {"text": "streptomycin market"}, {"text": "public health problem"}, {"text": "global penicillin"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " In terms of product type, the global market has been segmented into penicillin and streptomycin products.", "object": {"text": "into penicillin", "keywords": [{"text": "penicillin"}], "entities": [{"type": "Drug", "text": "penicillin"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "penicillin and streptomycin product", "keywords": [{"text": "streptomycin product"}, {"text": "penicillin"}], "entities": [{"type": "Drug", "text": "penicillin"}, {"type": "Drug", "text": "Streptomycin"}]}, "sentence": " Furthermore, penicillin and streptomycin product segmented into bulk and dosage.", "object": {"text": "into bulk and dosage", "keywords": [{"text": "dosage"}, {"text": "bulk"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "segmented", "normalized": "segment"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " In terms of route of administration, the global market has been categories into oral, intramuscular, and intravenous.", "object": {"text": "been categories into oral, intramuscular, and intravenous", "keywords": [{"text": "categories"}], "entities": []}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " In terms of manufacturing process, the global market has been segmented into natural, synthetic, and semi-synthetic.", "object": {"text": "segmented into natural, synthetic, and semi-synthetic"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "the global market", "keywords": [{"text": "global market"}], "entities": []}, "sentence": " In terms of manufacturing process, the global market has been segmented into natural, synthetic, and semi-synthetic.", "object": {"text": "into natural, synthetic, and semi-synthetic"}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "Asia Pacific", "keywords": [{"text": "Asia Pacific"}], "entities": [{"type": "Facility", "text": "Asia Pacific"}]}, "sentence": " Geographically, Asia Pacific was the largest regional market for penicillin and streptomycin in 2015 in terms of value.", "object": {"text": "the largest regional market", "keywords": [{"text": "largest regional market"}], "entities": [{"type": "Facility", "text": "Asia Pacific"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "This dominance", "keywords": [{"text": "dominance"}]}, "sentence": " This dominance is due to growing number of antibiotic manufacturers in the Asian countries and also due to the presence of some of the world\u2019s leading generics manufacturers in this region.", "object": {"text": "due to growing number of antibiotic manufacturers in the Asian countries and also due to the presence of some of the world\u2019s leading generics manufacturers in this region", "keywords": [{"text": "generics manufacturers"}, {"text": "antibiotic manufacturers"}, {"text": "Asian countries"}, {"text": "presence"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "some of the world", "keywords": [{"text": "world"}]}, "sentence": " This dominance is due to growing number of antibiotic manufacturers in the Asian countries and also due to the presence of some of the world\u2019s leading generics manufacturers in this region.", "object": {"text": "leading generics manufacturers", "keywords": [{"text": "generics"}, {"text": "manufacturers"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "has", "normalized": "has"}}, {"subject": {"text": "manufacturers", "keywords": [{"text": "manufacturers"}]}, "sentence": " This dominance is due to growing number of antibiotic manufacturers in the Asian countries and also due to the presence of some of the world\u2019s leading generics manufacturers in this region.", "object": {"text": "generics", "keywords": [{"text": "generics"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "s leading", "normalized": "s lead"}}, {"subject": {"text": "some other factors which will drive growth in Asia Pacific penicillin and streptomycin market", "keywords": [{"text": "Asia Pacific penicillin"}, {"text": "streptomycin market"}, {"text": "factors"}, {"text": "growth"}], "entities": [{"type": "Company", "text": "Asia Pacific"}, {"type": "Drug", "text": "penicillin"}, {"type": "Drug", "text": "Streptomycin"}]}, "sentence": " Additionally, growing incidences of bacterial infections such as Clostridium difficile and MRSA infections and growing patient awareness are some other factors which will drive growth in Asia Pacific penicillin and streptomycin market.", "object": {"text": "bacterial infections such as Clostridium difficile and MRSA infections and growing patient awareness", "keywords": [{"text": "bacterial infections"}, {"text": "MRSA infections"}, {"text": "Clostridium difficile"}, {"text": "patient awareness"}], "entities": [{"type": "HealthCondition", "text": "MRSA"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "some other factors", "keywords": [{"text": "factors"}]}, "sentence": " Additionally, growing incidences of bacterial infections such as Clostridium difficile and MRSA infections and growing patient awareness are some other factors which will drive growth in Asia Pacific penicillin and streptomycin market.", "object": {"text": "growth", "keywords": [{"text": "growth"}]}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "will drive", "normalized": "will drive"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America was identified as the second largest regional market in 2015 and is expected to register moderate growth rate during the forecast period due to loss of patent exclusivity, market maturity, generic infiltration and shortened drug lifecycles, etc.", "object": {"text": "identified"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America was identified as the second largest regional market in 2015 and is expected to register moderate growth rate during the forecast period due to loss of patent exclusivity, market maturity, generic infiltration and shortened drug lifecycles, etc.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "was identified", "normalized": "be identify"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America was identified as the second largest regional market in 2015 and is expected to register moderate growth rate during the forecast period due to loss of patent exclusivity, market maturity, generic infiltration and shortened drug lifecycles, etc.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America was identified as the second largest regional market in 2015 and is expected to register moderate growth rate during the forecast period due to loss of patent exclusivity, market maturity, generic infiltration and shortened drug lifecycles, etc.", "object": {"text": "moderate growth rate", "keywords": [{"text": "moderate growth rate"}]}, "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "Europe", "keywords": [{"text": "Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Europe was the third largest market for penicillin and streptomycin.", "object": {"text": "the third largest market for penicillin and streptomycin", "keywords": [{"text": "streptomycin"}, {"text": "penicillin"}, {"text": "largest market"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Drug", "text": "Penicillin"}, {"type": "Drug", "text": "Streptomycin"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "These three market growths", "keywords": [{"text": "market growths"}]}, "sentence": " These three market growths can be attributed to the investments done by governments to improve the present healthcare facility for better health of the people, which will enhance the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany.", "object": {"text": "to the investments done by governments to improve the present healthcare facility for better health of the people, which will enhance the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany", "keywords": [{"text": "present healthcare facility"}, {"text": "better health"}, {"text": "streptomycin"}, {"text": "penicillin"}], "entities": [{"type": "Drug", "text": "Penicillin"}, {"type": "Drug", "text": "Streptomycin"}, {"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"type": "Location", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "attribute", "tense": "future"}, "text": "can be attributed", "normalized": "can be attribute"}}, {"subject": {"text": "by governments", "keywords": [{"text": "governments"}]}, "sentence": " These three market growths can be attributed to the investments done by governments to improve the present healthcare facility for better health of the people, which will enhance the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany.", "object": {"text": "the investments", "keywords": [{"text": "investments"}]}, "action": {"verb": {"text": "do", "tense": "past"}, "text": "done", "normalized": "do"}}, {"subject": {"text": "the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany", "keywords": [{"text": "streptomycin"}, {"text": "penicillin"}, {"text": "growth"}, {"text": "countries"}], "entities": [{"type": "Drug", "text": "Penicillin"}, {"type": "Drug", "text": "Streptomycin"}, {"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"type": "Location", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " These three market growths can be attributed to the investments done by governments to improve the present healthcare facility for better health of the people, which will enhance the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany.", "object": {"text": "the people", "keywords": [{"text": "people"}]}, "action": {"verb": {"text": "enhance", "tense": "future"}, "text": "will enhance", "normalized": "will enhance"}}, {"subject": {"text": "Latin American countries such as Mexico and Brazil", "keywords": [{"text": "Latin American countries"}, {"text": "Brazil"}, {"text": "Mexico"}], "entities": [{"type": "Location", "text": "Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "Country", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Latin American countries such as Mexico and Brazil are expected to have considerable potential for driving the market growth due to evolving medical care infrastructure, and high incidences of bacterial infections.", "object": {"text": "considerable potential", "keywords": [{"text": "considerable potential"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "are expected to have", "normalized": "be expect to have"}}, {"subject": {"text": "Latin American countries such as Mexico and Brazil", "keywords": [{"text": "Latin American countries"}, {"text": "Brazil"}, {"text": "Mexico"}], "entities": [{"type": "Location", "text": "Mexico", "disambiguation": {"subtype": ["PoliticalDistrict", "Country", "GovernmentalJurisdiction", "FilmCinematographer", "Country"], "name": "Mexico", "dbpedia_resource": "http://dbpedia.org/resource/Mexico"}}, {"type": "Location", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Latin American countries such as Mexico and Brazil are expected to have considerable potential for driving the market growth due to evolving medical care infrastructure, and high incidences of bacterial infections.", "object": {"text": "the market growth due to evolving medical care infrastructure, and high incidences of bacterial infections", "keywords": [{"text": "medical care infrastructure"}, {"text": "bacterial infections"}, {"text": "high incidences"}, {"text": "market growth"}], "entities": []}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "The major players", "keywords": [{"text": "major players"}]}, "sentence": " The major players operating in this market include Astellas Pharma Inc., GlaxoSmithKline Plc, MiddleBrook Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Gilead Sciences Inc., Toyama Chemical Co., Ltd, Eli Lilly and Company, Astra Zeneca, Takeda Pharmaceutical Company Ltd., among other significant players worldwide.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Astellas Pharma Inc., GlaxoSmithKline Plc, MiddleBrook Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Gilead Sciences Inc., Toyama Chemical Co., Ltd, Eli Lilly and Company, Astra Zeneca, Takeda Pharmaceutical Company Ltd., among other significant players worldwide", "keywords": [{"text": "Toyama Chemical Co."}, {"text": "Astellas Pharma Inc."}, {"text": "Gilead Sciences Inc."}, {"text": "Takeda Pharmaceutical Company"}], "entities": [{"type": "Company", "text": "Astellas Pharma Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Astellas Pharma", "dbpedia_resource": "http://dbpedia.org/resource/Astellas_Pharma"}}, {"type": "Company", "text": "GlaxoSmithKline Plc", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "MiddleBrook Pharmaceuticals"}, {"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "Merck & Co.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Gilead Sciences Inc."}, {"type": "Company", "text": "Toyama Chemical Co."}, {"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Astra Zeneca", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}]}, "sentence": " The major players operating in this market include Astellas Pharma Inc., GlaxoSmithKline Plc, MiddleBrook Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Gilead Sciences Inc., Toyama Chemical Co., Ltd, Eli Lilly and Company, Astra Zeneca, Takeda Pharmaceutical Company Ltd., among other significant players worldwide.", "object": {"text": "The major players operating in this market", "keywords": [{"text": "major players"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}], "concepts": [{"text": "Bacteria", "relevance": 0.959153, "dbpedia_resource": "http://dbpedia.org/resource/Bacteria"}, {"text": "Penicillin", "relevance": 0.908113, "dbpedia_resource": "http://dbpedia.org/resource/Penicillin"}, {"text": "Antibiotic resistance", "relevance": 0.839299, "dbpedia_resource": "http://dbpedia.org/resource/Antibiotic_resistance"}, {"text": "Clostridium difficile", "relevance": 0.753538, "dbpedia_resource": "http://dbpedia.org/resource/Clostridium_difficile"}, {"text": "Infection", "relevance": 0.729619, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Immune system", "relevance": 0.6365, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Microbiology", "relevance": 0.63312, "dbpedia_resource": "http://dbpedia.org/resource/Microbiology"}, {"text": "Infectious disease", "relevance": 0.541075, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Virus", "relevance": 0.513841, "dbpedia_resource": "http://dbpedia.org/resource/Virus"}, {"text": "Antibiotic", "relevance": 0.51363, "dbpedia_resource": "http://dbpedia.org/resource/Antibiotic"}, {"text": "Antiseptic", "relevance": 0.504808, "dbpedia_resource": "http://dbpedia.org/resource/Antiseptic"}, {"text": "Medicine", "relevance": 0.459938, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Microorganism", "relevance": 0.444312, "dbpedia_resource": "http://dbpedia.org/resource/Microorganism"}, {"text": "Staphylococcus aureus", "relevance": 0.437641, "dbpedia_resource": "http://dbpedia.org/resource/Staphylococcus_aureus"}, {"text": "Disease", "relevance": 0.428031, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Tuberculosis", "relevance": 0.426925, "dbpedia_resource": "http://dbpedia.org/resource/Tuberculosis"}, {"text": "Escherichia coli", "relevance": 0.375668, "dbpedia_resource": "http://dbpedia.org/resource/Escherichia_coli"}, {"text": "Bacteriology", "relevance": 0.371148, "dbpedia_resource": "http://dbpedia.org/resource/Bacteriology"}, {"text": "Inflammation", "relevance": 0.370923, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Fungus", "relevance": 0.343405, "dbpedia_resource": "http://dbpedia.org/resource/Fungus"}, {"text": "Evolution", "relevance": 0.333871, "dbpedia_resource": "http://dbpedia.org/resource/Evolution"}, {"text": "Eli Lilly and Company", "relevance": 0.325546, "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly_and_Company"}, {"text": "Chloramphenicol", "relevance": 0.324932, "dbpedia_resource": "http://dbpedia.org/resource/Chloramphenicol"}, {"text": "Cytomegalovirus", "relevance": 0.324071, "dbpedia_resource": "http://dbpedia.org/resource/Cytomegalovirus"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.304531, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "United Kingdom", "relevance": 0.29986, "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}, {"text": "AstraZeneca", "relevance": 0.299432, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Measles", "relevance": 0.289461, "dbpedia_resource": "http://dbpedia.org/resource/Measles"}, {"text": "Fever", "relevance": 0.279999, "dbpedia_resource": "http://dbpedia.org/resource/Fever"}, {"text": "Economic growth", "relevance": 0.277496, "dbpedia_resource": "http://dbpedia.org/resource/Economic_growth"}, {"text": "Methicillin-resistant Staphylococcus aureus", "relevance": 0.271357, "dbpedia_resource": "http://dbpedia.org/resource/Methicillin-resistant_Staphylococcus_aureus"}], "categories": [{"score": 0.955596, "label": "/health and fitness/disease"}, {"score": 0.797198, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.711026, "label": "/health and fitness/therapy"}], "relations": [{"type": "hasAttribute", "sentence": "Due to their wide range of antibacterial scope, in current scenario Penicillin and Streptomycin are the most commonly used antibiotics for most of infections.", "score": 0.476409, "arguments": [{"text": "Penicillin", "location": [540, 550], "entities": [{"type": "Person", "text": "Penicillin"}]}, {"text": "infections", "location": [619, 629], "entities": [{"type": "HealthCondition", "text": "Tuberculosis"}]}]}, {"type": "locatedAt", "sentence": "These three market growths can be attributed to the investments done by governments to improve the present healthcare facility for better health of the people, which will enhance the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany.", "score": 0.712631, "arguments": [{"text": "facility", "location": [3664, 3672], "entities": [{"type": "Facility", "text": "facility"}]}, {"text": "governments", "location": [3618, 3629], "entities": [{"type": "GeopoliticalEntity", "text": "administration"}]}]}, {"type": "locatedAt", "sentence": "These three market growths can be attributed to the investments done by governments to improve the present healthcare facility for better health of the people, which will enhance the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany.", "score": 0.39468, "arguments": [{"text": "people", "location": [3698, 3704], "entities": [{"type": "Person", "text": "people"}]}, {"text": "facility", "location": [3664, 3672], "entities": [{"type": "Facility", "text": "facility"}]}]}, {"type": "locatedAt", "sentence": "These three market growths can be attributed to the investments done by governments to improve the present healthcare facility for better health of the people, which will enhance the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany.", "score": 0.386593, "arguments": [{"text": "countries", "location": [3778, 3787], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "U.K.", "location": [3797, 3801], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}]}, {"type": "locatedAt", "sentence": "These three market growths can be attributed to the investments done by governments to improve the present healthcare facility for better health of the people, which will enhance the growth of the penicillin and streptomycin in its countries, such as U.K., France, and Germany.", "score": 0.695151, "arguments": [{"text": "U.K.", "location": [3797, 3801], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "France", "location": [3803, 3809], "entities": [{"type": "GeopoliticalEntity", "text": "France", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "Latin American countries such as Mexico and Brazil are expected to have considerable potential for driving the market growth due to evolving medical care infrastructure, and high incidences of bacterial infections.", "score": 0.37919, "arguments": [{"text": "countries", "location": [3839, 3848], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Latin American", "location": [3824, 3838], "entities": [{"type": "GeopoliticalEntity", "text": "Latin American", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "Latin American countries such as Mexico and Brazil are expected to have considerable potential for driving the market growth due to evolving medical care infrastructure, and high incidences of bacterial infections.", "score": 0.623337, "arguments": [{"text": "Mexico", "location": [3857, 3863], "entities": [{"type": "GeopoliticalEntity", "text": "Mexico", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3839, 3848], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOfMany", "sentence": "Latin American countries such as Mexico and Brazil are expected to have considerable potential for driving the market growth due to evolving medical care infrastructure, and high incidences of bacterial infections.", "score": 0.801146, "arguments": [{"text": "Brazil", "location": [3868, 3874], "entities": [{"type": "GeopoliticalEntity", "text": "Brazil", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3839, 3848], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "Due to their wide range of antibacterial scope, in current scenario Penicillin and Streptomycin are the most commonly used antibiotics for most of infections.", "score": 0.423609, "arguments": [{"text": "Streptomycin", "location": [555, 567], "entities": [{"type": "Person", "text": "Streptomycin"}]}, {"text": "infections", "location": [619, 629], "entities": [{"type": "HealthCondition", "text": "Tuberculosis"}]}]}, {"type": "hasAttribute", "sentence": "Streptomycin is used in Tuberculosis treatment.", "score": 0.711854, "arguments": [{"text": "Streptomycin", "location": [735, 747], "entities": [{"type": "Person", "text": "Streptomycin"}]}, {"text": "Tuberculosis", "location": [759, 771], "entities": [{"type": "HealthCondition", "text": "Tuberculosis"}]}]}, {"type": "hasAttribute", "sentence": "Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis and so on.", "score": 0.58361, "arguments": [{"text": "Penicillin", "location": [631, 641], "entities": [{"type": "Person", "text": "Penicillin"}]}, {"text": "diseases", "location": [677, 685], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "partOfMany", "sentence": "Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis and so on.", "score": 0.436829, "arguments": [{"text": "infections", "location": [701, 711], "entities": [{"type": "HealthCondition", "text": "Tuberculosis"}]}, {"text": "diseases", "location": [677, 685], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "partOfMany", "sentence": "Penicillin drugs are used in the treatment of diseases such as throat infections, meningitis and so on.", "score": 0.594796, "arguments": [{"text": "meningitis", "location": [713, 723], "entities": [{"type": "HealthCondition", "text": "Tuberculosis"}]}, {"text": "diseases", "location": [677, 685], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "locatedAt", "sentence": "Geographically, Asia Pacific was the largest regional market for penicillin and streptomycin in 2015 in terms of value.", "score": 0.702473, "arguments": [{"text": "Pacific", "location": [2692, 2699], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Asia", "location": [2687, 2691], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Additionally, growing incidences of bacterial infections such as Clostridium difficile and MRSA infections and growing patient awareness are some other factors which will drive growth in Asia Pacific penicillin and streptomycin market.", "score": 0.646049, "arguments": [{"text": "Pacific", "location": [3173, 3180], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Asia", "location": [3168, 3172], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "This dominance is due to growing number of antibiotic manufacturers in the Asian countries and also due to the presence of some of the world's leading generics manufacturers in this region.", "score": 0.337734, "arguments": [{"text": "manufacturers", "location": [2845, 2858], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "countries", "location": [2872, 2881], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "This dominance is due to growing number of antibiotic manufacturers in the Asian countries and also due to the presence of some of the world's leading generics manufacturers in this region.", "score": 0.860162, "arguments": [{"text": "countries", "location": [2872, 2881], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Asian", "location": [2866, 2871], "entities": [{"type": "GeopoliticalEntity", "text": "Asian"}]}]}, {"type": "basedIn", "sentence": "This dominance is due to growing number of antibiotic manufacturers in the Asian countries and also due to the presence of some of the world's leading generics manufacturers in this region.", "score": 0.750412, "arguments": [{"text": "manufacturers", "location": [2951, 2964], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "world", "location": [2926, 2931], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "This dominance is due to growing number of antibiotic manufacturers in the Asian countries and also due to the presence of some of the world's leading generics manufacturers in this region.", "score": 0.362346, "arguments": [{"text": "manufacturers", "location": [2951, 2964], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "region", "location": [2973, 2979], "entities": [{"type": "GeopoliticalEntity", "text": "Asian"}]}]}], "keywords": [{"text": "streptomycin market", "sentiment": {"score": -0.606043, "mixed": "1", "label": "negative"}, "relevance": 0.6913, "count": 6}, {"text": "bacterial growth", "sentiment": {"score": -0.701523, "label": "negative"}, "relevance": 0.669724, "count": 1}, {"text": "bacterial infections", "sentiment": {"score": -0.701523, "label": "negative"}, "relevance": 0.635004, "count": 1}, {"text": "Penicillin", "sentiment": {"score": 0.596554, "label": "positive"}, "relevance": 0.596963, "count": 2}, {"text": "high growth", "sentiment": {"score": 0.596554, "label": "positive"}, "relevance": 0.594827, "count": 1}, {"text": "North America", "sentiment": {"score": -0.789599, "label": "negative"}, "relevance": 0.580423, "count": 1}, {"text": "Astellas Pharma Inc.", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.579421, "count": 1}, {"text": "types of antibiotics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573396, "count": 1}, {"text": "antibiotics", "sentiment": {"score": -0.730192, "label": "negative"}, "relevance": 0.566467, "count": 3}, {"text": "discovery of Penicillin", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.561833, "count": 1}, {"text": "antibiotic", "sentiment": {"score": -0.701523, "label": "negative"}, "relevance": 0.560608, "count": 1}, {"text": "Asia Pacific", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559579, "count": 1}, {"text": "growth of the global penicillin", "sentiment": {"score": -0.77196, "label": "negative"}, "relevance": 0.559423, "count": 2}, {"text": "medical sciences", "sentiment": {"score": -0.7782, "label": "negative"}, "relevance": 0.554424, "count": 1}, {"text": "Asian countries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554104, "count": 1}, {"text": "major cause of mortality", "sentiment": {"score": -0.789684, "label": "negative"}, "relevance": 0.553786, "count": 1}, {"text": "biggest challenge", "sentiment": {"score": -0.682379, "label": "negative"}, "relevance": 0.553315, "count": 1}, {"text": "Antibiotics", "sentiment": {"score": 0.848348, "label": "positive"}, "relevance": 0.549979, "count": 1}, {"text": "Astra Zeneca", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.549153, "count": 1}, {"text": "major players", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.545556, "count": 1}, {"text": "global market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543642, "count": 3}, {"text": "Gram-negative bacteria", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.543089, "count": 1}, {"text": "largest regional market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542207, "count": 1}, {"text": "major public health problem", "sentiment": {"score": -0.679522, "label": "negative"}, "relevance": 0.541578, "count": 1}, {"text": "wide range of antibacterial scope", "sentiment": {"score": -0.7782, "label": "negative"}, "relevance": 0.54087, "count": 1}, {"text": "bacteria", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539932, "count": 2}, {"text": "Streptomycin", "sentiment": {"score": -0.7782, "label": "negative"}, "relevance": 0.538561, "count": 3}, {"text": "development of antibiotic resistance", "sentiment": {"score": -0.682379, "label": "negative"}, "relevance": 0.537923, "count": 1}, {"text": "antibiotic resistance", "sentiment": {"score": -0.784224, "label": "negative"}, "relevance": 0.535565, "count": 1}, {"text": "Bacterial infections", "sentiment": {"score": -0.789684, "label": "negative"}, "relevance": 0.534554, "count": 1}, {"text": "growth", "sentiment": {"score": -0.734335, "label": "negative"}, "relevance": 0.534111, "count": 1}, {"text": "current scenario Penicillin", "sentiment": {"score": -0.7782, "label": "negative"}, "relevance": 0.533963, "count": 1}, {"text": "terms of product type", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533658, "count": 1}, {"text": "instance", "sentiment": {"score": -0.784224, "label": "negative"}, "relevance": 0.532799, "count": 1}, {"text": "improper use of antibiotics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531599, "count": 1}, {"text": "Company", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.531405, "count": 1}, {"text": "bacterial infection treatment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529373, "count": 1}, {"text": "Co.", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.528895, "count": 1}, {"text": "Ltd", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.528825, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.528338, "count": 2}, {"text": "penicillin", "sentiment": {"score": -0.737639, "label": "negative"}, "relevance": 0.52803, "count": 7}, {"text": "various government", "sentiment": {"score": -0.850217, "label": "negative"}, "relevance": 0.527256, "count": 1}, {"text": "MiddleBrook Pharmaceuticals", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.526686, "count": 1}, {"text": "Bacteria", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526653, "count": 1}, {"text": "awareness", "sentiment": {"score": -0.850217, "label": "negative"}, "relevance": 0.526503, "count": 1}, {"text": "governments", "sentiment": {"score": 0.831654, "label": "positive"}, "relevance": 0.526026, "count": 1}, {"text": "consumption", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.525673, "count": 1}, {"text": "countries", "sentiment": {"score": 0.349892, "mixed": "1", "label": "positive"}, "relevance": 0.525043, "count": 1}, {"text": "Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0.861318, "label": "positive"}, "relevance": 0.524198, "count": 1}, {"text": "factors", "sentiment": {"score": -0.734335, "label": "negative"}, "relevance": 0.523657, "count": 1}]}, "extracted_metadata": {"sha1": "3b036dcf90b38129ad2feed2c5954895fea1b7de", "filename": "1542368911565.zip-32c343c3f3e4a73d964faccc31261c5a.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/market-research/penicillin-and-streptomycin-market.asp", "https://www.persistencemarketresearch.com/samples/13582"], "title": "Penicillin and Streptomycin Global Industry Analysis and Forecast 2017 \u2013 2025", "forum_title": "Research Insights | Find Market Research - Part 3"}, {"id": "oLBZRraT-3zK7HoACpsDff2LHcrYw3K9sN7dg6hFnmTn6vpbm_ofSVMFgQmBEskz", "result_metadata": {"score": 34.333496}, "author": "euroinvestor.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.935718, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997761, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.832988, "count": 1}]}, "crawl_date": "2018-11-16T12:48:39Z", "url": "https://www.euroinvestor.com/news/2018/11/16/form-83-takeda-pharmaceutical-co-ltd/13931124", "host": "euroinvestor.com", "text": "Norges Bank - Form 8.3 - Takeda Pharmaceutical Co Ltd PR Newswire London, November 16 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the \u201cCode\u201d) 1.", "country": "DK", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-16T12:33:00+01:00", "enriched_text": {"entities": [{"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.847858, "type": "Company"}, {"count": 2, "sentiment": {"score": -0.266625, "label": "negative"}, "text": "Norges Bank", "relevance": 0.796975, "type": "Company", "disambiguation": {"subtype": ["Location"], "name": "Norges Bank", "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "London", "relevance": 0.56299, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire PLC", "relevance": 0.555089, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.539276, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Philippe Chiaroni", "relevance": 0.532782, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.516759, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.501703, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.489686, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.489686, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.489686, "type": "Quantity"}], "sentiment": {"document": {"score": 0.495591, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \u201cN/A\u201d", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors\u2019 and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors\u2019 and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel\u2019s Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}]}, "sentence": " The Panel\u2019s Market Surveillance Unit is available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation in relation to the Code\u2019s disclosure requirements on +44 (0)20 7638 0129", "keywords": [{"text": "relation"}, {"text": "consultation"}, {"text": "Code"}, {"text": "requirements"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel\u2019s website", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel\u2019s website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}, {"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "the Panel", "keywords": [{"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Code can be viewed on the Panel\u2019s website at www.thetakeoverpanel.org.uk .", "object": {"text": "website", "keywords": [{"text": "website"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}], "concepts": [{"text": "Option", "relevance": 0.978327, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Call option", "relevance": 0.544009, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.523884, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.517917, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.467684, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.438678, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Bond", "relevance": 0.422511, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Grammatical number", "relevance": 0.410813, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "Stock", "relevance": 0.387131, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Unit type", "relevance": 0.372252, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Option contract", "relevance": 0.371966, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.371413, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Security", "relevance": 0.362882, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Security", "relevance": 0.358251, "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"}, {"text": "Uniform Commercial Code", "relevance": 0.358055, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Derivative", "relevance": 0.357874, "dbpedia_resource": "http://dbpedia.org/resource/Derivative_(finance)"}, {"text": "Moneyness", "relevance": 0.338941, "dbpedia_resource": "http://dbpedia.org/resource/Moneyness"}, {"text": "Norges Bank", "relevance": 0.336251, "dbpedia_resource": "http://dbpedia.org/resource/Norges_Bank"}], "categories": [{"score": 0.94101, "label": "/real estate/buying and selling homes"}, {"score": 0.879176, "label": "/finance/financial news"}, {"score": 0.716148, "label": "/business and industrial/company/earnings"}], "relations": [{"type": "agentOf", "sentence": "Purchases and sales Class of relevant security Purchase/sale Number of securities Price per unit Ordinary Purchase 68,000 JPY 4,438.3647 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/", "score": 0.726237, "arguments": [{"text": "i", "location": [3227, 3228], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "Writing", "location": [3230, 3237], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "employedBy", "sentence": "exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) 4.", "score": 0.582263, "arguments": [{"text": "Price", "location": [3827, 3832], "entities": [{"type": "Person", "text": "Price"}]}, {"text": "unit", "location": [3837, 3841], "entities": [{"type": "Organization", "text": "unit"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4201, 4207], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4218, 4225], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 16/11/2018 Contact name: Philippe Chiaroni Telephone number: +4724073297 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5094, 5100], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5108, 5112], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5255, 5279], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5247, 5252], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5414, 5419], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5433, 5460], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}], "keywords": [{"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.710166, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.468535, "label": "positive"}, "relevance": 0.699134, "count": 1}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.468535, "label": "positive"}, "relevance": 0.674165, "count": 1}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.640272, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.584534, "count": 2}, {"text": "relevant securities", "sentiment": {"score": 0.685089, "label": "positive"}, "relevance": 0.582863, "count": 3}, {"text": "Full name of discloser", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.576686, "count": 1}, {"text": "Details", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.576004, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574372, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.468535, "label": "positive"}, "relevance": 0.567632, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56016, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.555457, "count": 3}, {"text": "Code", "sentiment": {"score": -0.478397, "mixed": "1", "label": "negative"}, "relevance": 0.551743, "count": 3}, {"text": "PERSON", "sentiment": {"score": 0.560119, "label": "positive"}, "relevance": 0.549233, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.468535, "label": "positive"}, "relevance": 0.548255, "count": 1}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.547443, "count": 3}, {"text": "options", "sentiment": {"score": 0.380708, "mixed": "1", "label": "positive"}, "relevance": 0.547056, "count": 4}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.544803, "count": 2}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.544567, "count": 1}, {"text": "Rights", "sentiment": {"score": 0.776464, "label": "positive"}, "relevance": 0.544567, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.543883, "count": 2}, {"text": "Takeover Panel", "sentiment": {"score": -0.737844, "label": "negative"}, "relevance": 0.54337, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538371, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.536933, "count": 1}, {"text": "Cash", "sentiment": {"score": 0.655553, "label": "positive"}, "relevance": 0.536095, "count": 2}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.535946, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.863885, "label": "negative"}, "relevance": 0.535756, "count": 1}, {"text": "disclosure", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.53451, "count": 4}, {"text": "FORM", "sentiment": {"score": 0.468535, "label": "positive"}, "relevance": 0.534173, "count": 1}, {"text": "Form", "sentiment": {"score": 0.468535, "label": "positive"}, "relevance": 0.534173, "count": 1}, {"text": "arrangements", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.53204, "count": 3}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531444, "count": 1}, {"text": "Stock", "sentiment": {"score": -0.737533, "label": "negative"}, "relevance": 0.531259, "count": 2}, {"text": "INTERESTS", "sentiment": {"score": 0.468535, "label": "positive"}, "relevance": 0.530928, "count": 1}, {"text": "agreement", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.529913, "count": 2}, {"text": "Rule", "sentiment": {"score": -0.737844, "label": "negative"}, "relevance": 0.529768, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528844, "count": 2}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.528203, "count": 2}, {"text": "Disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527624, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527384, "count": 1}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.527257, "count": 1}, {"text": "understandings", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.527217, "count": 3}, {"text": "Purchases", "sentiment": {"score": 0.655553, "label": "positive"}, "relevance": 0.527039, "count": 1}, {"text": "person", "sentiment": {"score": 0.85546, "label": "positive"}, "relevance": 0.524677, "count": 4}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.524154, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523027, "count": 1}, {"text": "INFORMATION", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.523, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522802, "count": 1}, {"text": "Panel\u2019s Market Surveillance Unit", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522277, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.522029, "count": 1}]}, "extracted_metadata": {"sha1": "1a3a1b836f8cb90cf9a02133dcdcf0f491771783", "filename": "1542372519368.zip-d4a5db77ef271104e6a1a154d3648f2c.xml", "file_type": "json"}, "external_links": ["https://www.thetakeoverpanel.org.uk/", "https://www.xmlnews.org/ns/"], "title": "Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "Latest Financial News, Stock News, Forex News and Commodity Market News - Euroinvestor"}, {"id": "Ha0Cz6iSKHUbog_eUBavk4pyV8mroGGIZIfHvEnRrgklxbrUwPljI4k8oMbryKro", "result_metadata": {"score": 33.219345}, "author": "Research and Markets", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pediatric Vaccine Manufacturers", "relevance": 0.33, "type": "JobTitle"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "Emerging Nations", "keywords": [{"text": "Nations"}]}, "sentence": "Human Vaccines 2016-2024 - Global Strategic Business Report 2018: Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers - ResearchAndMarkets.com", "object": {"text": "Huge Opportunities", "keywords": [{"text": "Huge Opportunities"}]}, "action": {"verb": {"text": "Offer", "tense": "present"}, "text": "Offer", "normalized": "Offer"}}], "concepts": [{"text": "Vaccine", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Vaccine"}], "categories": [{"score": 0.607774, "label": "/health and fitness/disease"}, {"score": 0.569424, "label": "/health and fitness/disease/cold and flu"}, {"score": 0.327951, "label": "/health and fitness/disease/epidemic"}], "relations": [], "keywords": [{"text": "Pediatric Vaccine Manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.991393}, {"text": "Global Strategic Business", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.822966}, {"text": "Human Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.644748}, {"text": "Huge Opportunities", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581492}, {"text": "ResearchAndMarkets.com", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.397894}]}, "crawl_date": "2018-11-15T16:12:52Z", "url": "http://business.malvern-online.com/malvern-online/news/read/37299360/human_vaccines_2016", "host": "business.malvern-online.com", "text": "(India) Shanghai BravoBio Co., Ltd.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-15T11:01:00-06:00", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Meningococcal Vaccine", "relevance": 0.90706, "type": "Drug"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi Pasteur Begins Vaccine Manufacturing", "relevance": 0.897771, "type": "Company"}, {"count": 7, "sentiment": {"score": 0.452379, "label": "positive"}, "text": "US", "relevance": 0.880806, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": -0.585745, "label": "negative"}, "text": "Hepatitis B Vaccine", "relevance": 0.863577, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.615973, "label": "negative"}, "text": "Influenza Vaccines Business Pfizer", "relevance": 0.849128, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HPV Vaccine", "relevance": 0.845746, "type": "Drug"}, {"count": 1, "sentiment": {"score": -0.213815, "label": "negative"}, "text": "Sanofi Pasteur SA", "relevance": 0.64844, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.238759, "label": "negative"}, "text": "Vaccines GeoVax Labs", "relevance": 0.647571, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi Pasteur Launches", "relevance": 0.616886, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi", "relevance": 0.610558, "type": "Company", "disambiguation": {"subtype": [], "name": "Sanofi", "dbpedia_resource": "http://dbpedia.org/resource/Sanofi"}}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.593025, "type": "Location", "disambiguation": {"subtype": ["GeographicFeature", "Island", "Country"], "name": "Taiwan", "dbpedia_resource": "http://dbpedia.org/resource/Taiwan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Sanofi Pasteur Ships", "relevance": 0.585192, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.558089, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.557611, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 3, "sentiment": {"score": -0.40537, "label": "negative"}, "text": "Ebola", "relevance": 0.550726, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Japan", "relevance": 0.535598, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.517206, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": -0.238759, "label": "negative"}, "text": "Astellas Sanofi", "relevance": 0.507532, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.504923, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.494757, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0.320383, "label": "positive"}, "text": "Bavarian Nordic A/S", "relevance": 0.486418, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bharat Biotech International Limited", "relevance": 0.47382, "type": "Company", "disambiguation": {"subtype": [], "name": "Bharat Biotech International", "dbpedia_resource": "http://dbpedia.org/resource/Bharat_Biotech_International"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ResearchAndMarkets.com", "relevance": 0.470775, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.469255, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.455377, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": -0.255989, "label": "negative"}, "text": "Janssen Pharmaceuticals", "relevance": 0.450553, "type": "Company", "disambiguation": {"subtype": [], "name": "Janssen Pharmaceutica", "dbpedia_resource": "http://dbpedia.org/resource/Janssen_Pharmaceutica"}}, {"count": 1, "sentiment": {"score": -0.238637, "label": "negative"}, "text": "Merck & Co.", "relevance": 0.444388, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.431156, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.615973, "label": "negative"}, "text": "GSK Pfizer", "relevance": 0.428258, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "FDA", "relevance": 0.425504, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 2, "sentiment": {"score": -0.438238, "label": "negative"}, "text": "Japan", "relevance": 0.42478, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Denmark", "relevance": 0.424339, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.238759, "label": "negative"}, "text": "Facility Bavarian Nordic", "relevance": 0.418257, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bharat Biotech Launches", "relevance": 0.417575, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Serum Institute of India Pvt", "relevance": 0.412438, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck", "relevance": 0.404996, "type": "Organization", "disambiguation": {"subtype": ["Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Variola Major", "relevance": 0.404958, "type": "HealthCondition", "disambiguation": {"subtype": ["OrganismClassification", "DiseaseOrMedicalCondition", "CauseOfDeath", "InfectiousDisease", "Disease"], "name": "Smallpox", "dbpedia_resource": "http://dbpedia.org/resource/Smallpox"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Israel", "relevance": 0.404622, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "FilmArtDirector", "Country"], "name": "Israel", "dbpedia_resource": "http://dbpedia.org/resource/Israel"}}, {"count": 1, "sentiment": {"score": -0.332536, "label": "negative"}, "text": "BiondVax Pharmaceuticals Ltd.", "relevance": 0.402902, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.401945, "type": "Organization", "disambiguation": {"subtype": ["Location", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Korea", "relevance": 0.401637, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Country"], "name": "South Korea", "dbpedia_resource": "http://dbpedia.org/resource/South_Korea"}}, {"count": 2, "sentiment": {"score": -0.238759, "label": "negative"}, "text": "Novartis", "relevance": 0.398347, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GSK", "relevance": 0.396291, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "European JV Split Serum Institute", "relevance": 0.396179, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tularemia", "relevance": 0.393418, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "InfectiousDisease", "Disease"], "name": "Tularemia", "dbpedia_resource": "http://dbpedia.org/resource/Tularemia"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Costa Rica GSK", "relevance": 0.393052, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.39105, "type": "Location", "disambiguation": {"subtype": ["Country"]}}], "sentiment": {"document": {"score": 0.510976, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "Global Strategic Business Reports\" report", "keywords": [{"text": "Global Strategic Business"}, {"text": "report"}, {"text": "Reports"}]}, "sentence": "The \"Human Vaccines - Global Strategic Business Reports\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "added to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The \"Human Vaccines - Global Strategic Business Reports\" report", "keywords": [{"text": "Human Vaccines"}, {"text": "Global Strategic Business"}, {"text": "Reports"}, {"text": "report"}]}, "sentence": "The \"Human Vaccines - Global Strategic Business Reports\" report has been added to ResearchAndMarkets.com's offering.", "object": {"text": "to ResearchAndMarkets.com's offering", "keywords": [{"text": "ResearchAndMarkets.com"}, {"text": "offering"}], "entities": [{"type": "Company", "text": "ResearchAndMarkets.com"}]}, "action": {"verb": {"text": "add", "tense": "past"}, "text": "has been added", "normalized": "have be add"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "object": {"text": "separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World", "keywords": [{"text": "separate comprehensive analytics"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}, {"text": "Rest"}], "entities": [{"type": "Location", "text": "United States", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "MusicalArtist", "RecordProducer", "Country"], "name": "Japan", "dbpedia_resource": "http://dbpedia.org/resource/Japan"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "provide", "tense": "present"}, "text": "provides", "normalized": "provide"}}, {"subject": {"text": "Annual estimates and forecasts", "keywords": [{"text": "Annual estimates"}, {"text": "forecasts"}]}, "sentence": " Annual estimates and forecasts are provided for the period 2016 through 2024.", "action": {"verb": {"text": "provide", "tense": "past"}, "text": "are provided", "normalized": "be provide"}}, {"subject": {"text": "a five-year historic analysis", "keywords": [{"text": "five-year historic analysis"}], "entities": [{"type": "Quantity", "text": "five-year"}]}, "sentence": " Also, a five-year historic analysis is provided for these markets.", "object": {"text": "provided for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "a five-year historic analysis", "keywords": [{"text": "five-year historic analysis"}], "entities": [{"type": "Quantity", "text": "five-year"}]}, "sentence": " Also, a five-year historic analysis is provided for these markets.", "object": {"text": "for these markets", "keywords": [{"text": "markets"}]}, "action": {"verb": {"text": "provide", "tense": "past"}, "text": "is provided", "normalized": "be provide"}}, {"subject": {"text": "This report", "keywords": [{"text": "report"}]}, "sentence": " This report analyzes the worldwide markets for Human Vaccines by the following Product Segments: Pediatric Vaccines Adult Vaccines Company profiles are primarily based on public domain information including company URLs.", "object": {"text": "the worldwide markets for Human Vaccines", "keywords": [{"text": "Human Vaccines"}, {"text": "worldwide markets"}]}, "action": {"verb": {"text": "analyze", "tense": "present"}, "text": "analyzes", "normalized": "analyze"}}, {"subject": {"text": "Pediatric Vaccines Adult Vaccines Company profiles", "keywords": [{"text": "Vaccines Adult Vaccines"}, {"text": "Pediatric"}]}, "sentence": " This report analyzes the worldwide markets for Human Vaccines by the following Product Segments: Pediatric Vaccines Adult Vaccines Company profiles are primarily based on public domain information including company URLs.", "object": {"text": "on public domain information including company URLs", "keywords": [{"text": "company URLs"}, {"text": "public domain information"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "are primarily based", "normalized": "be primarily base"}}, {"subject": {"text": "company URLs", "keywords": [{"text": "company URLs"}]}, "sentence": " This report analyzes the worldwide markets for Human Vaccines by the following Product Segments: Pediatric Vaccines Adult Vaccines Company profiles are primarily based on public domain information including company URLs.", "object": {"text": "public domain information", "keywords": [{"text": "public domain information"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report profiles 66 companies including many key and niche players such as: ALK Abell A/S (Denmark) Altimmune, Inc. (US) Bavarian Nordic A/S (Denmark) BiondVax Pharmaceuticals Ltd. (Israel) Bharat Biotech International Limited (India) GlaxoSmithKline Plc. (UK) Hualan Biological Engineering Inc. (China) Janssen Pharmaceuticals, Inc. (US) MedImmune (US) Merck & Co., Inc. (US) Pfizer Inc. (US) Sanofi Pasteur SA (France) Serum Institute of India Pvt.", "object": {"text": "66 companies including many key and niche players", "keywords": [{"text": "niche players"}, {"text": "companies"}]}, "action": {"verb": {"text": "profile", "tense": "present"}, "text": "profiles", "normalized": "profile"}}, {"subject": {"text": "many key and niche players such as: ALK Abell A/S (Denmark) Altimmune", "keywords": [{"text": "ALK Abell A/S"}, {"text": "niche players"}, {"text": "Denmark"}, {"text": "Altimmune"}], "entities": [{"type": "Location", "text": "Denmark", "disambiguation": {"subtype": ["Country"]}}, {"type": "Company", "text": "Altimmune, Inc."}]}, "sentence": " The report profiles 66 companies including many key and niche players such as: ALK Abell A/S (Denmark) Altimmune, Inc. (US) Bavarian Nordic A/S (Denmark) BiondVax Pharmaceuticals Ltd. (Israel) Bharat Biotech International Limited (India) GlaxoSmithKline Plc. (UK) Hualan Biological Engineering Inc. (China) Janssen Pharmaceuticals, Inc. (US) MedImmune (US) Merck & Co., Inc. (US) Pfizer Inc. (US) Sanofi Pasteur SA (France) Serum Institute of India Pvt.", "object": {"text": "66 companies", "keywords": [{"text": "companies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}], "concepts": [{"text": "Vaccine", "relevance": 0.96806, "dbpedia_resource": "http://dbpedia.org/resource/Vaccine"}, {"text": "Vaccines", "relevance": 0.957097, "dbpedia_resource": "http://dbpedia.org/resource/Vaccines"}, {"text": "Influenza vaccine", "relevance": 0.889405, "dbpedia_resource": "http://dbpedia.org/resource/Influenza_vaccine"}, {"text": "Influenza", "relevance": 0.792505, "dbpedia_resource": "http://dbpedia.org/resource/Influenza"}, {"text": "Clinical trial", "relevance": 0.666062, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Vaccination", "relevance": 0.588513, "dbpedia_resource": "http://dbpedia.org/resource/Vaccination"}, {"text": "DNA vaccination", "relevance": 0.544239, "dbpedia_resource": "http://dbpedia.org/resource/DNA_vaccination"}, {"text": "HPV vaccine", "relevance": 0.500247, "dbpedia_resource": "http://dbpedia.org/resource/HPV_vaccine"}, {"text": "Influenza A virus subtype H1N1", "relevance": 0.491327, "dbpedia_resource": "http://dbpedia.org/resource/Influenza_A_virus_subtype_H1N1"}, {"text": "Pneumonia", "relevance": 0.470016, "dbpedia_resource": "http://dbpedia.org/resource/Pneumonia"}, {"text": "Pneumococcal conjugate vaccine", "relevance": 0.45825, "dbpedia_resource": "http://dbpedia.org/resource/Pneumococcal_conjugate_vaccine"}, {"text": "Tuberculosis", "relevance": 0.436724, "dbpedia_resource": "http://dbpedia.org/resource/Tuberculosis"}, {"text": "Pandemic", "relevance": 0.402597, "dbpedia_resource": "http://dbpedia.org/resource/Pandemic"}, {"text": "2009 flu pandemic", "relevance": 0.389474, "dbpedia_resource": "http://dbpedia.org/resource/2009_flu_pandemic"}, {"text": "Smallpox", "relevance": 0.372699, "dbpedia_resource": "http://dbpedia.org/resource/Smallpox"}, {"text": "Infectious disease", "relevance": 0.360195, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Immune system", "relevance": 0.342931, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Vaccination schedule", "relevance": 0.341332, "dbpedia_resource": "http://dbpedia.org/resource/Vaccination_schedule"}, {"text": "HIV vaccine", "relevance": 0.32726, "dbpedia_resource": "http://dbpedia.org/resource/HIV_vaccine"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.319162, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Louis Pasteur", "relevance": 0.312785, "dbpedia_resource": "http://dbpedia.org/resource/Louis_Pasteur"}, {"text": "Malaria", "relevance": 0.303555, "dbpedia_resource": "http://dbpedia.org/resource/Malaria"}, {"text": "Microbiology", "relevance": 0.302171, "dbpedia_resource": "http://dbpedia.org/resource/Microbiology"}, {"text": "Swine influenza", "relevance": 0.300366, "dbpedia_resource": "http://dbpedia.org/resource/Swine_influenza"}, {"text": "Pharmaceutical industry", "relevance": 0.299848, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Infectious diseases", "relevance": 0.299358, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_diseases"}, {"text": "HIV", "relevance": 0.2961, "dbpedia_resource": "http://dbpedia.org/resource/HIV"}, {"text": "Influenza pandemic", "relevance": 0.289663, "dbpedia_resource": "http://dbpedia.org/resource/Influenza_pandemic"}, {"text": "Wyeth", "relevance": 0.285552, "dbpedia_resource": "http://dbpedia.org/resource/Wyeth"}, {"text": "Biotechnology", "relevance": 0.278434, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology"}, {"text": "MedImmune", "relevance": 0.277904, "dbpedia_resource": "http://dbpedia.org/resource/MedImmune"}, {"text": "Human papillomavirus", "relevance": 0.273848, "dbpedia_resource": "http://dbpedia.org/resource/Human_papillomavirus"}, {"text": "Botulism", "relevance": 0.271627, "dbpedia_resource": "http://dbpedia.org/resource/Botulism"}, {"text": "1976 swine flu outbreak", "relevance": 0.264709, "dbpedia_resource": "http://dbpedia.org/resource/1976_swine_flu_outbreak"}, {"text": "Pertussis", "relevance": 0.264251, "dbpedia_resource": "http://dbpedia.org/resource/Pertussis"}, {"text": "CSL Limited", "relevance": 0.261016, "dbpedia_resource": "http://dbpedia.org/resource/CSL_Limited"}, {"text": "Measles", "relevance": 0.25465, "dbpedia_resource": "http://dbpedia.org/resource/Measles"}, {"text": "Pandemic H1N1/09 virus", "relevance": 0.253999, "dbpedia_resource": "http://dbpedia.org/resource/Pandemic_H1N1/09_virus"}, {"text": "Merck & Co.", "relevance": 0.251836, "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}, {"text": "Influenza research", "relevance": 0.249676, "dbpedia_resource": "http://dbpedia.org/resource/Influenza_research"}, {"text": "Dengue fever", "relevance": 0.248915, "dbpedia_resource": "http://dbpedia.org/resource/Dengue_fever"}, {"text": "Avian influenza", "relevance": 0.246335, "dbpedia_resource": "http://dbpedia.org/resource/Avian_influenza"}, {"text": "Dow Jones Industrial Average", "relevance": 0.242246, "dbpedia_resource": "http://dbpedia.org/resource/Dow_Jones_Industrial_Average"}, {"text": "AIDS", "relevance": 0.239095, "dbpedia_resource": "http://dbpedia.org/resource/AIDS"}, {"text": "Gardasil", "relevance": 0.237879, "dbpedia_resource": "http://dbpedia.org/resource/Gardasil"}, {"text": "Meningococcal vaccine", "relevance": 0.233478, "dbpedia_resource": "http://dbpedia.org/resource/Meningococcal_vaccine"}, {"text": "Pfizer", "relevance": 0.230732, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Ebola", "relevance": 0.227952, "dbpedia_resource": "http://dbpedia.org/resource/Ebola"}, {"text": "Influenza-like illness", "relevance": 0.226225, "dbpedia_resource": "http://dbpedia.org/resource/Influenza-like_illness"}, {"text": "GlaxoSmithKline", "relevance": 0.225059, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}], "categories": [{"score": 0.799148, "label": "/health and fitness/disease/cold and flu"}, {"score": 0.476699, "label": "/health and fitness/disease/epidemic"}, {"score": 0.216242, "label": "/health and fitness/disease/aids and hiv"}], "relations": [{"type": "agentOf", "sentence": "The \"Human Vaccines - Global Strategic Business Reports\" report has been added to ResearchAndMarkets.com's offering.", "score": 0.512559, "arguments": [{"text": "Global Strategic Business Reports", "location": [22, 55], "entities": [{"type": "Organization", "text": "Global Strategic Business Reports", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "report", "location": [57, 63], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "employedBy", "sentence": "MARKET OVERVIEW & OUTLOOK Human Vaccines: A Prelude Human Vaccines Market A Snapshot Market Dynamics Growth Drivers in a Capsule Developed World: The Key Markets Emerging Markets: The Future Growth Area Vaccine Pricing: The Developed Developing Divide 2.", "score": 0.615872, "arguments": [{"text": "Human Vaccines Market", "location": [1307, 1328], "entities": [{"type": "Person", "text": "Human Vaccines Market"}]}, {"text": "Snapshot Market Dynamics Growth Drivers", "location": [1331, 1370], "entities": [{"type": "Organization", "text": "Snapshot Market Dynamics Growth Drivers"}]}]}, {"type": "partOf", "sentence": "MARKET TRENDS & ISSUES Prophylactic Pediatric Vaccines A Mature Market Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines Novel Vaccines against Emerging Infectious Diseases Ongoing Developments for a Vaccine against Zika Virus Sanofi's Dengue Vaccine First-to-Market Pipeline & Marketed Dengue Vaccine: 2016 Computational Tools Come to Aid in Development of Ebola Vaccines Vaccine for AIDS Ongoing Research for HIV Vaccine & Commercial Pipeline List of Clinical Trial (Phase II) AIDS Vaccines: 2015 Staggering Global Statistics of AIDS Opportunity Indicator Vaccination-Autism Link and Other Safety Concerns Thwarted Threat of Pandemic Rejuvenates Vaccine Market Influenza Vaccines on a Growing Spree Influenza Vaccines on the Current Market:", "score": 0.500459, "arguments": [{"text": "Pediatric Vaccine Manufacturers Rising Incidence of Infectious Diseases", "location": [1627, 1698], "entities": [{"type": "Organization", "text": "Pediatric Vaccine Manufacturers Rising Incidence of Infectious Diseases"}]}, {"text": "Fuel Growth of Anti-Infective Vaccines Novel Vaccines", "location": [1702, 1755], "entities": [{"type": "Organization", "text": "Fuel Growth of Anti-Infective Vaccines Novel Vaccines"}]}]}, {"type": "hasAttribute", "sentence": "MARKET TRENDS & ISSUES Prophylactic Pediatric Vaccines A Mature Market Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines Novel Vaccines against Emerging Infectious Diseases Ongoing Developments for a Vaccine against Zika Virus Sanofi's Dengue Vaccine First-to-Market Pipeline & Marketed Dengue Vaccine: 2016 Computational Tools Come to Aid in Development of Ebola Vaccines Vaccine for AIDS Ongoing Research for HIV Vaccine & Commercial Pipeline List of Clinical Trial (Phase II) AIDS Vaccines: 2015 Staggering Global Statistics of AIDS Opportunity Indicator Vaccination-Autism Link and Other Safety Concerns Thwarted Threat of Pandemic Rejuvenates Vaccine Market Influenza Vaccines on a Growing Spree Influenza Vaccines on the Current Market:", "score": 0.882169, "arguments": [{"text": "Zika Virus Sanofi", "location": [1836, 1853], "entities": [{"type": "Person", "text": "Zika Virus Sanofi"}]}, {"text": "Diseases", "location": [1784, 1792], "entities": [{"type": "HealthCondition", "text": "Diseases"}]}]}, {"type": "employedBy", "sentence": "MARKET TRENDS & ISSUES Prophylactic Pediatric Vaccines A Mature Market Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines Novel Vaccines against Emerging Infectious Diseases Ongoing Developments for a Vaccine against Zika Virus Sanofi's Dengue Vaccine First-to-Market Pipeline & Marketed Dengue Vaccine: 2016 Computational Tools Come to Aid in Development of Ebola Vaccines Vaccine for AIDS Ongoing Research for HIV Vaccine & Commercial Pipeline List of Clinical Trial (Phase II) AIDS Vaccines: 2015 Staggering Global Statistics of AIDS Opportunity Indicator Vaccination-Autism Link and Other Safety Concerns Thwarted Threat of Pandemic Rejuvenates Vaccine Market Influenza Vaccines on a Growing Spree Influenza Vaccines on the Current Market:", "score": 0.346053, "arguments": [{"text": "Zika Virus Sanofi", "location": [1836, 1853], "entities": [{"type": "Person", "text": "Zika Virus Sanofi"}]}, {"text": "Dengue Vaccine First", "location": [1856, 1876], "entities": [{"type": "Organization", "text": "Dengue Vaccine First"}]}]}, {"type": "partOf", "sentence": "MARKET TRENDS & ISSUES Prophylactic Pediatric Vaccines A Mature Market Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines Novel Vaccines against Emerging Infectious Diseases Ongoing Developments for a Vaccine against Zika Virus Sanofi's Dengue Vaccine First-to-Market Pipeline & Marketed Dengue Vaccine: 2016 Computational Tools Come to Aid in Development of Ebola Vaccines Vaccine for AIDS Ongoing Research for HIV Vaccine & Commercial Pipeline List of Clinical Trial (Phase II) AIDS Vaccines: 2015 Staggering Global Statistics of AIDS Opportunity Indicator Vaccination-Autism Link and Other Safety Concerns Thwarted Threat of Pandemic Rejuvenates Vaccine Market Influenza Vaccines on a Growing Spree Influenza Vaccines on the Current Market:", "score": 0.760472, "arguments": [{"text": "Market Pipeline & Marketed Dengue Vaccine", "location": [1880, 1921], "entities": [{"type": "Organization", "text": "Market Pipeline & Marketed Dengue Vaccine"}]}, {"text": "Dengue Vaccine First", "location": [1856, 1876], "entities": [{"type": "Organization", "text": "Dengue Vaccine First"}]}]}, {"type": "partOf", "sentence": "MARKET TRENDS & ISSUES Prophylactic Pediatric Vaccines A Mature Market Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines Novel Vaccines against Emerging Infectious Diseases Ongoing Developments for a Vaccine against Zika Virus Sanofi's Dengue Vaccine First-to-Market Pipeline & Marketed Dengue Vaccine: 2016 Computational Tools Come to Aid in Development of Ebola Vaccines Vaccine for AIDS Ongoing Research for HIV Vaccine & Commercial Pipeline List of Clinical Trial (Phase II) AIDS Vaccines: 2015 Staggering Global Statistics of AIDS Opportunity Indicator Vaccination-Autism Link and Other Safety Concerns Thwarted Threat of Pandemic Rejuvenates Vaccine Market Influenza Vaccines on a Growing Spree Influenza Vaccines on the Current Market:", "score": 0.77332, "arguments": [{"text": "Staggering Global Statistics of AIDS Opportunity Indicator Vaccination-Autism Link and Other Safety Concerns Thwarted Threat of Pandemic Rejuvenates Vaccine Market Influenza Vaccines", "location": [2119, 2301], "entities": [{"type": "Organization", "text": "Staggering Global Statistics of AIDS Opportunity Indicator Vaccination-Autism Link and Other Safety Concerns Thwarted Threat of Pandemic Rejuvenates Vaccine Market Influenza Vaccines"}]}, {"text": "Spree Influenza Vaccines", "location": [2315, 2339], "entities": [{"type": "Organization", "text": "Spree Influenza Vaccines"}]}]}, {"type": "memberOf", "sentence": "2016 H1N1 Vaccines Hit the Market in August 2009 H1N1 Influenza Vaccines and Manufacturers Influenza Market Faces Several Challenges Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market Unmet Demand for TB Vaccine Key TB Vaccine Candidates in the Pipeline: 2016 Need for a Human Vaccine for Leishmaniasis Economic Factors Hamper Optimal Vaccine Development and Delivery Increasing Need for Vaccine Promotion in the Developing Regions Changing Vaccine Needs Religious Concerns over Immunizing Young Girls against Human Papillomavirus Changing Travel Patterns Increase Demand for Hepatitis B Vaccine DNA Vaccines: Engineering Growth Noninjectable Vaccines: Gain without Pain Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines Conjugate Vaccines: A Technological Innovation Hib Vaccines on the Market: 2016 Growing Pricing Pressure A Major Market Deterrent Safety Issues Come to the Fore BioWarfare: Threat Perception and Preparedness Overview of Potential Bio-", "score": 0.425334, "arguments": [{"text": "Candidates", "location": [2636, 2646], "entities": [{"type": "Person", "text": "Candidates"}]}, {"text": "Global Meningococcal Vaccines Market Unmet Demand for TB Vaccine Key TB Vaccine", "location": [2556, 2635], "entities": [{"type": "Organization", "text": "Global Meningococcal Vaccines Market Unmet Demand for TB Vaccine Key TB Vaccine"}]}]}, {"type": "memberOf", "sentence": "2016 H1N1 Vaccines Hit the Market in August 2009 H1N1 Influenza Vaccines and Manufacturers Influenza Market Faces Several Challenges Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market Unmet Demand for TB Vaccine Key TB Vaccine Candidates in the Pipeline: 2016 Need for a Human Vaccine for Leishmaniasis Economic Factors Hamper Optimal Vaccine Development and Delivery Increasing Need for Vaccine Promotion in the Developing Regions Changing Vaccine Needs Religious Concerns over Immunizing Young Girls against Human Papillomavirus Changing Travel Patterns Increase Demand for Hepatitis B Vaccine DNA Vaccines: Engineering Growth Noninjectable Vaccines: Gain without Pain Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines Conjugate Vaccines: A Technological Innovation Hib Vaccines on the Market: 2016 Growing Pricing Pressure A Major Market Deterrent Safety Issues Come to the Fore BioWarfare: Threat Perception and Preparedness Overview of Potential Bio-", "score": 0.269248, "arguments": [{"text": "Human Papillomavirus Changing", "location": [2919, 2948], "entities": [{"type": "Person", "text": "Human Papillomavirus Changing"}]}, {"text": "Travel Patterns Increase Demand for Hepatitis B Vaccine DNA Vaccines", "location": [2949, 3017], "entities": [{"type": "Organization", "text": "Travel Patterns Increase Demand for Hepatitis B Vaccine DNA Vaccines"}]}]}, {"type": "employedBy", "sentence": "2016 H1N1 Vaccines Hit the Market in August 2009 H1N1 Influenza Vaccines and Manufacturers Influenza Market Faces Several Challenges Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market Unmet Demand for TB Vaccine Key TB Vaccine Candidates in the Pipeline: 2016 Need for a Human Vaccine for Leishmaniasis Economic Factors Hamper Optimal Vaccine Development and Delivery Increasing Need for Vaccine Promotion in the Developing Regions Changing Vaccine Needs Religious Concerns over Immunizing Young Girls against Human Papillomavirus Changing Travel Patterns Increase Demand for Hepatitis B Vaccine DNA Vaccines: Engineering Growth Noninjectable Vaccines: Gain without Pain Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines Conjugate Vaccines: A Technological Innovation Hib Vaccines on the Market: 2016 Growing Pricing Pressure A Major Market Deterrent Safety Issues Come to the Fore BioWarfare: Threat Perception and Preparedness Overview of Potential Bio-", "score": 0.711118, "arguments": [{"text": "Delivery Mechanism", "location": [3114, 3132], "entities": [{"type": "Person", "text": "Delivery Mechanism"}]}, {"text": "Oral Vaccines Conjugate Vaccines", "location": [3137, 3169], "entities": [{"type": "Organization", "text": "Oral Vaccines Conjugate Vaccines"}]}]}, {"type": "employedBy", "sentence": "2016 H1N1 Vaccines Hit the Market in August 2009 H1N1 Influenza Vaccines and Manufacturers Influenza Market Faces Several Challenges Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market Unmet Demand for TB Vaccine Key TB Vaccine Candidates in the Pipeline: 2016 Need for a Human Vaccine for Leishmaniasis Economic Factors Hamper Optimal Vaccine Development and Delivery Increasing Need for Vaccine Promotion in the Developing Regions Changing Vaccine Needs Religious Concerns over Immunizing Young Girls against Human Papillomavirus Changing Travel Patterns Increase Demand for Hepatitis B Vaccine DNA Vaccines: Engineering Growth Noninjectable Vaccines: Gain without Pain Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines Conjugate Vaccines: A Technological Innovation Hib Vaccines on the Market: 2016 Growing Pricing Pressure A Major Market Deterrent Safety Issues Come to the Fore BioWarfare: Threat Perception and Preparedness Overview of Potential Bio-", "score": 0.753616, "arguments": [{"text": "Vaccines", "location": [3202, 3210], "entities": [{"type": "Person", "text": "Human Vaccines Market"}]}, {"text": "Market", "location": [3218, 3224], "entities": [{"type": "Organization", "text": "Market Emerging Nations Offer Huge Opportunities"}]}]}, {"type": "locatedAt", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.903349, "arguments": [{"text": "Pacific", "location": [210, 217], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}, {"text": "Latin America", "location": [219, 232], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "partOfMany", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.938228, "arguments": [{"text": "Smallpox", "location": [3402, 3410], "entities": [{"type": "Person", "text": "Smallpox"}]}, {"text": "Agents", "location": [3395, 3401], "entities": [{"type": "Person", "text": "Agents"}]}]}, {"type": "partOfMany", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.895562, "arguments": [{"text": "Variola", "location": [3412, 3419], "entities": [{"type": "Person", "text": "Variola"}]}, {"text": "Agents", "location": [3395, 3401], "entities": [{"type": "Person", "text": "Agents"}]}]}, {"type": "partOfMany", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.834449, "arguments": [{"text": "Anthrax", "location": [3427, 3434], "entities": [{"type": "Person", "text": "Anthrax"}]}, {"text": "Agents", "location": [3395, 3401], "entities": [{"type": "Person", "text": "Agents"}]}]}, {"type": "partOfMany", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.73752, "arguments": [{"text": "Bacillus Anthracis", "location": [3436, 3454], "entities": [{"type": "Person", "text": "Bacillus Anthracis"}]}, {"text": "Agents", "location": [3395, 3401], "entities": [{"type": "Person", "text": "Agents"}]}]}, {"type": "partOfMany", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.689461, "arguments": [{"text": "Plague", "location": [3456, 3462], "entities": [{"type": "Person", "text": "Plague"}]}, {"text": "Agents", "location": [3395, 3401], "entities": [{"type": "Person", "text": "Agents"}]}]}, {"type": "partOfMany", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.761087, "arguments": [{"text": "Yersinia Pestis", "location": [3464, 3479], "entities": [{"type": "Person", "text": "Yersinia Pestis"}]}, {"text": "Agents", "location": [3395, 3401], "entities": [{"type": "Person", "text": "Agents"}]}]}, {"type": "partOfMany", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.741866, "arguments": [{"text": "Botulism", "location": [3481, 3489], "entities": [{"type": "Person", "text": "Botulism"}]}, {"text": "Agents", "location": [3395, 3401], "entities": [{"type": "Person", "text": "Agents"}]}]}, {"type": "playsRoleOf", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.443148, "arguments": [{"text": "Variola", "location": [3412, 3419], "entities": [{"type": "Person", "text": "Variola"}]}, {"text": "Smallpox", "location": [3402, 3410], "entities": [{"type": "Person", "text": "Smallpox"}]}]}, {"type": "playsRoleOf", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.350599, "arguments": [{"text": "Yersinia Pestis", "location": [3464, 3479], "entities": [{"type": "Person", "text": "Yersinia Pestis"}]}, {"text": "Plague", "location": [3456, 3462], "entities": [{"type": "Person", "text": "Plague"}]}]}, {"type": "partOf", "sentence": "Terrorist Agents Smallpox (Variola Major) Anthrax (Bacillus Anthracis) Plague (Yersinia Pestis) Botulism (Clostridium Botulinum) Tularemia (Francisella Tularensis) Tackling Cold Chain Issues Trade Statistics 3.", "score": 0.421443, "arguments": [{"text": "Tackling Cold Chain Issues Trade Statistics 3", "location": [3549, 3594], "entities": [{"type": "Organization", "text": "Tackling Cold Chain Issues Trade Statistics 3"}]}, {"text": "Francisella Tularensis", "location": [3525, 3547], "entities": [{"type": "Organization", "text": "Francisella Tularensis", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.524283, "arguments": [{"text": "Latin America", "location": [219, 232], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}, {"text": "World", "location": [246, 251], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "COMPETITIVE LANDSCAPE Pfizer Scores Big with Prevnar Trumenba Shows Promise in Phase III Clinical Trials GSK Takes Big Leap into the Meningococcal Vaccine Market Acquired Products Strengthen GSK's Vaccines Sales The Potential for MenABCWY Vaccine Sanofi Works on Production Issues to Boost Sales New Vaccines to Enhance Prospects for Sanofi Sanofi's Human Vaccine R&D Pipeline Weaker Sales Drive Merck and Sanofi's European JV Split Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market 4.", "score": 0.790641, "arguments": [{"text": "Pfizer Scores Big", "location": [3618, 3635], "entities": [{"type": "Organization", "text": "Pfizer Scores Big", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Prevnar Trumenba Shows", "location": [3641, 3663], "entities": [{"type": "Organization", "text": "Prevnar Trumenba Shows", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "COMPETITIVE LANDSCAPE Pfizer Scores Big with Prevnar Trumenba Shows Promise in Phase III Clinical Trials GSK Takes Big Leap into the Meningococcal Vaccine Market Acquired Products Strengthen GSK's Vaccines Sales The Potential for MenABCWY Vaccine Sanofi Works on Production Issues to Boost Sales New Vaccines to Enhance Prospects for Sanofi Sanofi's Human Vaccine R&D Pipeline Weaker Sales Drive Merck and Sanofi's European JV Split Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market 4.", "score": 0.985552, "arguments": [{"text": "Prevnar Trumenba Shows", "location": [3641, 3663], "entities": [{"type": "Organization", "text": "Prevnar Trumenba Shows", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Promise", "location": [3664, 3671], "entities": [{"type": "EventCommunication", "text": "Promise"}]}]}, {"type": "agentOf", "sentence": "COMPETITIVE LANDSCAPE Pfizer Scores Big with Prevnar Trumenba Shows Promise in Phase III Clinical Trials GSK Takes Big Leap into the Meningococcal Vaccine Market Acquired Products Strengthen GSK's Vaccines Sales The Potential for MenABCWY Vaccine Sanofi Works on Production Issues to Boost Sales New Vaccines to Enhance Prospects for Sanofi Sanofi's Human Vaccine R&D Pipeline Weaker Sales Drive Merck and Sanofi's European JV Split Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market 4.", "score": 0.553284, "arguments": [{"text": "Clinical Trials GSK Takes Big Leap", "location": [3685, 3719], "entities": [{"type": "Organization", "text": "Clinical Trials GSK Takes Big Leap"}]}, {"text": "Promise", "location": [3664, 3671], "entities": [{"type": "EventCommunication", "text": "Promise"}]}]}, {"type": "productOf", "sentence": "COMPETITIVE LANDSCAPE Pfizer Scores Big with Prevnar Trumenba Shows Promise in Phase III Clinical Trials GSK Takes Big Leap into the Meningococcal Vaccine Market Acquired Products Strengthen GSK's Vaccines Sales The Potential for MenABCWY Vaccine Sanofi Works on Production Issues to Boost Sales New Vaccines to Enhance Prospects for Sanofi Sanofi's Human Vaccine R&D Pipeline Weaker Sales Drive Merck and Sanofi's European JV Split Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market 4.", "score": 0.928173, "arguments": [{"text": "Vaccines", "location": [3793, 3801], "entities": [{"type": "Product", "text": "Vaccines GeoVax Labs Collaborates"}]}, {"text": "Meningococcal Vaccine Market Acquired Products Strengthen GSK", "location": [3729, 3790], "entities": [{"type": "Organization", "text": "Meningococcal Vaccine Market Acquired Products Strengthen GSK"}]}]}, {"type": "employedBy", "sentence": "COMPETITIVE LANDSCAPE Pfizer Scores Big with Prevnar Trumenba Shows Promise in Phase III Clinical Trials GSK Takes Big Leap into the Meningococcal Vaccine Market Acquired Products Strengthen GSK's Vaccines Sales The Potential for MenABCWY Vaccine Sanofi Works on Production Issues to Boost Sales New Vaccines to Enhance Prospects for Sanofi Sanofi's Human Vaccine R&D Pipeline Weaker Sales Drive Merck and Sanofi's European JV Split Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market 4.", "score": 0.739632, "arguments": [{"text": "Human Vaccine R&D Pipeline Weaker", "location": [3946, 3979], "entities": [{"type": "Person", "text": "Human Vaccine R&D Pipeline Weaker"}]}, {"text": "Enhance Prospects for Sanofi Sanofi", "location": [3908, 3943], "entities": [{"type": "Organization", "text": "Enhance Prospects for Sanofi Sanofi"}]}]}, {"type": "employedBy", "sentence": "COMPETITIVE LANDSCAPE Pfizer Scores Big with Prevnar Trumenba Shows Promise in Phase III Clinical Trials GSK Takes Big Leap into the Meningococcal Vaccine Market Acquired Products Strengthen GSK's Vaccines Sales The Potential for MenABCWY Vaccine Sanofi Works on Production Issues to Boost Sales New Vaccines to Enhance Prospects for Sanofi Sanofi's Human Vaccine R&D Pipeline Weaker Sales Drive Merck and Sanofi's European JV Split Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market 4.", "score": 0.440824, "arguments": [{"text": "Human Vaccine R&D Pipeline Weaker", "location": [3946, 3979], "entities": [{"type": "Person", "text": "Human Vaccine R&D Pipeline Weaker"}]}, {"text": "Merck", "location": [3992, 3997], "entities": [{"type": "Organization", "text": "Merck End Joint Venture", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "COMPETITIVE LANDSCAPE Pfizer Scores Big with Prevnar Trumenba Shows Promise in Phase III Clinical Trials GSK Takes Big Leap into the Meningococcal Vaccine Market Acquired Products Strengthen GSK's Vaccines Sales The Potential for MenABCWY Vaccine Sanofi Works on Production Issues to Boost Sales New Vaccines to Enhance Prospects for Sanofi Sanofi's Human Vaccine R&D Pipeline Weaker Sales Drive Merck and Sanofi's European JV Split Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market 4.", "score": 0.611936, "arguments": [{"text": "European JV Split Serum Institute", "location": [4011, 4044], "entities": [{"type": "Organization", "text": "European JV Split Serum Institute", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Sanofi", "location": [4002, 4008], "entities": [{"type": "Organization", "text": "Sanofi Pasteur SA", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "CLINICAL TRIALS IN THE VACCINES MARKET Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine Takeda Begins Phase2b Trial for World's First Norovirus Vaccine Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine Investigational Vaccine for P.vivax Malaria Enters Human Trials Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C.difficile Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial 6.", "score": 0.759495, "arguments": [{"text": "Zika DNA Vaccine Takeda Begins Phase2b", "location": [4218, 4256], "entities": [{"type": "Person", "text": "Zika DNA Vaccine Takeda Begins Phase2b"}]}, {"text": "Trial", "location": [4257, 4262], "entities": [{"type": "EventLegal", "text": "Trial"}]}]}, {"type": "basedIn", "sentence": "CLINICAL TRIALS IN THE VACCINES MARKET Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine Takeda Begins Phase2b Trial for World's First Norovirus Vaccine Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine Investigational Vaccine for P.vivax Malaria Enters Human Trials Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C.difficile Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial 6.", "score": 0.473867, "arguments": [{"text": "First Norovirus Vaccine Bavarian Nordic Announces", "location": [4275, 4324], "entities": [{"type": "Organization", "text": "First Norovirus Vaccine Bavarian Nordic Announces"}]}, {"text": "World", "location": [4267, 4272], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.488295, "arguments": [{"text": "Formulation", "location": [4889, 4900], "entities": [{"type": "Person", "text": "Formulation"}]}, {"text": "Protein Sciences Corporation", "location": [4904, 4932], "entities": [{"type": "Organization", "text": "Protein Sciences Corporation"}]}]}, {"type": "residesIn", "sentence": "The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.", "score": 0.280592, "arguments": [{"text": "Rest", "location": [238, 242], "entities": [{"type": "Cardinal", "text": "Rest"}]}, {"text": "World", "location": [246, 251], "entities": [{"type": "GeopoliticalEntity", "text": "World", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.45729, "arguments": [{"text": "Formulation", "location": [4889, 4900], "entities": [{"type": "Person", "text": "Formulation"}]}, {"text": "Dengue Vaccine Approved", "location": [4952, 4975], "entities": [{"type": "Organization", "text": "Dengue Vaccine Approved"}]}]}, {"type": "partOf", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.622666, "arguments": [{"text": "Flublok Sanofi", "location": [4935, 4949], "entities": [{"type": "Organization", "text": "Flublok Sanofi"}]}, {"text": "Protein Sciences Corporation", "location": [4904, 4932], "entities": [{"type": "Organization", "text": "Protein Sciences Corporation"}]}]}, {"type": "partOf", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.910532, "arguments": [{"text": "Dengue Vaccine Approved", "location": [4952, 4975], "entities": [{"type": "Organization", "text": "Dengue Vaccine Approved"}]}, {"text": "Flublok Sanofi", "location": [4935, 4949], "entities": [{"type": "Organization", "text": "Flublok Sanofi"}]}]}, {"type": "locatedAt", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.402995, "arguments": [{"text": "Dengue Vaccine Approved", "location": [4952, 4975], "entities": [{"type": "Organization", "text": "Dengue Vaccine Approved"}]}, {"text": "Costa Rica", "location": [4979, 4989], "entities": [{"type": "GeopoliticalEntity", "text": "Costa Rica", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.877306, "arguments": [{"text": "GSK Supplies Flu Vaccines", "location": [4990, 5015], "entities": [{"type": "Organization", "text": "GSK Supplies Flu Vaccines"}]}, {"text": "Costa Rica", "location": [4979, 4989], "entities": [{"type": "GeopoliticalEntity", "text": "Costa Rica", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.759313, "arguments": [{"text": "Dengvaxia Receives Marketing Authorization", "location": [5353, 5395], "entities": [{"type": "Organization", "text": "Dengvaxia Receives Marketing Authorization"}]}, {"text": "Investigational Ebola Vaccine Application for Review Sanofi", "location": [5291, 5350], "entities": [{"type": "Organization", "text": "Investigational Ebola Vaccine Application for Review Sanofi"}]}]}, {"type": "locatedAt", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.480648, "arguments": [{"text": "Dengvaxia Receives Marketing Authorization", "location": [5353, 5395], "entities": [{"type": "Organization", "text": "Dengvaxia Receives Marketing Authorization"}]}, {"text": "Mexico", "location": [5399, 5405], "entities": [{"type": "GeopoliticalEntity", "text": "Mexico", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "basedIn", "sentence": "PRODUCT LAUNCHES/APPROVALS FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok Sanofi's Dengue Vaccine Approved in Costa Rica GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine China Launches HFMD Vaccine Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection WHO Accepts Merck's Investigational Ebola Vaccine Application for Review Sanofi's Dengvaxia Receives Marketing Authorization in Mexico SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur Ships First Doses of Fluzone for the US Market Bharat Biotech Launches Made-in-India ROTAVAC Vaccine 7.", "score": 0.845611, "arguments": [{"text": "SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur", "location": [5406, 5471], "entities": [{"type": "Organization", "text": "SK Chemicals Launches Influenza Vaccine SKYCellflu Sanofi Pasteur", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Mexico", "location": [5399, 5405], "entities": [{"type": "GeopoliticalEntity", "text": "Mexico", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.653097, "arguments": [{"text": "Prevnar", "location": [5670, 5677], "entities": [{"type": "Organization", "text": "Prevnar Trumenba Shows", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Pfizer", "location": [5661, 5667], "entities": [{"type": "Organization", "text": "Pfizer Scores Big", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.729866, "arguments": [{"text": "Begins Vaccine Manufacturing", "location": [5696, 5724], "entities": [{"type": "Person", "text": "Begins Vaccine Manufacturing"}]}, {"text": "Sanofi Pasteur", "location": [5681, 5695], "entities": [{"type": "Organization", "text": "Sanofi Pasteur"}]}]}, {"type": "partOf", "sentence": "This report analyzes the worldwide markets for Human Vaccines by the following Product Segments: Pediatric Vaccines Adult Vaccines Company profiles are primarily based on public domain information including company URLs.", "score": 0.65292, "arguments": [{"text": "company", "location": [605, 612], "entities": [{"type": "Organization", "text": "Pediatric Vaccines Adult Vaccines Company", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "URLs", "location": [613, 617], "entities": [{"type": "Organization", "text": "URLs", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.732882, "arguments": [{"text": "Begins Vaccine Manufacturing", "location": [5696, 5724], "entities": [{"type": "Person", "text": "Begins Vaccine Manufacturing"}]}, {"text": "Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract", "location": [5728, 5822], "entities": [{"type": "Organization", "text": "Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract"}]}]}, {"type": "employedBy", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.632654, "arguments": [{"text": "Stellar Biotechnologies", "location": [5842, 5865], "entities": [{"type": "Person", "text": "Stellar Biotechnologies"}]}, {"text": "US Government", "location": [5828, 5841], "entities": [{"type": "GeopoliticalEntity", "text": "US Government", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.91289, "arguments": [{"text": "Dengvaxia", "location": [5941, 5950], "entities": [{"type": "Organization", "text": "Dengvaxia Receives Marketing Authorization"}]}, {"text": "Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi", "location": [5870, 5938], "entities": [{"type": "Organization", "text": "Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi"}]}]}, {"type": "basedIn", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.615826, "arguments": [{"text": "Dengvaxia", "location": [5941, 5950], "entities": [{"type": "Organization", "text": "Dengvaxia Receives Marketing Authorization"}]}, {"text": "Nations", "location": [5954, 5961], "entities": [{"type": "GeopoliticalEntity", "text": "Nations"}]}]}, {"type": "basedIn", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.74433, "arguments": [{"text": "Widespread Dengue Kaketsuken", "location": [5967, 5995], "entities": [{"type": "Organization", "text": "Widespread Dengue Kaketsuken", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Nations", "location": [5954, 5961], "entities": [{"type": "GeopoliticalEntity", "text": "Nations"}]}]}, {"type": "productOf", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.609101, "arguments": [{"text": "Vaccines GeoVax Labs Collaborates", "location": [6072, 6105], "entities": [{"type": "Product", "text": "Vaccines GeoVax Labs Collaborates"}]}, {"text": "Merck End Joint Venture", "location": [6045, 6068], "entities": [{"type": "Organization", "text": "Merck End Joint Venture", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.645167, "arguments": [{"text": "Evaxion for Vaccine", "location": [6183, 6202], "entities": [{"type": "Organization", "text": "Evaxion for Vaccine"}]}, {"text": "USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates", "location": [6111, 6177], "entities": [{"type": "Organization", "text": "USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates"}]}]}, {"type": "employedBy", "sentence": "RECENT INDUSTRY ACTIVITY WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue Kaketsuken to Sell Vaccines Business to Astellas Sanofi and Merck End Joint Venture on Vaccines GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA Bavarian Nordic Enters into License Agreement with Janssen CSL Rebrands Influenza Vaccines Business as Seqirus MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D GlaxoSmithKline Acquires Novartis'", "score": 0.381658, "arguments": [{"text": "Janssen CSL Rebrands", "location": [6267, 6287], "entities": [{"type": "Person", "text": "Janssen CSL Rebrands"}]}, {"text": "Influenza Vaccines Business", "location": [6288, 6315], "entities": [{"type": "Organization", "text": "Influenza Vaccines Business Pfizer to Acquire Meningitis Vaccines"}]}]}, {"type": "partOf", "sentence": "Vaccines Business Vaxin Changes Name to Altimmune Takeda Expands Commercialization Agreement with Nanotherapeutics MedImmune Enters Into License Agreement with Inovio Pharmaceuticals CSL Completes Acquisition of Novartis' Influenza Vaccines Business Pfizer to Acquire Meningitis Vaccines from GSK Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License 8.", "score": 0.542552, "arguments": [{"text": "Nanotherapeutics MedImmune Enters Into License Agreement", "location": [6545, 6601], "entities": [{"type": "Organization", "text": "Nanotherapeutics MedImmune Enters Into License Agreement"}]}, {"text": "Altimmune Takeda Expands Commercialization Agreement", "location": [6487, 6539], "entities": [{"type": "Organization", "text": "Altimmune Takeda Expands Commercialization Agreement"}]}]}, {"type": "partOf", "sentence": "Vaccines Business Vaxin Changes Name to Altimmune Takeda Expands Commercialization Agreement with Nanotherapeutics MedImmune Enters Into License Agreement with Inovio Pharmaceuticals CSL Completes Acquisition of Novartis' Influenza Vaccines Business Pfizer to Acquire Meningitis Vaccines from GSK Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License 8.", "score": 0.581914, "arguments": [{"text": "GSK Pfizer Stops Prevnar Vaccine Sales", "location": [6740, 6778], "entities": [{"type": "Organization", "text": "GSK Pfizer Stops Prevnar Vaccine Sales"}]}, {"text": "Influenza Vaccines Business Pfizer to Acquire Meningitis Vaccines", "location": [6669, 6734], "entities": [{"type": "Organization", "text": "Influenza Vaccines Business Pfizer to Acquire Meningitis Vaccines"}]}]}, {"type": "partOfMany", "sentence": "The report profiles 66 companies including many key and niche players such as: ALK Abell A/S (Denmark) Altimmune, Inc. (US) Bavarian Nordic A/S (Denmark) BiondVax Pharmaceuticals Ltd. (Israel) Bharat Biotech International Limited (India) GlaxoSmithKline Plc.", "score": 0.836531, "arguments": [{"text": "ALK Abell A/S", "location": [698, 711], "entities": [{"type": "Person", "text": "ALK Abell A/S"}]}, {"text": "players", "location": [681, 688], "entities": [{"type": "Person", "text": "players"}]}]}, {"type": "locatedAt", "sentence": "Vaccines Business Vaxin Changes Name to Altimmune Takeda Expands Commercialization Agreement with Nanotherapeutics MedImmune Enters Into License Agreement with Inovio Pharmaceuticals CSL Completes Acquisition of Novartis' Influenza Vaccines Business Pfizer to Acquire Meningitis Vaccines from GSK Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License 8.", "score": 0.664331, "arguments": [{"text": "GSK Pfizer Stops Prevnar Vaccine Sales", "location": [6740, 6778], "entities": [{"type": "Organization", "text": "GSK Pfizer Stops Prevnar Vaccine Sales"}]}, {"text": "China", "location": [6782, 6787], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOf", "sentence": "GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 63 (including Divisions/Subsidiaries 72) The United States (22) Canada (1) Japan (5) Europe (14) France (3) Germany (2) The United Kingdom (2) Spain (1) Rest of Europe (6) Asia-Pacific (Excluding Japan) (28) Latin America (1) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/hcpmgn/human_vaccines?w=4", "score": 0.606644, "arguments": [{"text": "Subsidiaries", "location": [6934, 6946], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}, {"text": "Divisions", "location": [6924, 6933], "entities": [{"type": "Organization", "text": "Divisions"}]}]}, {"type": "partOfMany", "sentence": "GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 63 (including Divisions/Subsidiaries 72) The United States (22) Canada (1) Japan (5) Europe (14) France (3) Germany (2) The United Kingdom (2) Spain (1) Rest of Europe (6) Asia-Pacific (Excluding Japan) (28) Latin America (1) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/hcpmgn/human_vaccines?w=4", "score": 0.417091, "arguments": [{"text": "The United States", "location": [6951, 6968], "entities": [{"type": "Organization", "text": "The United States", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Subsidiaries", "location": [6934, 6946], "entities": [{"type": "Organization", "text": "Subsidiaries"}]}]}, {"type": "residesIn", "sentence": "GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 63 (including Divisions/Subsidiaries 72) The United States (22) Canada (1) Japan (5) Europe (14) France (3) Germany (2) The United Kingdom (2) Spain (1) Rest of Europe (6) Asia-Pacific (Excluding Japan) (28) Latin America (1) Middle East (1) For more information about this report visit https://www.researchandmarkets.com/research/hcpmgn/human_vaccines?w=4", "score": 0.406001, "arguments": [{"text": "Rest", "location": [7063, 7067], "entities": [{"type": "Cardinal", "text": "Rest"}]}, {"text": "Europe", "location": [7071, 7077], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "employedBy", "sentence": "The report profiles 66 companies including many key and niche players such as: ALK Abell A/S (Denmark) Altimmune, Inc. (US) Bavarian Nordic A/S (Denmark) BiondVax Pharmaceuticals Ltd. (Israel) Bharat Biotech International Limited (India) GlaxoSmithKline Plc.", "score": 0.415953, "arguments": [{"text": "players", "location": [681, 688], "entities": [{"type": "Person", "text": "players"}]}, {"text": "Altimmune, Inc.", "location": [722, 737], "entities": [{"type": "Organization", "text": "Altimmune, Inc."}]}]}, {"type": "partOf", "sentence": "(UK) Hualan Biological Engineering Inc. (China) Janssen Pharmaceuticals, Inc. (US) MedImmune (US) Merck & Co., Inc. (US) Pfizer Inc. (US) Sanofi Pasteur SA (France) Serum Institute of India Pvt. Ltd. (India) Shanghai BravoBio Co., Ltd. (China) Seqirus (UK) SK Chemicals Co., Ltd. (Korea) Takeda Pharmaceutical Company Limited (Japan) Zydus Cadila (India) Key Topics Covered 1.", "score": 0.403402, "arguments": [{"text": "Sanofi Pasteur SA", "location": [1016, 1033], "entities": [{"type": "Organization", "text": "Sanofi Pasteur SA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "US", "location": [1012, 1014], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "(UK) Hualan Biological Engineering Inc. (China) Janssen Pharmaceuticals, Inc. (US) MedImmune (US) Merck & Co., Inc. (US) Pfizer Inc. (US) Sanofi Pasteur SA (France) Serum Institute of India Pvt. Ltd. (India) Shanghai BravoBio Co., Ltd. (China) Seqirus (UK) SK Chemicals Co., Ltd. (Korea) Takeda Pharmaceutical Company Limited (Japan) Zydus Cadila (India) Key Topics Covered 1.", "score": 0.800909, "arguments": [{"text": "BravoBio Co., Ltd.", "location": [1095, 1113], "entities": [{"type": "Organization", "text": "BravoBio Co., Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Shanghai", "location": [1086, 1094], "entities": [{"type": "GeopoliticalEntity", "text": "Shanghai"}]}]}], "keywords": [{"text": "Vaccine Investigational Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.904864}, {"text": "Ebola Vaccines Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.896978}, {"text": "Vaccine DNA Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.863444}, {"text": "Vaccines Adult Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.84497}, {"text": "Vaccines Novel Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.816287}, {"text": "Vaccines Conjugate Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.803821}, {"text": "MenABCWY Vaccine Sanofi", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.72588}, {"text": "Human Vaccines", "sentiment": {"score": 0.611914, "label": "positive"}, "relevance": 0.70971}, {"text": "Vaccine SKYCellflu Sanofi", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.702967}, {"text": "Vaccine Market Influenza", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.695595}, {"text": "Vaccine Bavarian Nordic", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.681881}, {"text": "Vaccine R&D", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.655695}, {"text": "vaccines market", "sentiment": {"score": 0.613365, "label": "positive"}, "relevance": 0.649203}, {"text": "Meningococcal Vaccine Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.645266}, {"text": "Dengue Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.644498}, {"text": "Human Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.643857}, {"text": "HPV Vaccine Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.63412}, {"text": "Human Vaccines Market", "sentiment": {"score": 0.613365, "label": "positive"}, "relevance": 0.630805}, {"text": "Dengue Vaccine First-to-Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.62779}, {"text": "Marketed Dengue Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.625998}, {"text": "Human Vaccine R&D", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.624064}, {"text": "Influenza Vaccine China", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.623585}, {"text": "Growth Area Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.620979}, {"text": "TB Vaccine Key", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.614196}, {"text": "Pediatric Vaccine Manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.609287}, {"text": "Norovirus Vaccine Bavarian", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.605249}, {"text": "Influenza Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.604271}, {"text": "Pasteur Launches Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.603673}, {"text": "TB Vaccine Candidates", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.59977}, {"text": "Optimal Vaccine Development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.599021}, {"text": "Ebola Vaccine Candidate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.598525}, {"text": "Vaccine Needs Religious", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597936}, {"text": "Vaccine Takeda Begins", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597724}, {"text": "Investigational Ebola Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.597146}, {"text": "Meningococcal Vaccines Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.595726}, {"text": "Advance Ebola Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593065}, {"text": "Dengue Vaccine Approved", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.591793}, {"text": "Prevnar Vaccine Sales", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589723}, {"text": "Vaccine Bharat Biotech", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.587951}, {"text": "Vaccine Vical Reports", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586378}, {"text": "Pasteur Begins Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.586307}, {"text": "H1N1 Influenza Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585076}, {"text": "Fever Vaccine Bavarian", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.583172}, {"text": "Spree Influenza Vaccines", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.582007}, {"text": "CMV vaccine Profectus", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.581642}, {"text": "VACCINES MARKET Inovio", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578107}, {"text": "OUTLOOK Human Vaccines", "sentiment": {"score": 0.610463, "label": "positive"}, "relevance": 0.574245}, {"text": "Vaccine R&D GlaxoSmithKline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.574023}, {"text": "Influenza Vaccines Business", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.57106}, {"text": "Made-in-India ROTAVAC Vaccine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.570743}]}, "extracted_metadata": {"sha1": "ae6e8f23f506a5cceb76abfdd0f25989961cc89c", "filename": "1542298372237.zip-7816818ed2761c6f0cbd46344b3d61e7.xml", "file_type": "json"}, "external_links": ["http://rss.financialcontent.com/images/feed/150px/110/66/11066358.img", "http://ads.financialcontent.com/www/delivery/ajs.php", "https://cts.businesswire.com/ct/CT?id=bwnews&sty=20181115005666r1&sid=56782&distro=ftp", "https://www.researchandmarkets.com/research/hcpmgn/human_vaccines?w=4"], "title": "Human Vaccines 2016-2024 - Global Strategic Business Report 2018: Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers - ResearchAndMarkets.com", "forum_title": "Stock Market | Malvern Daily Record"}, {"id": "YpqyXxHi3muesAZnRZaAbZYpNrdLxMr_uoJrAgrSaLLzWOKh9lkPUZsdP8TqDeVZ", "result_metadata": {"score": 33.166176}, "author": "tanuj", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Market", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Market"}, {"text": "Marketplace", "relevance": 0.8704, "dbpedia_resource": "http://dbpedia.org/resource/Marketplace"}, {"text": "Market square", "relevance": 0.822782, "dbpedia_resource": "http://dbpedia.org/resource/Market_square"}], "categories": [{"score": 0.965609, "label": "/health and fitness"}, {"score": 0.820354, "label": "/health and fitness/disease/heart disease"}], "relations": [], "keywords": [{"text": "Cardiovascular Drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.976728, "count": 1}, {"text": "Consumer Market places", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.023272, "count": 1}]}, "crawl_date": "2018-11-16T12:10:28Z", "url": "https://www.findmarketresearch.org/2018/09/cardiovascular-drugs-market-to-actively-foray-into-emerging-consumer-market-places-during-2015-to-2021/", "host": "findmarketresearch.org", "text": "Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-09-24T14:12:00+05:00", "enriched_text": {"entities": [{"count": 3, "sentiment": {"score": -0.867064, "label": "negative"}, "text": "hypertensive heart disease", "relevance": 0.888099, "type": "HealthCondition", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}, {"count": 2, "sentiment": {"score": -0.911619, "label": "negative"}, "text": "inflammatory heart disease", "relevance": 0.723923, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}, {"count": 3, "sentiment": {"score": -0.75901, "label": "negative"}, "text": "Cerebrovascular disease", "relevance": 0.545262, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}, {"count": 3, "sentiment": {"score": -0.787412, "label": "negative"}, "text": "rheumatic fever", "relevance": 0.448337, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"count": 6, "sentiment": {"score": -0.375028, "label": "negative"}, "text": "Japan", "relevance": 0.394836, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.832513, "label": "negative"}, "text": "kawasaki disease", "relevance": 0.312494, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}, {"count": 3, "sentiment": {"score": -0.0134332, "label": "negative"}, "text": "Asia", "relevance": 0.305742, "type": "Location", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}, {"count": 2, "sentiment": {"score": -0.767521, "label": "negative"}, "text": "group A streptococcal infection", "relevance": 0.289489, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}, {"count": 2, "sentiment": {"score": -0.450286, "label": "negative"}, "text": "North America", "relevance": 0.276973, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": -0.306977, "label": "negative"}, "text": "subarachnoid hemorrhage", "relevance": 0.245805, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "RiskFactor", "Disease"], "name": "Subarachnoid hemorrhage", "dbpedia_resource": "http://dbpedia.org/resource/Subarachnoid_hemorrhage"}}, {"count": 1, "sentiment": {"score": -0.337861, "label": "negative"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.2136, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tredaptive", "relevance": 0.207469, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eliquis", "relevance": 0.206418, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.", "relevance": 0.20444, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.20245, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.197709, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca PLC", "relevance": 0.195237, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": -0.292396, "label": "negative"}, "text": "Solvay SA", "relevance": 0.194971, "type": "Company", "disambiguation": {"subtype": [], "name": "Solvay (company)", "dbpedia_resource": "http://dbpedia.org/resource/Solvay_(company)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.193651, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": -0.224413, "label": "negative"}, "text": "Bayer AG", "relevance": 0.192438, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Forest Laboratories Inc.", "relevance": 0.186027, "type": "Company", "disambiguation": {"subtype": [], "name": "Forest Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Forest_Laboratories"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.179305, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": -0.292396, "label": "negative"}, "text": "Pfizer Inc.", "relevance": 0.178932, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daiichi Sankyo Co. Ltd.", "relevance": 0.178691, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "France", "relevance": 0.177138, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories Inc.", "relevance": 0.172053, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "India", "relevance": 0.171237, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "Region", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Spain", "relevance": 0.169414, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Germany", "relevance": 0.168428, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co. Ltd.", "relevance": 0.167736, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.K.", "relevance": 0.165053, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.1632, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche Ltd.", "relevance": 0.159933, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Italy", "relevance": 0.151305, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "five years", "relevance": 0.151305, "type": "Quantity"}], "sentiment": {"document": {"score": -0.709393, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Cardiovascular diseases,", "keywords": [{"text": "Cardiovascular diseases"}]}, "sentence": "Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "object": {"text": "as heart diseases", "keywords": [{"text": "heart diseases"}]}, "action": {"verb": {"text": "know", "tense": "past"}, "text": "also known", "normalized": "also know"}}, {"subject": {"text": "Cardiovascular diseases, also known as heart diseases,", "keywords": [{"text": "Cardiovascular diseases"}, {"text": "heart diseases"}]}, "sentence": "Cardiovascular diseases, also known as heart diseases, are diseases of heart and circulatory system.", "object": {"text": "diseases of heart and circulatory system", "keywords": [{"text": "diseases"}, {"text": "heart"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Some of the most common cardiovascular diseases", "keywords": [{"text": "common cardiovascular diseases"}]}, "sentence": " Some of the most common cardiovascular diseases are hypertensive heart disease, rheumatic heart disease, cerebrovascular heart disease, ischemic heart disease and inflammatory heart disease.", "object": {"text": "hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Major problems", "keywords": [{"text": "Major problems"}]}, "sentence": " Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina.", "object": {"text": "with hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "heart failure, hypertrophy, coronary heart disease and angina", "keywords": [{"text": "coronary heart disease"}, {"text": "heart failure"}, {"text": "hypertrophy"}, {"text": "angina"}]}, "sentence": " Major problems associated with hypertensive heart disease include heart failure, hypertrophy, coronary heart disease and angina.", "object": {"text": "Major problems associated with hypertensive heart disease", "keywords": [{"text": "hypertensive heart disease"}, {"text": "Major problems"}], "entities": [{"type": "HealthCondition", "text": "hypertensive heart disease", "disambiguation": {"subtype": [], "name": "Hypertensive heart disease", "dbpedia_resource": "http://dbpedia.org/resource/Hypertensive_heart_disease"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "Rheumatic heart disease", "keywords": [{"text": "Rheumatic heart disease"}]}, "sentence": " Rheumatic heart disease is caused by rheumatic fever.", "object": {"text": "by rheumatic fever", "keywords": [{"text": "rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "by rheumatic fever", "keywords": [{"text": "rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "sentence": " Rheumatic heart disease is caused by rheumatic fever.", "object": {"text": "Rheumatic heart disease", "keywords": [{"text": "Rheumatic heart disease"}]}, "action": {"verb": {"text": "cause", "tense": "past"}, "text": "is caused", "normalized": "be cause"}}, {"subject": {"text": "by preceding group A streptococcal infection", "keywords": [{"text": "streptococcal infection"}, {"text": "group"}], "entities": [{"type": "HealthCondition", "text": "group A streptococcal infection", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}]}, "sentence": " Rheumatic fever occurs by preceding group A streptococcal infection.", "object": {"text": "Rheumatic fever", "keywords": [{"text": "Rheumatic fever"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "It"}, "sentence": " It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "object": {"text": "one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries", "keywords": [{"text": "heart diseases"}, {"text": "countries"}, {"text": "children"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Cerebrovascular disease", "keywords": [{"text": "Cerebrovascular disease"}], "entities": [{"type": "HealthCondition", "text": "Cerebrovascular disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}]}, "sentence": " Cerebrovascular disease affects blood vessels of the brain.", "object": {"text": "blood vessels of the brain", "keywords": [{"text": "blood vessels"}, {"text": "brain"}], "entities": []}, "action": {"verb": {"text": "affect", "tense": "present"}, "text": "affects", "normalized": "affect"}}, {"subject": {"text": "Most common types of cerebrovascular disease", "keywords": [{"text": "cerebrovascular disease"}, {"text": "common types"}], "entities": [{"type": "HealthCondition", "text": "Cerebrovascular disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "Disease"], "name": "Cerebrovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cerebrovascular_disease"}}]}, "sentence": " Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA).", "object": {"text": "vascular dementia", "keywords": [{"text": "vascular dementia"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Ischemic heart disease", "keywords": [{"text": "Ischemic heart disease"}]}, "sentence": " Ischemic heart disease is characterized by reduced blood supply to the heart.", "object": {"text": "by reduced blood supply to the heart", "keywords": [{"text": "blood supply"}, {"text": "heart"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "by reduced blood supply to the heart", "keywords": [{"text": "blood supply"}, {"text": "heart"}]}, "sentence": " Ischemic heart disease is characterized by reduced blood supply to the heart.", "object": {"text": "Ischemic heart disease", "keywords": [{"text": "Ischemic heart disease"}]}, "action": {"verb": {"text": "characterize", "tense": "past"}, "text": "is characterized", "normalized": "be characterize"}}, {"subject": {"text": "It"}, "sentence": " It is one of the most common causes of death in western parts of the world.", "object": {"text": "one of the most common causes of death in western parts of the world", "keywords": [{"text": "common causes"}, {"text": "western parts"}, {"text": "death"}, {"text": "world"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Inflammatory heart disease", "keywords": [{"text": "Inflammatory heart disease"}], "entities": [{"type": "HealthCondition", "text": "inflammatory heart disease", "disambiguation": {"subtype": ["Disease"], "name": "Cardiovascular disease", "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}}]}, "sentence": " Inflammatory heart disease occurs due to the infection of bacteria and virus.", "object": {"text": "due to the infection of bacteria and virus", "keywords": [{"text": "bacteria"}, {"text": "infection"}, {"text": "virus"}], "entities": [{"type": "HealthCondition", "text": "group A streptococcal infection", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "InfectiousDisease", "RiskFactor"], "name": "Group A streptococcal infection", "dbpedia_resource": "http://dbpedia.org/resource/Group_A_streptococcal_infection"}}]}, "action": {"verb": {"text": "occur", "tense": "present"}, "text": "occurs", "normalized": "occur"}}, {"subject": {"text": "This type of inflammation", "keywords": [{"text": "inflammation"}, {"text": "type"}]}, "sentence": " This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.", "object": {"text": "often associated with episodes of rheumatic fever and kawasaki disease", "keywords": [{"text": "rheumatic fever"}, {"text": "kawasaki disease"}, {"text": "episodes"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"type": "HealthCondition", "text": "kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This type of inflammation", "keywords": [{"text": "inflammation"}, {"text": "type"}]}, "sentence": " This type of inflammation is often associated with episodes of rheumatic fever and kawasaki disease.", "object": {"text": "with episodes of rheumatic fever and kawasaki disease", "keywords": [{"text": "rheumatic fever"}, {"text": "kawasaki disease"}, {"text": "episodes"}], "entities": [{"type": "HealthCondition", "text": "rheumatic fever", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath", "DiseaseCause", "InfectiousDisease", "RiskFactor", "Disease"], "name": "Rheumatic fever", "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}}, {"type": "HealthCondition", "text": "kawasaki disease", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "CauseOfDeath"], "name": "Kawasaki disease", "dbpedia_resource": "http://dbpedia.org/resource/Kawasaki_disease"}}]}, "action": {"verb": {"text": "associate", "tense": "past"}, "text": "associated", "normalized": "associate"}}, {"subject": {"text": "The global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs.", "object": {"text": "based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs", "keywords": [{"text": "various anti-hypertensive drugs"}, {"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}]}, "action": {"verb": {"text": "categorize", "tense": "past"}, "text": "is categorized", "normalized": "be categorize"}}, {"subject": {"text": "The global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " The global cardiovascular drugs market is categorized based on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs.", "object": {"text": "on various anti-hypertensive drugs, anti-dyslipidemics drugs and anti-thrombotics drugs", "keywords": [{"text": "various anti-hypertensive drugs"}, {"text": "anti-dyslipidemics drugs"}, {"text": "anti-thrombotics drugs"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "based", "normalized": "base"}}, {"subject": {"text": "Anti-hypertensive drug segment", "keywords": [{"text": "Anti-hypertensive drug segment"}]}, "sentence": " Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "object": {"text": "further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL", "keywords": [{"text": "Benicar/Benicar HCT"}, {"text": "Micardis/Micardis HCT"}, {"text": "Exforge/Exforge HCT"}, {"text": "Norvasc"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive", "keywords": [{"text": "Niaspan"}, {"text": "Crestor"}, {"text": "Lipitor"}, {"text": "TriCor/Trilipix"}], "entities": [{"type": "Location", "text": "Tredaptive", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " Anti-dyslipidemics drug segment includes Lipitor, Crestor, Niaspan, TriCor/Trilipix, Zetia/Vytorin and Tredaptive.", "object": {"text": "Anti-dyslipidemics drug segment", "keywords": [{"text": "Anti-dyslipidemics drug segment"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "includes", "normalized": "include"}}, {"subject": {"text": "Anti-thrombotics drug segment", "keywords": [{"text": "Anti-thrombotics drug segment"}]}, "sentence": " Anti-thrombotics drug segment is further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis.", "object": {"text": "further sub-segmented into Plavix, Lovenox, Pradaxa, Xarelto, Brilique/Brilinta and Eliquis", "keywords": [{"text": "Plavix"}, {"text": "Lovenox"}, {"text": "Pradaxa"}, {"text": "Xarelto"}], "entities": [{"type": "Location", "text": "Eliquis", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " In terms of geographic, North America dominates the global cardiovascular drugs market.", "object": {"text": "the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "market"}]}, "action": {"verb": {"text": "dominate", "tense": "present"}, "text": "dominates", "normalized": "dominate"}}, {"subject": {"text": "The U.S.", "keywords": [{"text": "U.S"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}]}, "sentence": " The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "object": {"text": "the largest market for cardiovascular drugs followed by Canada in North America", "keywords": [{"text": "cardiovascular drugs"}, {"text": "largest market"}, {"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "action": {"verb": {"text": "represent", "tense": "present"}, "text": "represents", "normalized": "represent"}}, {"subject": {"text": "by Canada in North America", "keywords": [{"text": "North America"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "object": {"text": "cardiovascular drugs", "keywords": [{"text": "cardiovascular drugs"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "the U.K., Spain, Italy and France", "keywords": [{"text": "U.K."}, {"text": "Spain"}, {"text": "Italy"}, {"text": "France"}], "entities": [{"type": "Location", "text": "U.K.", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "MeteorologicalService", "Country"], "name": "United Kingdom", "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"}}, {"type": "Location", "text": "Spain", "disambiguation": {"subtype": ["Country"], "name": "Kingdom of Spain (Napoleonic)", "dbpedia_resource": "http://dbpedia.org/resource/Kingdom_of_Spain_(Napoleonic)"}}, {"type": "Location", "text": "Italy", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "France", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmDirector", "Country"], "name": "France", "dbpedia_resource": "http://dbpedia.org/resource/France"}}]}, "sentence": " In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "object": {"text": "major share of cardiovascular drugs market", "keywords": [{"text": "cardiovascular drugs"}, {"text": "major share"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "Asia", "keywords": [{"text": "Asia"}], "entities": [{"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "sentence": " However, Asia is expected to show high growth rates in the next five years in global cardiovascular drugs market.", "object": {"text": "high growth rates", "keywords": [{"text": "high growth rates"}]}, "action": {"verb": {"text": "show", "tense": "future"}, "text": "is expected to show", "normalized": "be expect to show"}}, {"subject": {"text": "many companies", "keywords": [{"text": "companies"}]}, "sentence": " This is due to many companies constructing their R&D facilities in the region.", "object": {"text": "their R&D facilities in the region", "keywords": [{"text": "R&D facilities"}, {"text": "region"}]}, "action": {"verb": {"text": "construct", "tense": "present"}, "text": "constructing", "normalized": "construct"}}, {"subject": {"text": "Less stringent wages and availability of skilled labor", "keywords": [{"text": "stringent wages"}, {"text": "skilled labor"}, {"text": "availability"}]}, "sentence": " Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia.", "object": {"text": "manufacturing companies", "keywords": [{"text": "manufacturing companies"}]}, "action": {"verb": {"text": "attract", "tense": "present"}, "text": "attracts", "normalized": "attract"}}, {"subject": {"text": "increasing awareness about heart related problems", "keywords": [{"text": "awareness"}, {"text": "heart"}, {"text": "problems"}]}, "sentence": " In addition, increasing awareness about heart related problems is also supporting in the growth of cardiovascular drugs market in the region.", "action": {"verb": {"text": "support", "tense": "present"}, "text": "is also supporting", "normalized": "be also support"}}, {"subject": {"text": "Japan, China and India", "keywords": [{"text": "Japan"}, {"text": "China"}, {"text": "India"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["HumanLanguage", "Region", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "India", "dbpedia_resource": "http://dbpedia.org/resource/India"}}]}, "sentence": " Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.", "object": {"text": "the fastest growing cardiovascular drugs markets in Asia", "keywords": [{"text": "cardiovascular drugs"}, {"text": "markets"}, {"text": "Asia"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Asia", "disambiguation": {"subtype": ["FieldOfStudy", "Continent"], "name": "Asia", "dbpedia_resource": "http://dbpedia.org/resource/Asia"}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "increasing prevalence of heart diseases and extensive pipeline drugs", "keywords": [{"text": "extensive pipeline drugs"}, {"text": "prevalence"}, {"text": "heart diseases"}]}, "sentence": " In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market.", "object": {"text": "some of the major drivers of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "major drivers"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Rising number of diabetic patients", "keywords": [{"text": "diabetic patients"}, {"text": "number"}]}, "sentence": " Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.", "object": {"text": "immense potential to the growth of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "immense potential"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "holds", "normalized": "hold"}}, {"subject": {"text": "stringent regulations and side-effects of cardiovascular drugs", "keywords": [{"text": "cardiovascular drugs"}, {"text": "stringent regulations"}, {"text": "side-effects"}]}, "sentence": " However, stringent regulations and side-effects of cardiovascular drugs hamper the growth of global cardiovascular drugs market.", "object": {"text": "the growth of global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "hamper", "tense": "present"}, "text": "hamper", "normalized": "hamper"}}, {"subject": {"text": "patent expiry of various blockbuster drugs", "keywords": [{"text": "various blockbuster drugs"}, {"text": "patent expiry"}]}, "sentence": " Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market.", "object": {"text": "the growth of the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "growth"}, {"text": "market"}]}, "action": {"verb": {"text": "obstruct", "tense": "present"}, "text": "obstructs", "normalized": "obstruct"}}, {"subject": {"text": "the major companies", "keywords": [{"text": "major companies"}]}, "sentence": " Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Some of the major companies operating in the global cardiovascular drugs market", "keywords": [{"text": "global cardiovascular drugs"}, {"text": "major companies"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "object": {"text": "Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA", "keywords": [{"text": "Bristol-Myers Squibb Company"}, {"text": "Forest Laboratories Inc."}, {"text": "F. Hoffmann-La Roche"}, {"text": "AstraZeneca PLC"}], "entities": [{"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Company", "text": "Abbott Laboratories Inc."}, {"type": "Company", "text": "AstraZeneca PLC", "disambiguation": {"subtype": ["Company"], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"type": "Company", "text": "Takeda Pharmaceutical Co. Ltd."}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Forest Laboratories Inc.", "disambiguation": {"subtype": [], "name": "Forest Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Forest_Laboratories"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Roche Ltd."}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Daiichi Sankyo Co. Ltd."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Solvay SA", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Solvay (company)", "dbpedia_resource": "http://dbpedia.org/resource/Solvay_(company)"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}], "concepts": [{"text": "Hypertension", "relevance": 0.981123, "dbpedia_resource": "http://dbpedia.org/resource/Hypertension"}, {"text": "Heart", "relevance": 0.806741, "dbpedia_resource": "http://dbpedia.org/resource/Heart"}, {"text": "Heart disease", "relevance": 0.7813, "dbpedia_resource": "http://dbpedia.org/resource/Heart_disease"}, {"text": "Cardiology", "relevance": 0.777104, "dbpedia_resource": "http://dbpedia.org/resource/Cardiology"}, {"text": "Blood", "relevance": 0.673926, "dbpedia_resource": "http://dbpedia.org/resource/Blood"}, {"text": "Circulatory system", "relevance": 0.635585, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_system"}, {"text": "Blood vessel", "relevance": 0.618942, "dbpedia_resource": "http://dbpedia.org/resource/Blood_vessel"}, {"text": "Myocardial infarction", "relevance": 0.589005, "dbpedia_resource": "http://dbpedia.org/resource/Myocardial_infarction"}, {"text": "Bristol-Myers Squibb", "relevance": 0.588081, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Genetic disorder", "relevance": 0.56009, "dbpedia_resource": "http://dbpedia.org/resource/Genetic_disorder"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.549874, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Ischaemic heart disease", "relevance": 0.54371, "dbpedia_resource": "http://dbpedia.org/resource/Ischaemic_heart_disease"}, {"text": "Cardiovascular system", "relevance": 0.536685, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_system"}, {"text": "Ischemia", "relevance": 0.528744, "dbpedia_resource": "http://dbpedia.org/resource/Ischemia"}, {"text": "Pfizer", "relevance": 0.52548, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Aspirin", "relevance": 0.514928, "dbpedia_resource": "http://dbpedia.org/resource/Aspirin"}, {"text": "Cardiovascular diseases", "relevance": 0.514311, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_diseases"}, {"text": "Stroke", "relevance": 0.497705, "dbpedia_resource": "http://dbpedia.org/resource/Stroke"}, {"text": "Diseases and disorders", "relevance": 0.479267, "dbpedia_resource": "http://dbpedia.org/resource/Diseases_and_disorders"}, {"text": "Circulatory System", "relevance": 0.449011, "dbpedia_resource": "http://dbpedia.org/resource/Circulatory_System"}, {"text": "Heart failure", "relevance": 0.432463, "dbpedia_resource": "http://dbpedia.org/resource/Heart_failure"}, {"text": "Streptococcus", "relevance": 0.42975, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus"}, {"text": "Rheumatic fever", "relevance": 0.426886, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatic_fever"}, {"text": "Clopidogrel", "relevance": 0.401533, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Pharmaceutical industry", "relevance": 0.386414, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Coronary artery disease", "relevance": 0.38327, "dbpedia_resource": "http://dbpedia.org/resource/Coronary_artery_disease"}, {"text": "Infection", "relevance": 0.381196, "dbpedia_resource": "http://dbpedia.org/resource/Infection"}, {"text": "Atherosclerosis", "relevance": 0.377519, "dbpedia_resource": "http://dbpedia.org/resource/Atherosclerosis"}, {"text": "Blood pressure", "relevance": 0.364417, "dbpedia_resource": "http://dbpedia.org/resource/Blood_pressure"}, {"text": "Pulmonary vein", "relevance": 0.34301, "dbpedia_resource": "http://dbpedia.org/resource/Pulmonary_vein"}, {"text": "Multinational companies", "relevance": 0.339934, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Rheumatism", "relevance": 0.337354, "dbpedia_resource": "http://dbpedia.org/resource/Rheumatism"}, {"text": "Medicine", "relevance": 0.334533, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Immune system", "relevance": 0.334197, "dbpedia_resource": "http://dbpedia.org/resource/Immune_system"}, {"text": "Inflammation", "relevance": 0.334021, "dbpedia_resource": "http://dbpedia.org/resource/Inflammation"}, {"text": "Genentech", "relevance": 0.329533, "dbpedia_resource": "http://dbpedia.org/resource/Genentech"}, {"text": "Amlodipine", "relevance": 0.325988, "dbpedia_resource": "http://dbpedia.org/resource/Amlodipine"}, {"text": "Disease", "relevance": 0.321473, "dbpedia_resource": "http://dbpedia.org/resource/Disease"}, {"text": "Infectious disease", "relevance": 0.317423, "dbpedia_resource": "http://dbpedia.org/resource/Infectious_disease"}, {"text": "Arthralgia", "relevance": 0.313346, "dbpedia_resource": "http://dbpedia.org/resource/Arthralgia"}, {"text": "Hypercholesterolemia", "relevance": 0.309095, "dbpedia_resource": "http://dbpedia.org/resource/Hypercholesterolemia"}, {"text": "Streptococcus pyogenes", "relevance": 0.305353, "dbpedia_resource": "http://dbpedia.org/resource/Streptococcus_pyogenes"}, {"text": "Cerebral hemorrhage", "relevance": 0.301609, "dbpedia_resource": "http://dbpedia.org/resource/Cerebral_hemorrhage"}, {"text": "Irbesartan", "relevance": 0.301606, "dbpedia_resource": "http://dbpedia.org/resource/Irbesartan"}, {"text": "AstraZeneca", "relevance": 0.297498, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Transient ischemic attack", "relevance": 0.29697, "dbpedia_resource": "http://dbpedia.org/resource/Transient_ischemic_attack"}, {"text": "Pharmaceutical drug", "relevance": 0.295992, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Cardiovascular disease", "relevance": 0.287028, "dbpedia_resource": "http://dbpedia.org/resource/Cardiovascular_disease"}, {"text": "Artery", "relevance": 0.28641, "dbpedia_resource": "http://dbpedia.org/resource/Artery"}, {"text": "Cardiac muscle", "relevance": 0.284561, "dbpedia_resource": "http://dbpedia.org/resource/Cardiac_muscle"}], "categories": [{"score": 0.999944, "label": "/health and fitness/disease/heart disease"}], "relations": [{"type": "affectedBy", "sentence": "Rheumatic fever occurs by preceding group A streptococcal infection.", "score": 0.668725, "arguments": [{"text": "group", "location": [573, 578], "entities": [{"type": "Person", "text": "group"}]}, {"text": "preceding", "location": [563, 572], "entities": [{"type": "EventCommunication", "text": "preceding"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.676207, "arguments": [{"text": "Benicar HCT", "location": [1515, 1526], "entities": [{"type": "GeopoliticalEntity", "text": "Benicar HCT"}]}, {"text": "Micardis", "location": [1528, 1536], "entities": [{"type": "GeopoliticalEntity", "text": "Micardis HCT"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.676207, "arguments": [{"text": "Micardis HCT", "location": [1537, 1549], "entities": [{"type": "GeopoliticalEntity", "text": "Micardis HCT"}]}, {"text": "Aprovel", "location": [1551, 1558], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.623328, "arguments": [{"text": "CoAprovel", "location": [1559, 1568], "entities": [{"type": "GeopoliticalEntity", "text": "CoAprovel"}]}, {"text": "Tekturna", "location": [1570, 1578], "entities": [{"type": "GeopoliticalEntity", "text": "Tekturna"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.829898, "arguments": [{"text": "Rasilez", "location": [1579, 1586], "entities": [{"type": "GeopoliticalEntity", "text": "Rasilez"}]}, {"text": "Edarbi", "location": [1588, 1594], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.529909, "arguments": [{"text": "Edarbi", "location": [1588, 1594], "entities": [{"type": "GeopoliticalEntity", "text": "Edarbi"}]}, {"text": "Cozaar", "location": [1596, 1602], "entities": [{"type": "GeopoliticalEntity", "text": "Cozaar"}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.92593, "arguments": [{"text": "Hyzaar", "location": [1603, 1609], "entities": [{"type": "GeopoliticalEntity", "text": "Hyzaar"}]}, {"text": "Norvasc", "location": [1611, 1618], "entities": [{"type": "GeopoliticalEntity", "text": "Norvasc"}]}]}, {"type": "locatedAt", "sentence": "The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "score": 0.840381, "arguments": [{"text": "drugs", "location": [2139, 2144], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Canada", "location": [2157, 2163], "entities": [{"type": "GeopoliticalEntity", "text": "Canada", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America.", "score": 0.637932, "arguments": [{"text": "drugs", "location": [2139, 2144], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "North America", "location": [2167, 2180], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "score": 0.954556, "arguments": [{"text": "Europe", "location": [2185, 2191], "entities": [{"type": "GeopoliticalEntity", "text": "Europe"}]}, {"text": "Germany", "location": [2193, 2200], "entities": [{"type": "GeopoliticalEntity", "text": "Germany", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drugs market.", "score": 0.704525, "arguments": [{"text": "U.K.", "location": [2206, 2210], "entities": [{"type": "GeopoliticalEntity", "text": "U.K."}]}, {"text": "Spain", "location": [2212, 2217], "entities": [{"type": "GeopoliticalEntity", "text": "Spain", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Rheumatic fever occurs by preceding group A streptococcal infection.", "score": 0.881228, "arguments": [{"text": "group", "location": [573, 578], "entities": [{"type": "Person", "text": "group"}]}, {"text": "infection", "location": [595, 604], "entities": [{"type": "HealthCondition", "text": "cerebrovascular disease"}]}]}, {"type": "ownerOf", "sentence": "This is due to many companies constructing their R&D facilities in the region.", "score": 0.268793, "arguments": [{"text": "companies", "location": [2420, 2429], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "facilities", "location": [2453, 2463], "entities": [{"type": "Facility", "text": "facilities"}]}]}, {"type": "locatedAt", "sentence": "This is due to many companies constructing their R&D facilities in the region.", "score": 0.950849, "arguments": [{"text": "facilities", "location": [2453, 2463], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2471, 2477], "entities": [{"type": "GeopoliticalEntity", "text": "Tredaptive"}]}]}, {"type": "locatedAt", "sentence": "Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia.", "score": 0.397101, "arguments": [{"text": "companies", "location": [2557, 2566], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Asia", "location": [2580, 2584], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Japan, China and India are expected to be the fastest growing cardiovascular drugs markets in Asia.", "score": 0.602137, "arguments": [{"text": "drugs", "location": [2805, 2810], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "Asia", "location": [2822, 2826], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "hasAttribute", "sentence": "In recent time, increasing prevalence of heart diseases and extensive pipeline drugs are some of the major drivers of global cardiovascular drugs market.", "score": 0.744416, "arguments": [{"text": "drivers", "location": [2935, 2942], "entities": [{"type": "Person", "text": "drivers"}]}, {"text": "cardiovascular", "location": [2953, 2967], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "Increasing aging population and rising number of life-style diseases are also contributing in the growth of global cardiovascular drugs market.", "score": 0.743664, "arguments": [{"text": "population", "location": [2999, 3009], "entities": [{"type": "Person", "text": "population"}]}, {"text": "diseases", "location": [3042, 3050], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "hasAttribute", "sentence": "Rising number of diabetic patients holds immense potential to the growth of global cardiovascular drugs market.", "score": 0.909393, "arguments": [{"text": "patients", "location": [3152, 3160], "entities": [{"type": "Person", "text": "patients"}]}, {"text": "diabetic", "location": [3143, 3151], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "locatedAt", "sentence": "Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drugs market.", "score": 0.499794, "arguments": [{"text": "drugs", "location": [3414, 3419], "entities": [{"type": "Substance", "text": "drugs"}]}, {"text": "blockbuster", "location": [3402, 3413], "entities": [{"type": "Facility", "text": "blockbuster"}]}]}, {"type": "affectedBy", "sentence": "Increasing mergers and acquisitions between drug manufacturing companies and rapid product launches are key trends of the global cardiovascular drugs market.", "score": 0.48594, "arguments": [{"text": "companies", "location": [3552, 3561], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "acquisitions", "location": [3512, 3524], "entities": [{"type": "EventBusiness", "text": "acquisitions"}]}]}, {"type": "hasAttribute", "sentence": "Request For Report Sample@ https://www.persistencemarketresearch.com/samples/3776 Some of the major companies operating in the global cardiovascular drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.", "score": 0.526147, "arguments": [{"text": "Report Sample@", "location": [3659, 3673], "entities": [{"type": "Person", "text": "Report Sample@"}]}, {"text": "cardiovascular", "location": [3781, 3795], "entities": [{"type": "HealthCondition", "text": "cardiovascular"}]}]}, {"type": "hasAttribute", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.927547, "arguments": [{"text": "children", "location": [662, 670], "entities": [{"type": "Person", "text": "children"}]}, {"text": "heart diseases", "location": [644, 658], "entities": [{"type": "HealthCondition", "text": "heart diseases"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.463019, "arguments": [{"text": "children", "location": [662, 670], "entities": [{"type": "Person", "text": "children"}]}, {"text": "countries", "location": [679, 688], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common acquired heart diseases in children in many countries of the world, especially in developing countries.", "score": 0.466845, "arguments": [{"text": "countries", "location": [679, 688], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "world", "location": [696, 701], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "Most common types of cerebrovascular disease are vascular dementia, stroke, subarachnoid hemorrhage and transient ischemic attack (TIA).", "score": 0.50584, "arguments": [{"text": "TIA", "location": [930, 933], "entities": [{"type": "Person", "text": "TIA"}]}, {"text": "attack", "location": [922, 928], "entities": [{"type": "EventViolence", "text": "attack"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common causes of death in western parts of the world.", "score": 0.506713, "arguments": [{"text": "western", "location": [1062, 1069], "entities": [{"type": "Location", "text": "western"}]}, {"text": "parts", "location": [1070, 1075], "entities": [{"type": "Location", "text": "parts"}]}]}, {"type": "locatedAt", "sentence": "It is one of the most common causes of death in western parts of the world.", "score": 0.780669, "arguments": [{"text": "parts", "location": [1070, 1075], "entities": [{"type": "Location", "text": "parts"}]}, {"text": "world", "location": [1083, 1088], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Anti-hypertensive drug segment is further sub-segmented into Diovan/Co-Diovan, Blopress, Benicar/Benicar HCT, Micardis/Micardis HCT, Aprovel/CoAprovel, Tekturna/Rasilez, Edarbi, Cozaar/Hyzaar, Norvasc, Exforge/Exforge HCT, Coversyl and Seloken/Toprol-XL.", "score": 0.68216, "arguments": [{"text": "Co-Diovan", "location": [1486, 1495], "entities": [{"type": "GeopoliticalEntity", "text": "Co-Diovan"}]}, {"text": "Blopress", "location": [1497, 1505], "entities": [{"type": "GeopoliticalEntity", "text": "Blopress"}]}]}], "keywords": [{"text": "Cardiovascular diseases", "sentiment": {"score": -0.960538, "label": "negative"}, "relevance": 0.766313, "count": 1}, {"text": "global cardiovascular drugs market", "sentiment": {"score": -0.615475, "label": "negative"}, "relevance": 0.713857, "count": 4}, {"text": "heart diseases", "sentiment": {"score": -0.906384, "label": "negative"}, "relevance": 0.704478, "count": 2}, {"text": "recent time", "sentiment": {"score": -0.908696, "label": "negative"}, "relevance": 0.659409, "count": 1}, {"text": "various anti-hypertensive drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.637701, "count": 1}, {"text": "hypertensive heart disease", "sentiment": {"score": -0.889217, "label": "negative"}, "relevance": 0.623714, "count": 2}, {"text": "common cardiovascular diseases", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.611416, "count": 1}, {"text": "diseases of heart", "sentiment": {"score": -0.960538, "label": "negative"}, "relevance": 0.599465, "count": 1}, {"text": "rheumatic heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.593472, "count": 1}, {"text": "Anti-hypertensive drug segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.585287, "count": 1}, {"text": "Major problems", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.577758, "count": 1}, {"text": "stringent wages", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.571679, "count": 1}, {"text": "anti-dyslipidemics drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569461, "count": 1}, {"text": "ischemic heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.564195, "count": 1}, {"text": "Hypertensive heart disease", "sentiment": {"score": -0.935836, "label": "negative"}, "relevance": 0.557982, "count": 1}, {"text": "common types of cerebrovascular disease", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.55741, "count": 1}, {"text": "Takeda Pharmaceutical Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556926, "count": 1}, {"text": "Abbott Laboratories Inc.", "sentiment": {"score": -0.502766, "label": "negative"}, "relevance": 0.55373, "count": 1}, {"text": "addition", "sentiment": {"score": -0.515029, "label": "negative"}, "relevance": 0.542644, "count": 1}, {"text": "Rheumatic heart disease", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541614, "count": 1}, {"text": "companies", "sentiment": {"score": -0.515029, "label": "negative"}, "relevance": 0.540047, "count": 2}, {"text": "cerebrovascular heart disease", "sentiment": {"score": -0.957113, "label": "negative"}, "relevance": 0.539427, "count": 1}, {"text": "anti-thrombotics drugs", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538215, "count": 1}, {"text": "vascular dementia", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.538209, "count": 1}, {"text": "Anti-dyslipidemics drug segment", "sentiment": {"score": -0.804171, "label": "negative"}, "relevance": 0.535891, "count": 1}, {"text": "Europe", "sentiment": {"score": -0.252491, "label": "negative"}, "relevance": 0.535022, "count": 1}, {"text": "Benicar HCT", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.534935, "count": 1}, {"text": "F. Hoffmann-La Roche Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533968, "count": 1}, {"text": "coronary heart disease", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.533735, "count": 1}, {"text": "rheumatic fever", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532781, "count": 1}, {"text": "high blood pressure", "sentiment": {"score": -0.876595, "label": "negative"}, "relevance": 0.532424, "count": 1}, {"text": "heart failure", "sentiment": {"score": -0.809269, "label": "negative"}, "relevance": 0.531292, "count": 1}, {"text": "largest market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53085, "count": 1}, {"text": "Japan", "sentiment": {"score": 0.321593, "label": "positive"}, "relevance": 0.530096, "count": 1}, {"text": "subarachnoid hemorrhage", "sentiment": {"score": -0.820147, "label": "negative"}, "relevance": 0.530012, "count": 1}, {"text": "Novartis AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529406, "count": 1}, {"text": "North America", "sentiment": {"score": -0.252491, "label": "negative"}, "relevance": 0.526731, "count": 2}, {"text": "major companies", "sentiment": {"score": -0.502766, "label": "negative"}, "relevance": 0.526197, "count": 1}, {"text": "Ischemic heart disease", "sentiment": {"score": -0.608359, "label": "negative"}, "relevance": 0.526037, "count": 1}, {"text": "Co-Diovan", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524978, "count": 1}, {"text": "AstraZeneca PLC", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522816, "count": 1}, {"text": "high growth rates", "sentiment": {"score": -0.719509, "label": "negative"}, "relevance": 0.52222, "count": 1}, {"text": "Germany", "sentiment": {"score": -0.252491, "label": "negative"}, "relevance": 0.520329, "count": 1}, {"text": "Rheumatic fever", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520184, "count": 1}, {"text": "problems", "sentiment": {"score": -0.515029, "label": "negative"}, "relevance": 0.51991, "count": 1}, {"text": "awareness", "sentiment": {"score": -0.564468, "label": "negative"}, "relevance": 0.519492, "count": 2}, {"text": "population", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519162, "count": 1}, {"text": "stringent regulations", "sentiment": {"score": -0.867135, "label": "negative"}, "relevance": 0.51909, "count": 1}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": -0.502766, "label": "negative"}, "relevance": 0.517907, "count": 1}, {"text": "China", "sentiment": {"score": 0.321593, "label": "positive"}, "relevance": 0.51726, "count": 1}]}, "extracted_metadata": {"sha1": "f6c3ae4b69e7644ad5f9f90d69fcd393b75c62a6", "filename": "1542370228526.zip-5a26dd9d31b755c02ff5a793eb384945.xml", "file_type": "json"}, "external_links": ["https://www.persistencemarketresearch.com/samples/3776", "https://www.persistencemarketresearch.com/market-research/cardiovascular-drugs-market.asp"], "title": "Cardiovascular Drugs to Actively Foray into Emerging Consumer Market places During 2015 to 2021", "forum_title": "Automotive &amp; Transportation | Find Market Research - Part 2"}]}